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Introduction	  
	  Type	   I	   hypersensitivity	   reactions	   are	   immune	   system	   responses	   of	   the	   body	  triggered	  by	  the	  IgE/antigen-­‐mediated	  activation	  of	  tissue	  localized	  mast	  cells	  but	  also	   by	   circulating	   basophils	   or	   eosinophils.	   Within	   minutes	   from	   their	  stimulation,	  mast	  cells	  release	  a	  plethora	  of	  preformed	  molecules	  whose	  activity	  induces	   vasodilatation	   and	   broncho-­‐constriction	   and	   increases	   the	   vascular	  permeability,	  enhancing	  the	  recruitment	  of	  leukocytes.	  Such	  a	  hyperactivation	  of	  the	   immune	   system	   in	   response	   to	   a	   foreign	  molecule	   is	   commonly	   defined	   as	  allergic	   reaction.	   The	   stimulation	   of	   the	   high	   affinity	   IgE	   receptors,	   FcεRI,	  expressed	   on	   the	   surface	   of	   mast	   cells	   is	   induced	   by	   the	   clustering	   of	   several	  IgE/FcεRI	  complexes	  and	  promotes	  the	  formation	  of	  an	  intracellular	  signalosome	  that	   generates	   a	   cascate	   of	   signalling	   events.	   Class	   I	   phosphatydilinositol-­‐3-­‐kinases	   (PI3Ks)	   are	   activated	   downstream	  FcεRI	   clustering	   and	   are	   responsible	  for	  the	  generation	  of	  PtdIns(3,4,5)P3	  at	  the	  plasma	  membrane.	  On	  the	  other	  hand,	  the	   5’-­‐phosphatase	   SHIP1	   is	   recruited	   via	   its	   SH2	   domain	   at	   the	   plasma	  membrane	   where	   binds	   tyrosine-­‐phosphorylated	   domains	   of	   several	   receptors	  and	   hydrolyses	   the	   PtdIns(3,4,5)P3	   at	   the	   5’	   position	   of	   the	   inositol	   ring,	  generating	  PtdIns(3,4)P2.	  Being	  recognised	  by	  PH-­‐domain	  bearing	  proteins,	  both	  PtdIns(3,4,5)P3	  and	  PtdIns(3,4)P2	  participates	  to	  the	  recruitment	  of	  a	  wide	  variety	  of	  effectors.	  PI3Kγ,	  the	  sole	  member	  of	  class	  IB	  PI3Ks,	  has	  been	  showed	  to	  have	  a	  pivotal	  role	  in	  mast	  cells	  recruitment	  to	  the	  tissues	  and	  degranulation	  as	  well	  as	  in	  systemic	   anaphylactic	   reactions;	   therefore	   PI3Kγ	   has	   been	   proposed	   as	   a	  pharmacological	  target	  for	  the	  treatment	  of	  inflammatory	  diseases.	  Interestingly,	  the	  current	   treatment	  of	   the	  allergic	   responses	   is	  based	  on	   the	  pharmacological	  amelioration	  of	  the	  symptoms	  and	  does	  not	  target	  the	  aetiology	  of	  the	  disease.	  In	  the	  present	  work	  we	  demonstrate	  the	  possibility	  of	  inhibiting	  PI3Kγ	  signalling	  in	  mast	   cells	   in	   order	   to	  modulate	   hypersensitivity	   responses	  without	   affecting	  the	  phisiological	  functionality	  of	  class	  I	  PI3Ks	  in	  the	  other	  tissues.	  	  	  In	  the	  first	  project	  described	  in	  the	  present	  manuscript,	  we	  show	  that	  during	  mast	  cells	   activation,	   the	   GPCR-­‐mediated	   activation	   of	   PI3Kγ induces	   a	   signalling	  cascade	  that	   is	  not	   inhibited	  by	  the	  phosphatase	  activity	  of	  SHIP1	  and	  therefore	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contribute	   to	   the	   reinforcement	   of	   the	   antigen-­‐induced	   mast	   cells	   activation.	  Moreover	   we	   demonstrate	   that	   PI3Kγ and	  SHIP1	  are	   two	   valid	   targets	   for	   a	  combined	   pharmacological	   inhibition	   of	   mast	   cells	   activation.	   In	   the	   second	  project	  described	  in	  the	  manuscript,	  we	  demonstrate	  the	  possibility	  to	  selectively	  modulate	   PI3Kγ	   activation	   in	   mast	   cells	   by	   blocking	   the	   plasma	   membrane	  localization	  of	  the	  monomeric	  GTPase	  Ras	  using	  farnesyltransferase	  inhibitor.	  We	  demonstrate	  that	  Ras	  is	  required	  for	  the	  activation	  of	  PI3Kγ	   in	  cells	  that	  express	  p84	  as	  adaptor	   subunit	   (p110γ/p84	  heterodimer),	   such	  as	  mast	   cells	  but	  not	   in	  cells	   where	   the	   PI3Kγ	   active	   complex	   is	   p110γ/p101.	   In	   the	   final	   part	   of	   the	  manuscript	   we	   described	   the	   generation	   of	   three	   genetically	   modified	   mouse	  strains	  we	  developed:	  p101	  knock-­‐out,	  p84	  knock-­‐out	  and	  p84	  knock-­‐in.	  The	  two	  p84-­‐mutant	   mice	   were	   designed	   as	   novel	   tools	   for	   the	   analysis	   of	   the	  physiological	  p110γ/p84	  signalling	  in	  vivo	  and	  ex	  vivo,	  while	  the	  generation	  of	  the	  p101	  mutant	  has	  been	  already	  characterised	  by	  other	  groups	  but	  will	  be	  further	  used	  in	  our	  research.	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Allergy	  and	  allergic	  responses	  	  In	  allergic	  individuals,	  also	  called	  atopic,	  the	  contact	  of	  the	  allergen	  with	  the	  body	  induces	   an	   “immediate”	   hypersensitivity	   reaction	   (type	   I	   reaction)	   that	   occurs	  within	  minutes	  from	  the	  exposure	  to	  the	  allergen.	  Indeed,	  IgE	  molecules	  that	  are	  already	   bound	   on	   the	   surface	   of	  mast	   cells	   or	   basophils	   due	   to	   the	   presence	   of	  high	  affinity	  receptors	  for	  IgE,	  are	  cross-­‐linked	  by	  a	  multivalent	  antigen,	  resulting	  in	   the	   release	   of	   several	   preformed	   molecules	   and	   the	   generation	   of	   newly	  synthesized	   ones	   (Table	   1).	   The	   release	   of	   those	   signalling	   molecules	   causes	  vasodilation,	   increased	  vascular	  permeability	  associated	  with	  oedema	  and	  acute	  functional	  changes	  in	  affected	  organs	  (such	  as	  bronchoconstriction,	  airway	  mucus	  secretion,	   urticaria,	   vomiting	   and	   diarrhoea)(1,	   2).	   Allergy	   is	   currently	   a	   public	  concern	   of	   pandemic	   proportions,	   affecting	   more	   than	   150	   million	   people	   in	  Europe	  and	  with	  the	  increasing	  potential	  risk	  that	  within	  15	  years,	  more	  then	  half	  of	  the	  European	  population	  will	  be	  affected	  by	  some	  kind	  of	  allergic	  disease	  (data	  from:	  European	  Academy	  of	  Allergy	  and	  Clinical	  Immunology,	  EAACI).	  
	  
Introduction	  to	  mast	  cell’s	  biology	  
	  Mast	  cells	  are	  immune	  cells	  of	  hematopoietic	  origin,	  first	  described	  in	  1863	  by	  Dr.	  Von	  Recklinghausen	  that	  identified	  granular	  cells	  in	  the	  mesentery	  of	  the	  frog(3).	  In	  1878	  Paul	  Ehrich	  described	  a	  connective	  tissue	  cell	  population	  with	  a	  peculiar	  chemical	   staining	   phenotype	   that	   revealed	   the	   presence	   of	   big	   granules.	  Due	   to	  their	   peculiar	   phenotype,	   those	   cells	   appeared	   “well	   fed”	   (the	   German	   word	   is	  “mästung”)	   and	   Ehrich	   named	   them	   “Mastzellen”(4).	   Mast	   cells	   are	   generally	  localized	  at	  the	  interface	  between	  the	  organism	  and	  the	  external	  milieu	  and	  their	  tissue	  localization	  makes	  them	  able	  to	  serve	  as	  immune	  sentinel	  cells	  but	  also	  to	  directly	   respond	   to	   external	   insults;	   at	   the	   same	   time	  mast	   cells	  modulate	   both	  innate	   and	   adaptive	   immune	   responses(5,	   6)	   and	   play	   a	   protective	   role	   against	  pathogens(7).	   Mast	   cells	   are	   also	   involved	   in	   the	   generation	   of	   the	   allergic	  responses	   induced	  by	  antigen	  (IgE	  or	   IgG	  dependent)	  or	  peptide	  stimulation(8).	  The	  main	  feature	  that	  became	  evident	  as	  soon	  as	  mast	  cells	  were	  first	  described	  is	  the	  heterogeneity	  of	  such	  cell	  population.	  In	  rodents,	  mast	  cells	  can	  be	  divided	  in	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Table	  1:	  Main	  mast	  cell	  mediators	  and	  their	  physiological	  function	  	  
Mediators	  	   Function	  
Granule-­‐associated	  	  Histamine	  and	  serotonin	   	  Alter	  vascular	  permeability	  (12)	  Heparin	  and/or	  chondroitin	  sulphate	  peptidoglycans	   Enhance	  chemokine	  and/or	  cytokine	  functions	  and	  angiogenesis	  (12)	  Tryptase,	  chymase,	  carboxypeptidase	  and	  other	  proteases	  	   Tissue	  remodeling	  and	  recruitment	  of	  effector	  cells(13,	  14)	  TNF-­‐α,	  VEGF	  and	  FGF2	  	   Recruitment	  of	  effector	  cells	  and	  angiogenesis	  promotion(15–18)	  
Lipid-­‐derived	  	  LTC4,	  LTB4,	  PGD2	  and	  PGE2	  	   Recruit	  effector	  cells,	  regulate	  immune	  responses	  and	  promote	  angiogenesis,	  oedema	  and	  bronchoconstriction	  (19–21)	  Platelet-­‐activating	  factor	  	   Activates	  effector	  cells,	  enhances	  angiogenesis	  and	  induces	  physiological	  inflammation(21)	  
Cytokine	  	  TNF-­‐α,	  IL-­‐1α,	  IL-­‐1β,	  IL-­‐6,	  IL-­‐18,	  GM-­‐CSF,	  LIF,	  IFN-­‐α	  and	  IFN-­‐β	  	   Phlogosis	  promoters	  (22,	  23)	  IL-­‐3,	  IL-­‐4,	  IL-­‐5,	  IL-­‐9,	  IL-­‐13,	  IL-­‐15	  and	  IL-­‐16	  	   Function	  of	  Th2-­‐type	  cytokines(24,	  25)	  IL-­‐12	  and	  IFN-­‐γ	  	   Functions	  of	  Th1-­‐type	  cytokines(26,	  27)	  IL-­‐10,	  TGF-­‐β	  and	  VEGF	   Regulate	  inflammation	  and	  angiogenesis	  (28)	  
Chemokine	  	  
CCL2,	  CCL3,	  CCL4,	  CCL5,	  CCL11	  and	  CCL20	   Recruit	  effector	  cells,	  including	  dendritic	  cells,	  and	  regulate	  immune	  responses	  (29,	  30)	  CXCL1,	  CXCL2,	  CXCL8,	  CXCL9,	  CXCL10	  and	  CXCL11	  	   Recruit	  effector	  cells	  and	  regulate	  immune	  responses(30,	  31)	  
Other	  	  Nitric	  oxide	  and	  superoxide	  radicals	  	   Bactericidal	  (32,	  33)	  Antimicrobial	  peptides	   Bactericidal	  (34)	  	  
Legend:	  CCL,	  CC-­‐chemokine	  ligand;	  CXCL,	  CXC-­‐chemokine	  ligand;	  FGF2,	   fibroblast	  growth	  factor	  2;	   GM-­‐CSF,	   granulocyte/macrophage	   colony-­‐stimulating	   factor;	   IFN,	   interferon;	   IL,	   interleukin;	  
LIF,	  leukemia	  inhibitory	  factor;	  LTB4,	  leukotriene	  B4;	  LTC4,	  leukotriene	  C4;	  PGD2,	  prostaglandin	  D2;	  PGE2,	  prostaglandin	  E2;	  TGF-­‐β,	   transforming	  growth	  factor-­‐β;	  TNF-­‐α ,	   tumor	  necrosis	  factor	  alpha;	  VEGF,	  vascular	  endothelial	  growth	  factor.	  Adapted	  from(35)	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Table	  2:	  Murine	  mast	  cells	  main	  features	  	  	  
	  
	  
Legend:	  A	  different	  sensibility	  to	  the	  formaldehyde	  fixation	  is	  one	  of	  the	  main	  features	  that	  distinguish	   the	   two	   cell	   populations.	   Indeed,	   following	   fixation	   with	   a	  formaldehyde-­‐buffered	  solution,	  MMC	  do	  not	  stain,	  or	  stain	  poorly,	  with	  toluidine	  blue,	  whereas	  CTMC	  are	  resistant	  to	  this	  treatment	  and	  stain	  well.	  Depending	  on	  the	  different	   glycosaminoglycan	   content	  within	   the	  granules,	  mast	   cells	   react	   to	  Safranin	  or	  Alcian	  blue.	  RMCP	  I	  and	  II:	  serine	  proteases.	  Adapted	  from(9).	  	  




















	  	  	  	  	  	  	  	  	  	  	  Introduction	  
11	  	  
Mast	  cell	  growth	  and	  development	  	  Mature	  mast	   cells	   are	   tissue	   resident	   cells	   of	   hematopoietic	   origin	   generated	  as	  precursor	   progenitors	   in	   the	   bone	   marrow.	   Mast	   cells	   progenitors	   migrate	   all	  through	   the	   body	   in	   different	   localizations	   and	   undergo	   to	   the	   final	   stage	   of	  differentiation	  upon	  cytokine	  stimulation	  in	  the	  tissue	  of	  destination.	  Although	  is	  commonly	   accepted	   that	  mast	   cells	   originate	   from	   a	  multipotent	   hematopoietic	  progenitor	   population,	   is	   still	   debated	   whether	   mast	   cells	   arise	   from	   a	  megakaryocyte/erythrocyte	   progenitor	   or	   a	   granulocyte/monocyte	  progenitor(36–38).	  A	  reasonable	  synthesis	  proposed	  by	  J.S.	  Dahlin	  and	  J.Hallgren	  is	   that	   murine	   committed	   mast	   cell	   precursors	   originate	   from	   a	   bi-­‐potent	  progenitor	  present	  in	  the	  granulocyte/monocyte	  precursor	  population	  that	  is	  able	  to	   generate	   both	   mast	   cells	   and	   basophils(39).	   Mature	   mast	   cells	   are	  characterized	   by	   the	   expression	   of	   FcεRI,	   although	   has	   been	   reported	   that	   the	  majority	   of	   the	   precursor	  mast	   cell	   population	   founded	   in	   the	   blood	   of	   BALB/c	  mice	   is	   FcεRI+	   and	   FεRI-­‐	  in	   C57BL	  mice,	   both	   being	   able	   to	   generate	   adult	  mast	  cells	  FcεRI+	  (40,	  41).	  In	  humans,	  mast	  cells	  develop	  from	  a	  CD13+/CD34+/CD117+	  pluripotent	   progenitors	   (9,	   42).	   A	   fundamental	   stimulus	   for	   tissue	   mast	   cells	  maturation	   is	   the	  Stem	  Cell	  Factor	   (SCF)	   that	  binds	   to	   c-­‐kit	   (CD117),	   a	   receptor	  tyrosine	   kinase	   localized	   on	   mast	   cell’s	   surface.	   SCF	   induces	   c-­‐kit	   dimerization	  and	  auto-­‐phosphorylation(43,	  44).	  	  For	  in	  vitro	  studies,	  several	  possibilities	  have	  been	  developed	  in	  order	  to	  derivate	  mast	  cells	  from	  precursors	  populations.	  One	  of	  the	  first	  attempts	  reported	  in	  the	  literature	   is	   the	   cultivation	   of	   mouse	   bone	   marrow	   cells	   with	   a	   conditioned	  medium	   obtained	   from	   concavalin	   A	   stimulated	   splenocytes(45);	   under	   these	  conditions	  is	  possible	  to	  generate	  a	  cell	  population	  that,	  by	  phenotype,	  resemble	  the	  mucosal	  mast	  cell	  population.	  Interesting,	  it	  became	  clear	  that	  such	  a	  cellular	  population	   could	  be	   further	   stimulated	  by	   the	  exposure	   to	   cytokines.	   Indeed,	   in	  presence	  of	   IL-­‐3	  containing	  media	   is	  possible	   to	  generate	  a	  mast	  cell	  population	  characterised	  by	  an	  increased	  synthesis	  of	  heparin	  proteoglycans,	  a	  characteristic	  Safranin	   staining	   and	   an	   increased	   histamine	   content	   that	   resemble	   the	  phenotype	  of	  connective	  tissue	  mast	  cells(9).	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In	   the	   present	   study	  we	   generated	   bone	  marrow-­‐derived	  mast	   cells,	   BMMC,	   by	  cultivating	  bone	  marrow	  cells	   in	  presence	  of	   stem	  cell	   factor,	   SCF	  and	   IL-­‐3.	  The	  combination	   of	   the	   two	   stimuli	   induces	   the	   differentiation	   of	   a	   mast	   cell	  population	  that	  resemble	  the	  CTMC	  phenotype(46).	  	  
Mast	  cell	  mediators	  and	  their	  release	  	  The	  mediators	  of	  the	  allergic	  response	  produced	  by	  mast	  cells	  can	  be	  grouped	  in	  three	   main	   classes:	   preformed	   granule	   associated	   molecules,	   newly	   generated	  lipid	  mediators	  and	  cytokines	  and	  chemokines(47,	  48)	  (Table	  1).	  The	  presence	  of	  several	  preformed	  granules	  localized	  in	  the	  cytoplasm	  is	  the	  main	  feature	  of	  mast	  cells.	   The	   granules	   are	   located	   in	   close	   vicinity	   with	   the	   plasma	  membrane,	   all	  around	   the	   cell	   perimeter	   and	   contain	  bioactive	   compounds	   that	   can	   rapidly	  be	  released	   and	   protect	   the	   host	   against	   diverse	   external	   insults(49).	   The	  degranulation	   reaction	   is	   based	   on	  multiple	  membrane	   fusion	   events	   (granule-­‐granule	   or	   granule-­‐membrane),	   all	   dependent	   on	   the	   interaction	   between	   v-­‐SNAREs	   proteins	   (vesicle	   soluble	   N-­‐ethylmaleimide-­‐sensitive	   factor	   attachment	  protein	  receptors)	  expressed	  at	  the	  granule’s	  membrane	  and	  t-­‐SNARE	  present	  at	  the	   target	  membrane	   side(50).	  Although	   the	  degranulation	  mechanisms	   are	  not	  fully	   understood	   yet,	   it	   has	   been	   proposed	   that	   FcεRI	   activation	   in	   BMMC	  generates	  a	  signalling	  cascade	  that	  can	  be	  ideally	  splitted	  in	  two	  branches.	  Indeed	  while	   the	   activation	   of	   the	   Lyn	   tyrosine	   kinase	   promotes	   the	   downstream	  activation	  of	  class	   I	  PI3K	  and	   the	  PLCγ	  mediated	  production	  of	  Ca2+	   that	   lead	   to	  the	   granule-­‐membrane	   fusion,	   on	   the	   other	   hand,	   a	   Fyn/Gab2/RhoA	   mediated	  mechanism	  promotes	   the	  microtubules	   formation	  and	   the	  granule	   translocation	  in	  proximity	  of	  the	  plasma	  membrane,	  in	  a	  calcium	  independent	  mechanism(51).	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FcεRI,	  high	  affinity	  receptor	  for	  IgE	  	  FcεRI	  binds	  with	  high	  affinity	  the	  Fc	  portion	  of	  IgE	  molecules	  and	  is	  crucial	  in	  the	  onset	   of	   IgE-­‐mediated	   allergic	   diseases	   and	   in	   the	   development	   of	   the	   most	  common	   cases	   of	   asthma,	   allergic	   rhinitis,	   atopic	   dermatitis	   and	   food	   or	   drug	  allergies.	  FcεRI	  exists	  as	  a	  tetrameric	  or	  trimeric	  complex.	  As	  a	  tetramer,	  FcεRI	  is	  formed	  by	  an	  α-­‐chain,	  a	  β-­‐chain	  and	  an	  homo-­‐dimer	  of	   two	  disulphide-­‐linked	  γ-­‐chains;	  this	  structure	  is	  often	  indicated	  as	  αβγ2(52)	  (Figure	  1).	  The	  trimeric	  form	  is	   defined	   as	   αγ2(52).	   The	   α-­‐chain	   is	   a	   trans-­‐membrane	   polypeptidic	   chain,	  member	   of	   the	   immunoglobulin	   superfamily.	   It	   shows	   two	   extracellular	  immunoglobulin-­‐like	  domains	  (D1	  and	  D2)	  that	  mediate	  the	  binding	  with	  a	  single	  IgE	   molecule	   (1:1	   ratio),	   a	   trans-­‐membrane	   domain	   with	   a	   conserved	   aspartic	  residue	   and	   a	   short	   cytoplasmic	   tail	   that	   apparently	   does	   not	   have	   signalling	  function(53).	   The	   crystal	   structure	   of	   the	   Fc	   region	   of	   IgE	   bound	   to	   FcεRIα	  revealed	  that	  the	  Cε3	  domain	  of	  IgE-­‐Fc	  binds	  two	  distinct	  sites	  located	  in	  the	  D2	  domain	  of	  FcεRIα(53).	  The	  FcεRI	  β	  and	  γ-­‐chains	  do	  not	  have	  any	  role	  in	  binding	  the	   IgE	  molecules	  and	  are	   characterized	  by	  an	   Immunoreceptor	  Tyrosine-­‐based	  Activation	  Motif	  (ITAM).	  The	  ITAM	  consensus	  sequence	  D/E-­‐XX-­‐YXXL-­‐X7-­‐11-­‐L/I,	  is	  the	   site	   where	   the	   tyrosine	   residues	   are	   phosphorylated	   by	   protein	   tyrosine	  kinases	  (PTKs)(54).	  The	  β	  chain,	  with	  its	  four	  trans-­‐membrane	  domains,	  is	  also	  a	  component	  of	  the	  low	  affinity	  IgG	  receptor	  (FcγRIII)	  in	  mast	  cells	  and,	  as	  well,	  the	  γ-­‐chain	   is	   a	   component	   of	   the	   high-­‐affinity	   receptor	   for	   IgG	   (FcγRI).	   The	  tetrameric	  form	  of	  the	  FcεRI	  is	  solely	  expressed	  in	  mast	  cells	  and	  basophils	  with	  a	  density	  of	  3x105	  molecules	  per	  single	  cell	  in	  mouse(55).	  The	  trimeric	  form	  of	  the	  FcεRI,	   lacking	   the	   FcεRIβ,	   has	   been	   detected	   only	   in	   humans,	   in	   epidermal	  Langerhans	   cell(56,	   57),	   monocytes(58),	   eosinophils(59),	   peripheral	   blood	  dendritic	   cells(60)	   and	   platelets(61).	   IgE	   have	   also	   another	   receptor,	   FcεRII	  (CD23)	  defined	  as	   IgE	   “low	  affinity”	   receptor.	  CD23	  exist	  as	  a	  membrane	  bound	  glycoprotein	   or	   a	   soluble	   processed	  molecule.	   The	  membrane	   CD23	   is	   a	   type	   II	  integral	  membrane	  protein	  with	   a	   C-­‐type	   (calcium	  dependent)	   lectin	   domain	   at	  the	   C-­‐terminal	   and	   is	   expressed	   as	   two	   different	   isoforms	   that	   differ	   in	   their	  cytoplasmic	   region.	   CD23a	   is	   constitutively	   expressed	   on	   B	   cells	   and	   CD23b	  expression	   is	   induced	   by	   IL-­‐4	   and	   is	   also	   found	   on	   T	   cells,	   Langerhans	   cells,	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monocytes,	  macrophages,	  platelets,	  and	  eosinophils(62).	  Upon	  proteolysis	  of	  the	  CD23,	   several	   different	   soluble	   peptides	   are	   generated,	   all	   with	   cytokine-­‐like	  activity(63).	   Both	   soluble	   and	  membrane	   bound	   CD23	   isoforms	   are	   thought	   to	  have	   an	   active	   role	   in	   promoting	   allergic	   responses	   in	   a	   way	   that	   is	   directly	  stimulated	  by	  the	  binding	  with	  IgE(62).	  	  	  	  	  	  	  	  	  
	  
	  
Figure	   1:	   Structure	   of	   IgE	   and	   IgE	   high	   affinity	   receptor	   (FcεRI).	   A	   class	   E	  immunoglobulin,	   IgE,	   is	  composed	  by	  two	  isotype-­‐specific	  heavy	  chains	  and	  two	  light	   chains	   (H2L2).	   The	   epsilon	   heavy	   chain	   is	   characterised	   by	   four	   Ig-­‐like	  domains	  (CH1-­‐CH4),	   three	  of	  them	  generating	  the	  Fc	  portion	  of	  the	  molecule.	   In	  red	   are	   represented	   the	   intra-­‐molecular	   disulphide	   bonds.	   The	   high	   affinity	  receptor	   for	   IgE,	  FcεRI,	  consist	  of	  one	  α	  chain,	  one	  β	  chain	  and	  two	  γ	  chains(52,	  64).	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Signalling	  downstream	  of	  FcεRI	  activation	  	  The	  signalling	  downstream	  of	  the	  FcεRI	  is	  initiated	  by	  the	  binding	  of	  a	  multivalent	  antigen	   able	   to	   contact	   several	   IgE	  molecules	   that	   are	   already	   localized	   on	   the	  surface	  of	  basophils	  or	  mast	  cells,	  bound	  to	  the	  FcεRI.	  Since	  FcεRI	  does	  not	  have	  any	   catalytic	   signalling	  activity	  per	   se,	   it	   recruits	  or	  activates	   several	   associated	  signalling	   proteins	   by	   conformational	   modification	   induced	   after	   the	   FcεRIα	  clustering	   (Figure	   2).	   The	   Src	   family	   kinase	   Lyn	   is	   constitutively	   bound	   to	   the	  FcεRIβ	   chain	   and	   upon	   receptor	   clustering	   phosphorylates	   the	   two	   tyrosine	  residues	  within	  the	  ITAMs	  of	  both	  β	  and	  γ	  chain(65,	  66).	  This	  allows	  the	  tyrosine	  kinase	  Syk	  to	  bind	  to	  the	  phosphorylated	  ITAMs	  of	  the	  γ-­‐chain	  via	  its	  tandem	  SH2-­‐domain,	   to	   be	   activated	   via	   phosphorylation	   and	   stabilized	   in	   an	   active	  conformation(67).	  Downstream	  of	   the	  activation	  of	  Syk,	   the	   linker	   for	  activation	  of	   T	   cell	   (LAT)(68,	   69)and	   the	   non-­‐T	   cell	   activation	   linker	   (NTAL)(70)	   are	  phosphorylated	   and	   act	   as	   a	   scaffold	   for	   multimeric	   signalling	   complexes,	  including	  Grb2,	  Gab2,	  Gads	  but	   also	  PLCγ1	   and	  PLCγ2(71).	   The	  phosphorylated	  form	  of	  Gab2	  is	  then	  able	  to	  recruit	  Class	  IA	  PI3K	  via	  its	  p85	  regulatory	  subunits	  and	   induces	   the	   generation	   of	   PtdIns(3,4,5)P3(72)	   by	   phosphorylating	  PtdIns(4,5)P2.	   PtdIns(3,4,5)P3	   is	   a	   secondary	   intracellular	   messenger	   able	   to	  recruits	  PH	  domain	  containing	  proteins	  such	  as	  Vav,	  PKB,	  PDK1,	  Btk	  and	  PLCγ(73,	  74)	  (Table	  3).	  Active	  PLCγ	  enzymes	  catalyse	  the	  hydrolysis	  of	  PtdIns(4,5)P2	  and	  generate	   DAG	   and	   IP3.	   DAG	   is	   known	   to	   promotes	   the	   catalytic	   activity	   of	   PKC,	  	  while	  IP3	  binds	  to	  its	  own	  receptor	  on	  the	  endoplasmic	  reticulum	  and	  promotes	  intracellular	   Ca2+	   liberation.	   The	   release	   of	   calcium	   ions	   from	   the	   ER	   induces	  conformational	  changes	  in	  the	  calcium-­‐binding	  protein	  STIM1,	  localized	  in	  the	  ER	  membrane,	   that	   interact	  with	   the	  store-­‐operated	  calcium	  channels	  ORAI1	   in	   the	  plasma	  membrane	  inducing	  their	  opening	  and	  the	  extracellular	  calcium	  entry(75,	  76).	   The	   complex	   orchestration	   of	   all	   those	   signals	   leads	   to	   the	   cellular	  degranulation	  and	  the	  “de	  novo”	  generation	  of	  signalling	  molecules	  to	  be	  released	  to	  the	  cellular	  milieu.	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Figure	   2:	   Signalling	   downstream	   of	   FcεRI.	   Representation	   of	   the	   fundamental	  events	   induced	   upon	   clustering	   of	   FcεRIα	   chains	   aggregation.	   Tyrosine	   kinases	  Lyn	  or	  Fyn	  are	  responsible	  for	  the	  phosphorylation	  of	  the	  ITAM	  motif	  present	  in	  FcεRIβ and	   FcεRIγ	  and	  for	  the	  phosphorylation	  of	  the	  adapter	  proteins Gab2,	   LAT	  or	  NTAL.	  The	  assembly	  of	  such	  a	  signalosome	  is	  required	  for	  the	  recruitment	  of	  SH2-­‐bearing	  proteins	  at	  the	  plasma	  membrane.	  The	  activation	  of	  class	  IA	  PI3Ks	  in	  this	  representation	  is	  induced	  by	  direct	  interaction	  between	  the	  pYxxM	  motifs	  of	  Gab2	   and	   the	   SH2	   domain	   of	   p85s.	   PtdIns(3,4,5)P3	   is	   a	   fundamental	   secondary	  messenger	   able	   to	   recruit	   several	   PH-­‐domain	   bearing	   proteins	   at	   the	   plasma	  membrane,	   such	  as	  Btk	   and	  PLCγ1	  and	   to	  mediate	   their	   activation.	  Btk	   is	   a	  PH-­‐domain	   bearing	   Tek	   family	   non-­‐receptor	   tyrosine	   kinase	   member.	   Once	   at	   the	  plasma	  membrane,	  Btk	  is	  phosphorylated	  by	  the	  Lyn	  kinase	  and	  undergoes	  auto-­‐phosphorylation	  as	  well	  becoming	  able	  to	  phosphorylate	  and	  activate	  PLCγ1(77).	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c-­‐Kit,	  the	  receptor	  for	  SCF	  
	  Together	   with	   the	   FcεRI,	   the	   c-­‐Kit	   receptor	   is	   one	   of	   the	   most	   characterised	  surface	   receptors	   in	   mast	   cells.	   Identified	   as	   CD117,	   c-­‐Kit	   is	   a	   transmembrane	  tyrosine	  kinase	  receptor(78)	  expressed	  on	  the	  surface	  of	  hematopoietic	  stem	  cells	  and	  on	  several	  different	  non-­‐hematopoietic	  tissues(79).	  Stem	  cells	  factor	  (SCF)	  is	  the	  ligand	  of	  c-­‐Kit	  and	  its	  binding	  induces	  homo-­‐dimerization	  of	  the	  receptor	  and	  auto-­‐phosphorylation	   of	   the	   tyrosine	   residues	   present	   in	   the	   cytoplasmic	  portion(80).	   c-­‐Kit	   activation	   induces	   direct	   binding	   of	   class	   IA	   PI3Ks	   adaptor	  subunits(81)	   to	   the	   phosphorylated	   tyrosine	   residues,	   via	   SH2	   domain,	   and	  therefore	   generation	   of	   PtdIns(3,4,5)P3.	   c-­‐Kit	   signalling	   in	  mast	   cell	   is	   not	   only	  involved	   in	   cellular	   growth	   and	   differentiation	   of	   hematopoietic	   progenitors	  (check	   “Mast	  cell	   growth	  and	  development”)	  but	   is	  also	   required	   for	  a	   full	   scale	  mast	   cell	   activation.	   Indeed,	   SCF	   stimulation	   induces	   a	   direct	   activation	   of	  PI3Kδ(82–85)	   whose	  product	   potentiate	   the	   antigen-­‐induced	   BMMC	  degranulation	   but	   is	   not	   able	   to	   induce	   degranulation	   per	   se.	   Moreover,	   SCF	  function	   as	   chemotactic	   factor	   for	  mast	   cells(86,	   87)	   inducing	   the	   activation	   of	  MAP	  kinase	  signalling	  and	  activation	  of	  the	  Src	  family	  kinase	  Lyn(82,	  88,	  89).	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ITIM	  containing	  immunoreceptors	  
	  The	  role	  of	  the	  immunoreceptor	  tyrosine-­‐based	  inhibitory	  motif	  (ITIM)	  sequences	  was	   first	   studied	  on	  FcγRIIb	  expressed	   in	  B	   cells	  where	   they	  modulate	   the	  BCR	  mediated	  activation	  in	  vitro(91).	  The	  ITIM-­‐bearing	  receptors	  belong	  to	  either	  the	  Ig	   Superfamily	   or	   C-­‐type	   (calcium	   dependent)	   lectin	   superfamily	   and	   are	  responsible	   for	   the	   membrane	   recruitment	   of	   lipid	   and	   protein	   phosphatases.	  Those	   receptors	   can	   bear	   one	   or	  more	   ITIM	   or	   ITIM-­‐like	   domains	   and	  most	   of	  them	   are	   still	   orphan	   for	   their	   ligands;	   consequently,	   most	   of	   the	   experiments	  performed	   on	   ITIM	   containing	   immunoreceptor	   were	   performed	   via	   chemical	  induced	  co-­‐clustering	  or	   in	  genetically	  modified	  mice.	  For	   instance,	   the	  receptor	  gp49B1	   express	   two	   Ig-­‐like	   domains	   on	   the	   extracellular	   portion	   and	   presents	  two	  cytoplasmic	  ITIMs.	  Its	  ligand	  has	  only	  been	  described	  in	  vitro	  as	  the	  integrin	  αvβ3(92)	  and	  its	  activation	  leads	  to	  the	  inhibition	  of	  the	  FcεRI	  signalling	  in	  mast	  cells	   via	   recruitment	   of	   SH2	   domain-­‐containing	   tyrosine	   phosphatase	   1	   (SHP1)	  rather	   than	   the	   SH2	   domain-­‐containing	   lipid	   phosphatase	   SHIP1(93).	   It	   is	  noteworthy	  that	  gp49B1	  does	  not	  require	  immunoglobulins,	  a	  product	  of	  adaptive	  immune	   response,	   to	   induces	   its	   inhibitory	   signalling.	   Paired	   Ig-­‐like	   receptor	   B	  (PIR-­‐B)	   has	   six	   Ig-­‐like	   extracellular	   domains	   and	   four	   ITIM	   domains	   and	   is	   a	  ligand	   orphan	   receptor	   as	   well.	   It	   is	   continuously	   tyrosine	   phosphorylated	   and	  associated	   with	   SHP1	   tyrosine	   phosphatase	   and	   it	   also	   controls	   mast	   cell	  activity(94).	  Mast	  Cell	   function-­‐associated	  antigen	   (MAFA)	   is	   a	   trans-­‐membrane	  receptor	  with	  a	  C-­‐type	  lectin	  domain	  on	  its	  extracellular	  domain	  and	  a	  single	  ITIM	  domain;	  it	  is	  ligand-­‐orphan	  and	  relays	  on	  SHIP1	  for	  its	  inhibitory	  activity(95).	  One	  of	   the	   most	   recently	   discovered	   ITIM-­‐bearing	   receptor	   is	   Allergin-­‐1,	   expressed	  both	   in	   human	   (mast	   cells,	   basophils,	   neutrophils	   and	   DC)	   and	   mice	   (not	  expressed	  in	  basophils)(96).	  Indeed,	  murine	  Allergin-­‐1	  is	  preferentially	  expressed	  in	  mast	  cells	  where,	  due	  to	  the	  presence	  of	  an	  ITIM-­‐like	  intracellular	  domain,	  it	  is	  able	   to	   recruit	   the	   tyrosine	   phosphatases	   SHP-­‐1	   and	   2	   as	   well	   as	   the	   5’	   lipid	  phosphatase	  SHIP1	  at	  the	  plasma	  membrane.	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FcγRIIb,	  low	  affinity	  receptor	  for	  IgG	  	  FcγRIIb	  (CD32b)	  is	  a	  low-­‐affinity	  single	  chain	  receptor	  for	  IgG,	  broadly	  expressed	  in	  hematopoietic	  cells	  as	  a	  monomeric	  trans-­‐membrane	  protein.	  FcγRIIb	  has	  two	  C2-­‐type	   IgG-­‐like	   domains	   on	   the	   extracellular	   portion	   of	   the	   membrane,	   the	  second	   of	   which	   binds	   the	   allergen-­‐specific	   IgG(97),	   whereas	   the	   cytoplasmic	  portion	   is	   characterised	   by	   the	   presence	   of	   an	   ITIM	   domain,	   a	   landmark	   of	   the	  “inhibitory	  receptors”.	   	  FcγRIIb	   is	  expressed	  on	  the	  surface	  of	  B	  cells	  but	  also	   in	  mouse	  mast	  cells	  and	  in	  human	  basophils,	  where	  it	  counteracts	  the	  FcεRI-­‐induced	  activation(98–100).	   Both	   the	   FcεRI	   and	   FcγRIIb	   are	   members	   of	   the	   Ig	  superfamily	   and	   in	   humans,	   at	   the	   level	   of	   the	   extracellular	   domain,	   the	   two	  receptors	  share	  38%	  of	   the	  primary	  sequence.	  Although	  both	   the	  α	  chain	  of	   the	  FcεRI	   (FcεRIα)	   and	   FcγRIIb	   share	   a	   typical	   conserved	   pattern	   characterized	   by	  two	  IgG-­‐like	  globular	  disulphide-­‐bonded	  domains	  of	  the	  C2	  type(101),	  they	  have	  different	   affinity	   for	   Ig.	   FcεRIα	   binds	   IgE	  with	   high	   affinity	   (Ka	  =1010	  M-­‐1)(102)	  whereas	  FcγRIIb	  binds	  IgG	  with	  low	  affinity	  (Ka	  =106	  M-­‐1)(97).	  Both,	  in	  mast	  cells	  and	  basophils,	  co-­‐aggregation	  of	  FcεRI	  with	  FcγRIIb	  protects	  the	  cells	  from	  FcεRI-­‐dependent	  activation(98,	  103).	  At	  a	  molecular	   level,	   the	  co-­‐aggregation	  of	  FcεRI	  and	   FcγRIIb	   induces	   the	   activation	   of	   the	   protein	   tyrosine	   kinase	   Lyn	   that	  phosphorylates	  the	  ITAM	  domains	  of	  FcεRI	  but	  also	  the	  ITIM	  domains	  of	  FcγRIIb	  due	  to	  the	  close	  vicinity(104).	  Phosphorylation	  of	  the	  FcγRIIb	  ITIM	  then	  induces	  the	  recruitment	  of	  the	  SH2-­‐containing	  inositol	  phosphatase	  (SHIP1)	  (105).	  	  The	  ability	  of	  antigen-­‐specific	  IgG	  to	  inhibit	  the	  IgE	  mediated	  signalling	  is	  part	  of	  the	  mechanism	  behind	  the	  allergic	  desensitization	  therapy.	   Indeed,	  the	  repeated	  and	   prolonged	   allergen	   administration	   in	   atopic	   patients	   is,	   currently,	   the	   only	  therapy	  that	  modulates	  the	  progression	  of	  the	  allergies	  by	  modifying	  the	  allergen	  specific	  T	  cell	  response.	  Interestingly,	  one	  of	  the	  effects	  produced	  in	  response	  to	  the	   therapy	   is	   the	   generation	   of	   allergen	   specific	   IgG1	   and	   IgG4(106,	   107);	  although	   the	   recruitment	   of	   the	   inhibitory	   receptor	   FcγRIIb	   mediates	   the	  silencing	  of	  the	  IgE	  mediated	  signalling,	  some	  evidences	  report	  that	  the	  inhibitory	  ability	   of	   the	   antigen-­‐specific	   IgG	   molecules	   relies	   on	   the	   ability	   to	   block	   the	  interaction	  between	  IgE	  and	  antigen(108).	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The	  phosphoinositide	  3-­‐kinase	  (PI3K)	  family	  	  The	   family	   of	   phosphoinositide	   3-­‐kinase	   enzymes	   unites	   several	   protein	  complexes	  capable	  of	  phosphorylating	  the	  inositol	  group	  of	  phosphoinositides	  at	  their	   3’	   position.	   Phosphoinositides	   are	   the	   phosphorylated	   form	   of	  phosphatidylinositol,	  a	  natural	  component	  of	  cellular	  membranes	  and	  contain	  two	  non-­‐polar	   fatty	   acids	   that	   anchor	   the	   molecule	   to	   the	   membrane,	   linked	   to	   a	  glycerol	  backbone	  and	  an	   inositol	  ring	  connected	  via	  a	  phosphate	  group	  (Figure	  4)(109).	   The	   generation	   of	   different	   phosphoinositides	   activates	   a	   plethora	   of	  downstream	  signalling	  events	  that	  regulate	  cellular	  growth,	  proliferation	  but	  also	  cellular	  migration	  and	  endo/exocytotic	  events.	  The	  first	  reports	  of	  proteins	  with	  phosphatidylinositol	   kinase	   activity	   were	   published	   almost	   thirty	   years	   ago	  describing	   the	   ability	   of	   tyrosine	   kinase	   proteins	   involved	   in	   tumorigenesis	   to	  phosphorylate	  phosphatidylinositol(110–112),	  while	  some	  years	  later	  Cantley	  lab	  published	   the	   first	   work	   that	   described	   a	   novel	   inositol	   phospholipid,	  phosphatidylinositol-­‐3-­‐phosphate(113)	   and	   since	   then	   the	   PI3K	   field	   has	   been	  extensively	   investigated.	  The	  discovery	  of	   the	  first	  molecular	   inhibitors	  of	  PI3Ks	  enzymes,	   such	   as	   wortmannin(114,	   115),	   enhanced	   the	   understanding	   of	   the	  basic	   mechanism	   regulating	   phospholipid	   biology	   and	   allowed	   researchers	   to	  focus	  on	  PI3K	  as	  a	  potential	  therapeutical	  target.	  	  PI3Ks	   enzymes	   catalyse	   the	   transfer	   of	   the	   γ-­‐phosphate	   group	   of	   adenosine	  triphosphate	   (ATP)	   to	   the	   D-­‐3	   position	   of	   the	   inositol	   ring	   of	   the	   phosphatidyl	  inositol.	  Enzymes	  belonging	   to	   the	  PI3K	   family	  generate	  different	  products	  such	  as	   PtdIns(3)P,	   PtdIns(3,4)P2	   or	   PtdIns(3,4,5)P3	   and	   such	   molecules	   function	   as	  docking	   sites	   for	   various	   protein	   effectors	   that	   interact	   with	   phospholipidic	  domains.	   Indeed,	   class	   I	   PI3K	   enzymes	   are	   able	   to	   phosphorylate	   the	   plasma	  membrane	   localized	   PtdIns(4,5)P2	   and	   generate	   PtdIns(3,4,5)P3,	   a	   molecule	  recognized	   by	   proteins	   containing	   a	   pleckstrin	   homology	   (PH)	   domain	   such	   as	  Grp1	  or	  Btk	   (Table	  3)(116,	  117).	  One	  of	   the	  most	   investigated	   targets	  activated	  downstream	  of	  PI3Ks	  is	  the	  Ser/Thr	  protein	  kinase	  B	  (PKB,	  also	  called	  Akt).	  PKB	  is	  recruited	  at	  the	  plasma	  membrane	  due	  to	  its	  PH	  domain	  and	  is	  phosphorylated	  and	   activated	   by	   the	   phosphoinositide-­‐dependent	   kinase	   (PDK1)	   at	   the	   level	   of	  the	  Threonine	  308	  and	  by	  mammalian	  target	  of	  rapamycin	  complex	  2	  (mTORC2)	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at	  the	  level	  of	  the	  Serine	  473(118).	  This	  event	  is	  followed	  by	  a	  plethora	  of	  cellular	  responses	   that	   lead	   to	   cellular	   growth,	   cytoskeletal	   reorganization,	   changes	   in	  cellular	  metabolism	  and	  differentiation.	  The	  PI3K	  family	  has	  been	  divided	  in	  three	  classes,	   I,	   II	   and	   III,	   based	  on	   sequence	  homology,	   protein	  domain	  organization,	  substrate	  specificity	  and	  regulation	  (109,	  119).	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Class	  I	  PI3Ks	  	  Class	   I	   PI3K	   enzymes	   are	   heterodimeric	   proteins	   composed	   by	   a	   regulatory	  subunit	  and	  a	  catalytic	  subunit	  and	  share	  a	  common	  domain	  organization	  having	  a	  N-­‐terminal	   adaptor-­‐binding	  domain	   (ABD),	   a	  Ras-­‐binding	  domain	   (RBD),	   a	  C2	  domain,	  a	  helical	  domain	  and	  a	  kinase	  domain	  divided	  in	  a	  N-­‐	  and	  a	  C-­‐lobe	  (Figure	  5).	   The	   region	   containing	   the	   helical	   domain	   and	   the	   two	   lobes	   has	   some	  similarities	   with	   the	   catalytic	   domain	   of	   protein	   kinases(127).	   The	   class	   IA	  regulatory	  subunits	  contain	  two	  Src	  homology	  2	  domains,	  nSH2	  and	  cSH2,	  with	  an	  interposed	  coiled-­‐coil	  domain	  called	   inter-­‐SH2	  (iSH2)	   that	  mediates	   the	  binding	  to	   p110.	   Class	   I	   PI3K	   enzymes	   are	   the	   only	   family	   members	   able	   to	   convert	  plasma	   membrane	   localized	   PtdIns(4,5)P2	   to	   PtdIns(3,4,5)P3	   and	   are	   activated	  either	   via	   receptor	   tyrosine	   kinases	   (RTK)	   or	   G	   protein-­‐coupled	   receptors	  (GPCRs)	  activation.	  Based	  on	  the	  activation	  mode,	  class	  I	  is	  further	  sub-­‐divided	  in	  class	  IA	  a	  class	  IB.	  
	  
	  
Class	  IA	  PI3Ks	  	  Class	  IA	  PI3K	  enzymes	  are	  heterodimeric	  protein	  complexes	  containing	  a	  catalytic	  subunit	  variant	  of	  p110	  (one	  among	  p110α,	  p110β	  and	  p110δ)	  and	  one	  of	  the	  five	  adaptor	  subunit	  variants	  (p85α,	  p55α,	  p50α,	  p85β	  or	  p55γ).	  Three	  genes,	  Pik3ca,	  
Pik3cb	  and	  Pik3cd,	  code	  for	  the	  three	  catalytic	  subunits,	  p110α,	  p110β	  and	  p110δ	  respectively,	  whereas	   the	  adaptor	  subunits	  p85α,	  p55α	  and	  p50α	  are	  generated	  by	   alternative	   splicing	   from	   the	   Pik3r1	   gene;	   p85β	   and	   p55γ	   are	   encoded	   by	  Pik3r2	   gene	   and	   Pik3r3	   gene	   respectively	   (details	   about	   the	   genes	   encoding	  different	   PI3K	   subunits	   are	   present	   in	   Table	   2).	   Not	   a	   lot	   of	   information	   is	  available	  about	  preferences	  or	  specificity	  of	  the	  interaction	  between	  the	  catalytic	  and	  the	  adaptor	  subunits,	  since	  all	  the	  three	  catalytic	  subunits	  can	  complex	  with	  the	   five	  adaptors.	  Class	   IA	  PI3Ks	  can	  be	  activated	  upon	  receptor	  tyrosine	  kinase	  activation	   or	   phosphorylation	   of	   adaptor	   proteins.	   The	   binding	   of	   a	   ligand	   to	   a	  receptor	   tyrosine	   kinase	   (RTK)	   induces	   dimerization	   of	   the	   receptor	   and	   auto-­‐phosphorylation	   of	   its	   tyrosine	   residues	   that	   are	   recognized	   by	   SH2	   domain-­‐
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containing	  molecules,	   for	   instance	  p85.	  The	  binding	  of	   the	  regulatory	  subunit	   to	  tyrosine-­‐phosphorylated	  pYXXM	  motifs	  (Y	   is	  Tyr,	  X	   is	  any	  amino	  acid,	  M	   is	  Met)	  triggers	  the	  activation	  of	  the	  p110	  catalytic	  subunit	  of	  PI3Ks(128).	  In	  the	  case	  of	  p110α,	   a	   crystal	   structure	   analysis	   showed	   that	   the	   iSH2	   domain	   of	   p85α	   is	  localised	   in	   a	   crevasse	   formed	  by	   the	   catalytic	   subunit,	   in	   contact	  with	   the	  ABD	  and	   the	   C2	   domain	   of	   p110(129).	   The	   binding	   of	   the	   regulatory	   subunit	   to	   the	  phospho-­‐tyrosine	  motifs	  induces	  modifications	  in	  the	  inhibitory	  contacts	  between	  p85	   and	   p110	   that	   keeps	   the	   enzyme	   in	   an	   inactive	   state	   and	   leads	   to	   the	  activation	   of	   the	   lipid	   kinase	   at	   the	   plasma	   membrane.	   Class	   IA	   PI3Ks	   can	   be	  recruited	  and	  activated	  by	  plasma	  membrane	  localized	  adaptor	  proteins	  as	  well.	  For	  instance,	  PI3Ks	  can	  be	  activated	  via	  insulin	  receptor	  substrate	  1	  (IRS1)	  or	  via	  the	   growth	   factor	   receptor-­‐bound	   protein	   2,	   Grb2,	   which	   binds	   to	   the	   Grb2-­‐associated	   binding	   protein,	   GAB;	   in	   both	   case	   p85	   interacts	   with	   the	  phosphorylated	   tyrosine	   residues	   of	   those	   proteins,	   leading	   to	   the	   activation	   of	  p110.	  In	  addition	  there	  is	  a	  third	  possibility:	  it	  is	  the	  case	  of	  Grb2,	  which	  binds	  to	  the	  phosphor-­‐YXN	  motif	  of	  the	  RTK	  and	  recruits	  SOS	  (Son	  of	  Sevenless),	  Ras	  and	  GAB,	  activating	  p110	  independently	  of	  p85(130).	  Due	  to	  their	  involvement	  in	  the	  regulation	  of	   the	  cellular	  growth,	  motility	  and	  differentiation,	  aberrations	  of	   the	  class	  IA	  PI3K	  family	  enzymes	  signalling	  are	  one	  of	  the	  most	  frequent	  occurrences	  in	  human	  cancer(131,	  132).	  The	  most	  prominent	  example	  is	  the	  case	  of	  activating	  somatic	  mutations	  at	  the	  level	  of	  the	  PIK3CA	  gene	  (p110α)(133,	  134).	  	  A	  lot	  of	  informations	  about	  PI3K	  signalling	  have	  been	  gained	  by	  the	  generation	  of	  genetically	  modified	  mice	  bearing	  either	  a	  null	  allele	  or	  expressing	  a	  kinase	  dead	  enzyme	   for	   the	   three	   members	   of	   class	   IA	   PI3K	   family.	   The	   first	   attempts	   to	  generate	   mice	   lacking	   p110α	   or	   p110β	   demonstrated	   that	   the	   two	   catalytic	  subunits	   of	   class	   I	   PI3K	   are	   indispensable	   for	   a	   correct	   development	   since	   the	  mice	   died	   as	   embryos(135,	   136).	   However,	   the	   targeting	   of	   the	   two	   catalytic	  subunits	  has	  been	  obtained	  either	  by	  using	  a	  tissue	  specific	  deletion	  of	  the	  gene	  or	  by	   the	   overexpression	   of	   a	   kinase-­‐dead	   isoform	   of	   the	   enzyme,	   both	   for	  p110α(137,	  138)	  and	  p110β(139,	  140).	  Mice	  lacking	  PI3Kδ	  are	  generally	  healthy	  and	   without	   an	   external	   phenotype;	   the	   generation	   of	   the	   first	   knock-­‐in	   strain	  contributed	  to	  elucidate	  the	  role	  of	  p110δ	  in	  antigen	  receptor	  signalling	  in	  B	  and	  T	  cells(141).	  




Figure	   5:	   Class	   I	   PI3K	   enzymes	   family.	   The	   N-­‐terminal	   portion	   of	   the	   four	  catalytic	  subunit	  shares	  a	  similar	  domain	  organization	  and	  the	  main	  difference	  is	  in	  the	  adaptor	  subunit-­‐binding	  domain	  (p85	  isoform	  for	  class	  IA	  and	  p84	  /	  p101	  for	  class	   IB).	  All	   the	  p85	  adaptors	  have	  two	  Src	  homology	  2	  (SH2)	  domains	  that	  mediate	   the	   plasma	   membrane	   recruitment.	   In	   p85α	   and	   p85β	   there	   is	   a	   N-­‐terminal	  SH3	  domain	  that	  mediates	  the	  binding	  to	  proline	  rich	  and	  hydrophobic	  regions,	  two	  proline-­‐rich	  repeats	  and	  a	  Breakpoint	  cluster	  BCR	  homology	  domain,	  BH	   that	   mediates	   the	   interaction	   with	   the	   Rho	   GTPase	   family	   members.	   The	  specificity	  of	  the	  single	   isoform	  of	  the	  p85	  adaptors	   is	  not	  known.	  Both	  p84	  and	  p101	   present	   a	   N-­‐terminal	   Ras	   binding	   domain	   and	   a	   C-­‐terminal	   Gβ/γ	   binding	  domain	  that	  mediate	  the	  plasma	  membrane	  localization	  and	  activation	  of	  PI3Kγ.	  p101	  present	   three	  nuclear	   localization	  sequences	  (NLS)	   that	  are	  not	  present	   in	  p84	  but	  their	  functional	  role	  is	  currently	  not	  known.	  Adapted	  from(142).	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Class	  IB	  PI3Ks	  	  PI3Kγ	   is	   the	   only	   member	   of	   class	   IB	   PI3K	   family	   identified	   so	   far	   and	   is	   a	  heterodimeric	   enzyme	   formed	  by	  a	   catalytic	   subunit,	   p110γ	  and	  one	  of	   the	   two	  adaptor	  subunits,	  p84	  and	  p101.	  p110γ	  shares	  several	  features	  with	  the	  catalytic	  subunits	  of	  the	  class	  IA	  PI3Ks	  but	  appears	  to	  be	  solely	  expressed	  in	  mammalians	  and	   particularly	   in	  white	   blood	   cells(143–145).	   The	   two	   adaptor	   subunits,	   p84	  and	  p101	  are	  encoded	  by	  two	  neighbours	  genes,	  Pik3r6	  and	  Pik3r5	  respectively,	  localized	  on	  the	  same	  chromosome	  both	  in	  human	  (17p13.1)	  and	  mouse	  (11	  band	  B3)	  (Table	  4).	  The	  two	  adaptors	  present	  about	  30%	  of	  aminoacid	  identity	  at	  the	  N-­‐	   and	   C-­‐terminus	   of	   the	   protein	   and	   differ	   in	   the	   core.	   The	   main	   difference	  between	  the	  two	  proteins	  is	  the	  presence	  of	  a	  nuclear	  localization	  sequence	  (NLS)	  in	  p101,	  but	  not	  in	  p84,	  whose	  physiological	  role	  is	  currently	  not	  known.	  Both	  p84	  and	  p101	  present	  a	  binding	  domain	  that	  mediates	  the	  interaction	  with	  p110γ	  at	  the	   N-­‐terminus	   end(146,	   147),	   whereas	   at	   the	   C-­‐terminus	   present	   a	   Gβγ	  association	   region(146);	   p84	   and	   p101	   bind	   to	   p110γ	   in	   a	   mutual	   exclusive	  fashion(148).	  PI3Kγ	   is	   mainly	   activated	   downstream	   G	   protein-­‐coupled	   receptors	   (GPCRs).	  Heterotrimeric	  G	  proteins	  are	  composed	  by	  an	  α,	  a	  β	  and	  a	  γ	  subunit	  and	  in	  their	  inactive	  status	  are	  bound	  to	  guanosine	  diphosphate	  (GDP).	  The	  binding	  of	  a	  ligand	  to	  GPRCs	  induces	  a	  conformational	  change	  in	  the	  receptor,	  resulting	  in	  a	  reduced	  affinity	   of	  Gα	   subunit	   for	  GDP	  and	   increased	   affinity	   for	  GTP;	   together	  with	   the	  switch	  GDP-­‐GTP,	  there	  is	  also	  the	  dissociation	  of	  Gα	  from	  the	  complex(149).	  This	  leads	   to	   the	   separation	   from	   the	   Gβγ	   dimer	   that	   now	   is	   able	   to	   diffuse	   at	   the	  plasma	  membrane	  and	  to	  contact	  potential	  effector	  proteins(150).	  	  Currently,	   little	   information	   is	   available	   about	   the	   physiological	   role	   of	   the	   two	  adaptor	  subunits	  in	  the	  activation	  of	  PI3Kγ.	  Indeed,	  Bohnacker	  et	  al.	  showed	  that	  PI3Kγ	   uses	   only	   p84	   as	   adaptor	   subunit	   in	   BMMC	   (p101	   not	   being	   expressed)	  although	  overexpression	  experiments	  showed	  a	  partial	  redundancy	  between	  p84	  and	  p101	  activity	  in	  PI3Kγ	  mediated	  cellular	  responses(151).	  In	  the	  same	  year	  it	  was	   showed	   that	   the	   small	   monomeric	   GTPase	   Ras	   is	   an	   indispensable	   co-­‐activator	  of	   the	  p110γ/p84	  complex,	  but	  not	  of	   the	  p110γ/p101	  heterodimer	   in	  transfected	  HEK293	  cells	  and	  complemented	  BMMC.	  Interestingly,	  a	  recent	  work	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published	  by	  Walser	  et	  al(152)	  showed	  that	  PI3Kγ	  can	  be	  activated	  without	   the	  support	   of	   the	   adaptor	   subunit	   p84	   in	   BMMC.	   Indeed,	   by	   using	   Thapsigargin,	   a	  Ca2+-­‐mobilising	  agent,	   they	  demonstrated	   that	  PKCβ	   is	  activated	  upon	   increased	  level	  of	   intracellular	  Ca2+	   and	   is	   able	   to	  phosphorylate	   the	   serine	  582	  of	  p110γ,	  promoting	  its	  lipid	  kinase	  activity.	  It	  is	  noteworthy	  that	  the	  activation	  of	  PI3Kγ	  by	  phosphorylation	  requires	  p110γ	  not	  to	  be	  in	  complex	  with	  p84,	  since	  the	  binding	  of	   p84	   to	   p110γ	  masks	   the	   phosphorylation	   site	   and	   inhibits	   the	   access	   to	   the	  residue.	  However,	  the	  complete	  understanding	  of	  the	  dynamics	  and	  the	  functions	  of	  the	  adaptor	  subunits	  of	  PI3Kγ	  has	  not	  been	  achieved	  yet.	  The	   role	   of	   PI3Kγ	   is	   not	   only	   restricted	   to	   the	   immune	   system.	   For	   instance,	  Perino	   A.	   et	   al.(153)	   showed	   that	   PI3Kγ	   has	   an	   important	   role	   in	   regulating	  myocardial	   contractility	   due	   to	   its	   ability	   to	   bind	   protein	   kinase	  A,	   PKA,	   and	   to	  induce	   the	   formation	  of	  a	   complex	   together	  with	   the	  phosphodiesterase	  PDE3B.	  Interestingly,	  on	  one	  hand	  PKA	  is	  a	  cAMP-­‐dependent	  protein	  kinase	  that	  activates	  PDE3B,	   a	  physiological	   regulator	  of	   the	  myocardial	   contractility	   that	  hydrolyses	  cAMP	   to	  5’-­‐AMP.	  On	   the	   other	  hand	  PKA	  phosphorylates	  p110γ	   and	   inhibits	   its	  lipid	   kinase	   activity.	   In	   this	   context	   p110γ	   becomes	   the	   centre	   of	   a	   signalling	  complex	   that	   modulate	   the	   cAMP	   signalling	   and,	   consequently	   the	   myocardial	  contractility,	   but	   also	   controls	   the	   generation	   of	   plasma	   membrane	  PtdIns(3,4,5)P3	  and	  the	  activation	  of	  the	  PtdIns(3,4,5)P3-­‐dependent	  downstream	  pathways.	  Another	  example	   is	  given	  by	  two	  publications	   from	  2011	  that	  showed	  a	  role	   for	  PI3Kγ	   as	   a	   promoter	   of	   obesity	   and	   insulin	   resistance	   in	   high	   fat	   diet	   fed	  mice.	  Interestingly,	   Kobayashi	   et	   al.(154)	   demonstrate	   that	   mice	   lacking	   PI3Kγ	   are	  protected	   from	   high-­‐fat	   diet	   induced	   insulin	   resistance	   and	   elevated	   hepatic	  content	   of	   triglyceride	   (steatosis)	   and	   show	   a	   reduction	   of	   macrophage	  infiltration	   in	   adipose	   tissue,	   a	   recognised	   key	   feature	   of	   metabolic	   syndrome.	  Interestingly	  the	  same	  phenotype	  was	  reproduced	  by	  knocking	  out	  PI3Kγ	  in	  mice	  that	  develop	  obesity	  as	  a	  consequence	  of	  their	  genetic	  background,	  demonstrating	  that	   PI3Kγ	   exert	   its	   protective	   role	   by	   influencing	   the	   generation	   of	   a	   systemic	  inflammation,	  independently	  from	  the	  body	  weight	  status.	  	  Few	  months	  later	  Becattini	  et	  al.	  (155)	  described	  PI3Kγ	  as	  a	  negative	  regulator	  of	  the	   diet-­‐induced	   thermogenesis	   and	   as	   a	   promoter	   of	   obesity	   and	   insulin	  
	  	  	  	  	  	  	  	  	  	  	  Introduction	  
30	   	  
resistance.	  Furthermore,	  by	  performing	  bone	  marrow	  reconstitution	  experiments,	  they	  demonstrated	  that	  PI3Kγ	  activity	  on	  diet-­‐induced	  obese	  mice	  depends	  on	  its	  lipid	  kinase	  activity	  within	  a	  non-­‐hematopoietic	  compartment,	  not	  identified	  yet.	  This	  represent	  an	  extremely	  interesting	  finding	  since	  it	  allowed	  us	  to	  postulate	  a	  more	   convoluted	   involvement	   of	   the	   class	   IB	   PI3K	   member	   outside	   of	   its	  traditional	  role	  in	  leukocytes/GPCR-­‐associated	  responses	  and	  designate	  PI3Kγ	  as	  a	  potential	  pharmaceutical	  target	  as	  a	  metabolic	  regulator.	  	  	  	  	  	  	  	  	  	  
Table	  4:	  Class	  I	  PI3K	  family	  members	  and	  chromosomal	  location	  
	  	  	  	  	  	  	  
Gene Chr Gene Chr
p110	α PIK3CA 3q26.3 Pik3ca 3	B
p110	β PIK3CB 3q22.3 Pik3cb 9	E4




p85	β PIK3R2 19q13.2 PIK3r2 8	B3.3
p55	γ PIK3R3 1p34.1 PIK3r3 4	D1
p110	γ PIK3CG 7q22.3 Pik3cg 12	B
p84 PIK3R5 17p13.1 PIK3r5 11	B3









PIK3R1 5q13.1 PIK3r1 13	D1
	  	  	  	  	  	  	  	  	  	  	  Introduction	  
31	  	  
Role	  of	  class	  I	  PI3K	  in	  lymphocytes	  biology	  	  Three	   classes	   of	   receptors	   mainly	   regulate	   lymphocyte’s	   development	   and	  functionality:	   cytokines	   receptors	   superfamily,	   B	   and	   T	   cell	   antigen	   specific	  receptors	   and	   co-­‐stimulatory	   receptors.	   While	   the	   stimulation	   of	   cytokines	  receptors	   superfamily	  mainly	   induces	   the	   activation	   of	   the	   JAK	   protein	   kinases	  family(156),	   antigen-­‐specific	   and	   co-­‐stimulatory	   receptors	   stimulation	   mainly	  promotes	   the	   activation	   of	   Src,	   Tec	   and	   Zap70/Syk	   tyrosine	   kinases.	   Although	  some	   evidences	   correlate	   the	   activation	   of	   cytokines	   receptors/JAK	   pathway	   to	  PI3K	   signalling(157,	   158),	   the	   canonical	   activation	   of	   class	   IA	   PI3K	  members	   is	  based	  on	   the	   interaction	  between	  phosphorylated	   tyrosine	   residues	  and	   the	  Src	  Homology	  2	   (SH2)	   domains	   of	   p85	   adaptor	   subunits.	   Is	   noteworthy	   to	  mention	  that	   chemokines,	   a	   family	   of	   signalling	   proteins	   involved	   in	   chemotaxis	  (chemotactic	   cytokines),	   due	   to	   their	   ability	   to	   interact	  with	   GPCRs,	   induce	   the	  activation	  of	   class	   IB	  PI3K,	   PI3Kγ,	   although	   there	   are	   evidences	   that	   also	  PI3Kβ	  might	  be	  activated	  by	  chemokine	  receptors(139,	  159).	  The	   TCR-­‐mediated	   recognition	   of	   the	   antigen-­‐MHC	   complex	   in	   naïve	   T	   cells,	   a	  process	   described	   as	   immunological	   synapsis,	   is	   characterised	   by	   a	   plethora	   of	  cytoplasmic	   modifications	   that	   lead	   to	   the	   formation	   of	   a	   signalosome.	   The	  recruitment	  of	  p85	  adaptor	   subunits	  at	   the	  plasma	  membrane	   leads	   to	  a	   rise	   in	  PtdIns(3,4,5)P3	  production	  and	  a	  rapid	  increase	  of	  cytoplasmic	  calcium	  ions	  due	  to	   the	   activation	   of	   PLCγ1	   and	   to	   the	   following	   intracellular	   calcium	   stores	  opening(160–162).	  	  Evidences	  that	  PI3Ks	  play	  a	  role	  in	  lymphocytes	  biology	  came	  from	  experiments	  performed	  in	  presence	  of	  pan-­‐PI3K	  inhibitors.	  Wortmannin	  and	  LY294002	  were	  showed	   to	   be	   able	   to	   block	   both	   antigen-­‐induced	   IL-­‐2	   production	   and	   CD4+	  differentiation	   but	   also	   co-­‐receptor	   (CD3)	   induced	   IL-­‐2	   production	   and	   CD8+	  proliferation	  in	  T	  cells(163,	  164).	  The	  secretion	  of	  IL2	  and	  the	  expression	  of	  IL-­‐2	  receptors	   produces	   an	   autocrine	   stimulation	   that	   lead	   to	   a	   clonal	   expansion,	  resulting	  in	  the	  creation	  of	  a	  pool	  of	  antigen-­‐specific	  cells	  ready	  to	  respond	  to	  the	  stimulation.	  	  Interestingly,	   mice	   lacking	   p110γ show	   a	   diminished	   proliferative	   response	   to	  antibody-­‐mediates	   stimulation	   of	   CD3,	   the	   TCR	   co-­‐stimulatory	   receptor	   whose	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canonical	   activation	   promotes	   Lck	   and	   ZAP-­‐70	   tyrosine	   kinases	   activation	   and	  recruitment	  of	  class	  IA	  PI3Ks.	  Interestingly,	  this	  inhibition	  is	  partially	  rescued	  by	  anti-­‐CD28	  or	  IL2	  stimulation(165).	  In	  the	  same	  study,	  the	  authors	  demonstrated	  that	  PI3Kγ is	  activated	  upon	  TCR	  ligation,	  it	  associates	  with	  Lck,	  Zap70	  and	  Gαq/11	  and	   contributes	   to	   the	   generation	   of	   a	   pool	   of	   PIP3	   that	   localizes	   at	   the	  immunological	  synapsis	  formed	  during	  the	  APC-­‐T	  cells	  interaction.	  Mice	   lacking	   p110γ also show	   a	   reduced	   thymocyte	   populations	   that	   reflect	  defects	   during	   the	   maturation	   process	   with	   an	   increase	   of	   CD4-­‐	   CD8-­‐	   double	  negative	   T	   cells	   compared	   to	   wild	   type	   littermates(166).	   Interestingly,	  PI3Kγ seems	  not	  to	  play	  a	  key	  role	  in	  B	  cells(167).	  	  	  The	   complete	  ablation	  of	  p110δ	   generate	  mice	   that	  do	  not	   show	  any	   significant	  difference	  in	  the	  morphology	  and	  composition	  of	  the	  peripheral	  blood	  or	  the	  bone	  marrow	  and	  do	  not	  show	  any	  significant	  defect	  in	  stimulation-­‐induced	  responses	  in	  T	  cells	  in	  comparison	  with	  wild	  type	  mice;	  on	  the	  other	  hand	  those	  mice	  show	  both	  a	  defective	  B1	  and	  marginal	   zone	  B-­‐cell	   development,	   a	   general	  decreased	  expression	   of	   serum	   immunoglobulin	   in	   unstimulated	   cells	   (especially	   IgM	   and	  IgG1)	  and	  a	  defective	  humoral	  response(168,	  169).	   Interestingly,	  as	  result	  of	   the	  targeting,	   those	  mice	  showed	  a	  reduced	  expression	  of	   the	  class	   IA	  PI3K	  adaptor	  subunits.	   Interestingly,	   mice	   expressing	   a	   catalytically	   inactive	   isoform	   of	  p110δ (p110δ knock-­‐in)	   show	   a	   reduced	   antigen	   receptor	   signalling	   in	   B	   and	   T	  cells(141),	   an	   increased	   IgE	   production	   and	   a	   tendency	   to	   develop	  autoimmunity(170–172).	   More	   over	   it	   has	   been	   show	   that	   mice	   lacking	  p110δ, fail	   to	   down-­‐regulate	   the	   RAG	   genes	   expression	   in	   immature	   B-­‐cells,	   a	  process	   that	   is	   essential	   for	   the	   receptor	   editing	   and	   the	   progression	   to	   the	  mature	  B	  cells	  stage(173).	  Interestingly	  this	  phenomenon	  was	  already	  reported	  in	  experiment	  performed	  using	  Wortmannin,	  a	  pan-­‐PI3K	  inhibitor(174,	  175).	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Ras	  small	  GTPases	  and	  Class	  I	  PI3K	  	  Ras	   is	   one	   of	   the	   most	   extensively	   investigated	   families	   of	   small	   monomeric	  GTPases	  and	  class	   I	  PI3Ks	  are	  well-­‐known	  effectors	  of	  Ras.	  Ras	   family	  members	  are	   ubiquitously	   expressed	   21kDa	   proteins,	   whose	   identification	   is	   due	   to	   the	  pioneering	   studies	   performed	   on	   the	   tumorigenic	   ability	   of	   unidentified	   virus	  preparations	   in	   rodents	   that	   revealed	   the	   existence	   of	  mutated	   gene	   sequences	  able	   to	  promote	   cancerous	  growth	  of	   the	   tissues(176,	  177).	   Indeed,	  Ras	  plays	  a	  key	  regulatory	  role	  in	  cellular	  proliferation,	  differentiation	  and	  apoptosis(178)	  by	  modulating	   the	   activation	  of	   several	   intracellular	   pathways	   such	   as	  MAPK	   (Raf-­‐MEK-­‐ERK)	  or	  PI3K	  itself.	  Members	  of	  Ras	  protein	  family	  share	  more	  then	  80%	  of	  sequence	   homology	   and	   generally	   differ	   in	   their	   C-­‐terminal	   sequence,	   the	  hypervariable	   domain(179).	   Nevertheless,	   all	   Ras	   isoform	   present	   a	   four	  aminoacid	  sequence	  at	  the	  C-­‐terminus,	  named	  CAAX	  box,	  where	  C	  is	  a	  cysteine,	  A	  is	   an	   aliphatic	   amino	   acid	   and	   X	   is	   a	   variable	   aminoacid,	   that	   upon	   post-­‐translational	  modifications	  allows	  Ras	  localization	  at	  the	  plasma	  membrane.	  After	  protein	  translation,	  the	  first	  modification	  of	  the	  CAAX	  box	  is	  the	  isoprenylation	  of	  Ras,	   namely	   the	   attachment	   of	   a	   15-­‐carbon	   isoprenyl	   group	   farnesyl	   to	   the	  sulfhydryl	  group	  of	  the	  cysteine(180).	  The	  same	  cysteine	  residue	  can	  alternatively	  be	  modified	  with	   the	  adding	  of	  a	  20-­‐carbon	  geranylgeranyl	   isoprenyl	  unit(181).	  Two	   different	   enzymes	   have	   been	   identified	   in	   eukaryotes:	   Farnesyltransferase	  (FTase)	  and	  Geranylgeranyltransferase-­‐I	  (GGTase-­‐I)(180).	  After	  farnesylation	  of	  the	  cysteine	  residue	  of	  the	  CAAX,	  the	  last	  three	  amino	  acids	  of	   the	   CAAX	   box	   are	   cleaved	   by	   RAS-­‐converting	   enzyme-­‐1	   (RCE-­‐1)	   and	   the	  carboxy	   terminal	   cysteine	   is	   methylated(179,	   182,	   183);	   those	   modifications	  allow	  Ras	  to	  localize	  at	  the	  plasma	  membrane	  and	  to	  be	  able	  to	  participate	  to	  the	  signalling.	  	  Once	   at	   the	   plasma	   membrane,	   Ras	   proteins	   are	   founded	   in	   their	   active	   state,	  bound	  to	  guanosine	  triphosphate	  (GTP)	  or	  in	  a	  inactive	  form,	  bound	  to	  guanosine	  diphosphate	   (GDP)(184)	   and	   by	   virtue	   of	   their	   dual	   ontology,	   Ras	   proteins	  function	  as	  a	  molecular	  switch	  within	  the	  cellular	  systems.	  Indeed,	  the	  exchange	  of	  GDP	  for	  GTP	  induces	  a	  conformational	  status	  change	  that	  influences	   the	   binding	   of	   Ras	   to	   their	   effectors,	   mainly	   by	   affecting	   two	  motile	  
	  	  	  	  	  	  	  	  	  	  	  Introduction	  
34	   	  
regions	  of	  the	  proteins,	  the	  switch	  I	  (residue	  32-­‐40)	  and	  switch	  II	  (residue60-­‐76)	  regions(185).	  	  Both	  the	  rate	  of	  GTP	  hydrolysis	  and	  the	  nucleotide	  exchange	  in	  Ras	  proteins	  are	  enhanced	   and	   regulated	   by	   accessory	   proteins	   such	   as	   guanine	   nucleotide	  exchange	  factors,	  GEFs(186),	  or	  GTPase	  activating	  proteins,	  GAPs(187).	  While	  the	  GEFs	  promote	  the	   formation	  of	  active	   -­‐	  GTP-­‐associated	   -­‐	  Ras,	   the	  GAPs	  promote	  the	  Ras	  hydrolytic	  activity	  and	   the	   transition	   to	  an	   inactive	  status.	   Interestingly,	  germline	  deletions	   or	   loss	   of	   function	  mutations	   in	   one	  of	   the	  GAP	  of	  Ras,	  NF1,	  result	  in	  a	  deregulation	  of	  Ras	  signalling	  that	  leads	  to	  elevated	  levels	  of	  Ras-­‐GTP	  and	  is	  associated	  with	  a	  predisposition	  to	  develop	  a	  variety	  of	  benign	  and	  malign	  tumors(188).	  	  All	  Ras	  effectors	  contain	  a	  Ras	  binding	  domain	  (RBD)	  that	  in	  class	  I	  PI3K	  enzymes	  is	  localized	  at	  the	  N-­‐terminus,	  just	  after	  the	  adaptor	  subunit	  binding	  domain	  and	  whose	   tertiary	   structure	   consist	   of	   5	   β-­‐sheets	   flanked	   by	   2	   α-­‐helices	   (189).	   A	  recent	  work	  describes	   7	  members	   of	  Ras	   family	   being	   able	   to	   interact	  with	   the	  p110-­‐RBD:	  H-­‐Ras,	  K-­‐Ras4A,	  K-­‐Ras4B,	  N-­‐Ras,	  R-­‐Ras,	  R-­‐Ras2,	  R-­‐Ras3(190).	  The	   result	   of	   the	   crystal	   structure	   analysis	   of	   the	   p110γ/Ras	   complex(191),	  published	   in	  2000,	   	   provided	   several	   indication	  about	   the	  molecular	   interaction	  between	   the	   two	   molecules.	   Indeed,	   X-­‐ray	   crystallography	   analysis	   showed	   a	  critical	   loop	   in	   the	   p110γ RBD	   that,	   differently	   from	   other	   Ras	   downstream	  effectors,	  interacts	  with	  both	  switch	  I	  and	  switch	  II	  regions	  of	  GTP-­‐bound	  Ras	  and	  indicate	   a	   possible	   allosteric	   modulation	   of	   Ras-­‐mediated	   p110γ activation.	  Furthermore,	  the	  same	  work	  indicated	  that	  the	  substitution	  of	  five	  residues	  in	  the	  p110γ RBD	   (T232D,	   K251A,	   K254S,	   K255A	   and	   K256A,	   “DASAA”	   mutant)	  generates	   a	   Ras-­‐binding	   deficient	   PI3Kγ.	   The	   first	   “in	   vivo”	   report	   showing	   the	  interaction	  between	  Ras	  and	  PI3K	  describes	  a	  reduced	  PtdIns(3,4,5)P3	  generation	  in	   neutrophils	   isolated	   from	   genetically	   modified	   p110γDASAA	   mice(192)	   and	  indicates	  the	  requirement	  of	  Ras	  for	  PI3Kγ activation.	  	  The	  “Project	  II”	  part,	  contained	  in	  this	  manuscript,	  describes	  how	  we	  explored	  the	  possibility	   of	   inhibiting	   Ras	   farnesylation	   in	   order	   to	   selectively	   inhibit	  PI3Kγ activation	   in	   cell	   that	   express	  PI3Kγ as	  a	  p110γ/p84	  heterodimer,	  without	  effecting	  the	  PI3Kγ	  activity	  in	  cells	  where	  PI3Kγ	  is	  expressed	  as	  p110γ/p101.	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Class	  II	  and	  Class	  III	  PI3K	  	  	  Class	   II	   PI3Ks	   enzymes	   are	   high	  molecular	  weight	  monomers	   identified	   for	   the	  first	  time	  in	  Drosophila	  M.(193)	  In	  mammals	  are	  present	  three	  isoforms	  of	  class	  II	  PI3Ks:	   PI3KC2α,	  PI3KC2β	  and	  PI3KC2γ(194)	   that	   are	  ubiquitously	   expressed	   in	  human.	   They	   all	   present	   a	   Ras-­‐binding	   domain,	   a	   C2-­‐like	   domain	   and	   a	   core	  kinase	   domain	   but	   they	   lack	   of	   a	   binding	   domain	   for	   adaptor	   subunits.	   Being	  presently	  the	  least	  class	  of	  PI3K	  studied,	  there	  are	  still	  divergent	  data	  about	  their	  substrate	  specificity.	  Undoubtedly,	  such	  a	  lack	  of	  information	  about	  Class	  II	  PI3Ks	  enzymes	  is	  due	  to	  the	  absence	  of	  specific	  inhibitory	  molecules	  that	  in	  the	  case	  of	  class	  I	  PI3Ks	  have	  had	  a	  pivotal	  role	  in	  understanding	  their	  cellular	  and	  molecular	  dynamics.	  The	   sole	  member	   of	   class	   III	   PI3K	   enzymes	   is	   VPS34	   (Vacuolar	   Sorting	   Protein	  34),	   discovered	   and	   cloned	   in	   1990	   in	   S.	   Cerevisiae(198).	   As	   member	   of	   the	  family,	   VPS34	   posses	   PI3-­‐kinase	   activity	   and	   homologous	   proteins	   have	   been	  isolated	  in	  Drosophila	  M.,	  C.	  Elegans	  and	  in	  mammals	  as	  well,	  where	  the	  protein	  is	  ubiquitously	  expressed(199–201).	  PtdIns	  is	  the	  molecular	  substrate	  of	  VPS34	  and	  its	   catalytic	   product,	   PtdIns(3)P,	   is	   a	   molecule	   recognized	   by	   FYVE	   and	   PX	  domain-­‐containing	   proteins.	   VPS34	   is	   associated	   to	   VPS15,	   which	   posses	   an	  intrinsic	   serine/threonine	   kinase	   activity	   and	   is	   considered	   its	   regulatory	  subunit(202).	  Due	  to	  their	  cellular	  localization	  and	  physiological	  role,	  VPS34	  and	  PtdIns(3)P	  have	  been	  often	  associated	  with	  the	  activation	  of	  mTORC1(203,	  204),	  an	   atypical	   serine/threonine	   kinase	   multiprotein	   complex	   modulated	   by	   the	  cellular	  energy	  status	  and	  in	  particular	  by	  amino	  acids	  sensing.	  Unfortunately,	  due	  to	   the	   lack	  of	  specific	  molecular	   inhibitors	  and	   to	   the	   fact	   that	  PtdIns(3)P	   is	  not	  solely	   produced	   by	   class	   III	   PI3K	   but	   also	   by	   class	   II,	   the	   possibility	   of	   a	   cross-­‐regulation/interaction	  need	  to	  still	  be	  investigated.	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Pharmacological	  inhibition	  of	  PI3K’s	  activity	  	  As	  already	  mentioned	  in	  this	  manuscript,	  the	  development	  of	  molecular	  inhibitors	  of	   lipid	   kinase	   enzymes	   improved	   significantly	   the	   understanding	   of	   the	   role	   of	  the	   different	   lipid	   kinase	   family	  members.	   The	   first	   two	  molecular	   inhibitors	   of	  PI3K	   used	   in	   research	   were	   wortmannin(205,	   206)	   and	   LY294002(207).	  Wortmannin,	   isolated	  from	  the	  filamentous	  fungus	  Penicillium	  funiculosum(208),	  does	  not	  show	  any	  antibacterial	  property	  but	  is	  able	  to	  inhibit	  PI3K	  activity	  with	  an	   in	   vitro	   IC50	   in	   the	   nanomolar	   range(205).	  Wortmannin	   binds	   into	   the	   ATP-­‐binding	   pocket	   of	   PI3K	   to	   a	   lysine	   residue	   (Lys802	   in	   p110α,	   Lys833	   in	  p110γ(209–211)).	  LY294002,	  a	  molecule	  derived	  by	  the	  flavonoid	  quercetin,	  is	  a	  less	  active	  compound	  than	  wortmannin	  with	  an	  IC50	  value	  of	  around	  of	  4μM(205,	  212).	  Ly294002	  targets	  the	  ATP-­‐binding	  pocked	  of	  PI3K	  as	  well,	  without	  forming	  a	   covalent	   bond.	   Due	   to	   their	   molecular	   conformation,	   the	   targets	   of	   both	  compounds	   are	  not	   only	  PI3Ks	   family	   enzymes	  but	   also	  phosphatidylinositol	   3-­‐kinase	   related	   kinases	   (PIKKs)	   such	   as	   DNA-­‐PKcs,	   mTOR,	   ATM	   and	   ATR(213–215).	  	  In	   the	   last	   years	   a	   particular	   interest	   has	   been	   focused	   on	   the	   generation	   of	  isoform	   selective	   inhibitors	   (Figure	   6).	   One	   example	   is	   the	   development	   of	  BYL719(216),	  a	  selective	  inhibitor	  of	  PI3Kα,	  whose	  gene	  sequence	  is	  mutated	  in	  many	   human	   cancers	   and	   generates	   an	   over-­‐activation	   of	   the	   kinase	   activity.	  BYL719	   is	   currently	   in	   clinical	   trial	   for	   the	   treatment	   of	   adult	   patients	   with	  advanced	  solid	  tumors	  and	  is	  also	  going	  to	  be	  studied	  in	  combination	  with	  other	  anti-­‐neoplastic	   drugs	   for	   a	   broad	   range	   of	   cancer	   diseases.	   Another	   interesting	  example	   is	   the	   case	   of	   TGX221(217),	   an	   isoform	   selective	   PI3Kβ	   inhibitor,	  developed	  starting	  from	  the	  core	  structure	  of	  LY294002	  and	  ameliorated	  to	  gain	  selectivity	   towards	   the	   p110β	   catalytic	   subunit.	   Indeed	   the	   development	   of	  TGX221	   complements	   the	   reduced	   amount	   of	   information	   available	   about	   this	  isoform	  due	  to	  the	   lethal	  phenotype	  of	  PI3Kβ	  knock	  out	  animals.	   IC87114	  is	   the	  first	  developed	  selective	  PI3Kδ	  inhibitor	  with	  an	  IC50	  =	  0.5	  μM(218)	  and	  a	  58-­‐fold	  higher	  selectivity	  relative	  to	  PI3Kγ.	  IC87114	  was	  first	  used	  to	  investigate	  the	  role	  of	  PI3Kδ	  in	  neutrophils	  activation(218).	   In	  the	  present	  manuscript	  we	  used	  NVS	  PI3-­‐4,	  a	  selective	  PI3Kγ	  inhibitor(219,	  220)	  for	  our	  experiments.	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NVS-­‐PI3-­‐4	   binds	   into	   the	   ATP-­‐binding	   pocket	   of	   PI3Kγ	   and	   inhibits	   the	   fMLP-­‐induced	   respiratory	   burst	   assay	   in	   human	   neutrophil	   with	   an	   IC50	   =	   0.22	   µM;	  moreover	   the	   molecule	   shows	   a	   minimal	   inhibitory	   activity	   against	   protein	  kinases.	  Nevertheless,	   if	   the	   isoform	  selective	  PI3K	   inhibitors	  contributed	   to	   the	  understanding	   of	   the	   single	   molecular	   pathways,	   the	   use	   of	   the	   pan-­‐PI3Ks	  inhibitors	  is	  gaining	  an	  increasing	  interest	  in	  clinical	  applications.	  	  For	  instance,	  PX866	  is	  an	  analog	  of	  wortmannin	  with	  irreversible	  PI3K	  inhibitor	  activity	  that	  is	  currently	  in	  clinical	  phase	  2	  for	  the	  treatment	  of	  different	  types	  of	  solid	   cancer	   (ClinicalTrial.gov).	   SF1126	   is	   a	   pan-­‐PI3K	   inhibitor,	   analog	   of	  LY294002	  and	   is	   currently	  undergoing	   clinical	   phase	   I	   test	   for	   the	   treatment	  of	  advanced	  or	  metastatic	   solid	   tumors	   and	   relapsed	  or	   refractory	  neuroblastoma.	  NVP-­‐BKM120(221)	  is	  a	  pan-­‐class	  I	  PI3K	  inhibitor,	  currently	  in	  clinical	  trials,	  alone	  or	   in	   combination	   with	   other	   compounds,	   for	   the	   treatment	   of	   advanced	   solid	  tumors	   (ClinicalTrial.gov).	   In	   table	   5	   are	   indexed	   all	   the	   class	   I	   PI3K/mTOR	  inhibitors	  that	  are	  currently	  in	  clinical	  trials	  (November	  2015,	  ClinicalTrial.gov).	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Phosphoinositide	  phosphatases	  	  	  The	   phosphatidylinositol	   signalling	   regulates	   several	   aspects	   of	   the	   cellular	  homeostasis	   and	   is	   constantly	   modulated	   by	   two	   classes	   of	   enzymes:	   lipid	  kinases	  and	  phosphatases.	  The	  product	  of	  PI3K	  class	  I	  enzymes,	  PtdIns(3,4,5)P3,	  is	  a	  fundamental	  intracellular	  second	  messenger	  and	  can	  be	  hydrolyzed	  by	  three	  inositol	  polyphosphate	  phosphatases:	  PTEN,	  SHIP1	  and	  SHIP2.	  PTEN	  is	  a	  3’	  poly-­‐phosphatase	  that	  generates	  PtdIns(4,5)P2,	  while	  SHIP1	  and	  SHIP2	  (Figure	  7)	  are	  5’	  poly-­‐phosphatases	  and	  produce	  PtdIns(3,4)P2.	  	  SH2-­‐containing	   inositol-­‐5’-­‐phosphatase	  1	  (SHIP1)	   is	  best	  known	  as	   the	  effector	  of	   the	   inhibitory	   signalling	   by	   FcγRIIb	   and	   is	   able	   to	   negatively	   regulates	  BCR(222),	  FcεRI(223)	  and	  TCR(224)	  signalling.	  The	  INPP5D	  gene,	  that	  produces	  SHIP1,	  was	  independently	  cloned	  in	  1996	  by	  three	  groups	  and	  the	  product	  of	  this	  gene	  was	  first	  described	  as	  a	  protein	  that	  becomes	  tyrosine	  phosphorylated	  and	  associates	  with	  the	  Shc	  protein	  upon	  cytokine	  or	  grow	  factors	  stimulation(225–227).	  	  Presently,	   two	  mechanisms	   are	   known	   to	   be	   responsible	   for	   SHIP1	   dependent	  inhibitory	  activity.	  On	  one	  hand,	  being	  a	  lipid	  phosphatase,	  SHIP1	  is	  recruited	  via	  its	  SH2	  domain	  at	   the	  plasma	  membrane	  where	  binds	   tyrosine-­‐phosphorylated	  domains	  of	   several	   receptors(228)	  and	  hydrolyses	   the	  PtdIns(3,4,5)P3	  at	   the	  5’	  position	  of	  the	  inositol	  ring,	  generating	  PtdIns(3,4)P2;	  consequently,	  elimination	  of	   the	   plasma	   membrane	   PtdIns(3,4,5)P3	   prevents	   the	   recruitment	   and	  activation	   of	   several	   Pleckstrin	   Homology	   (PH)	   containing	   molecules	   such	   as	  phosphoinositide	   dependent	   kinase	   1	   (PDK1),	   Bruton’s	   Tyrosine	   Kinase	   (Btk)	  and	  Phospholipase	  C-­‐γ	  (PLCγ)(229).	  Interestingly,	  due	  to	  the	  different	  ability	  of	  PH-­‐domain	   bearing	   proteins	   to	   bind	   both	   PtdIns(3,4,5)P3	   or	   PtdIns(3,4)P2,	   the	  phosphatase	   activity	   of	   SHIP1	   can	   be	   considered	   a	   modulation	   of	   the	   PI3K	  signalling	  more	  then	  a	  termination.	  On	  the	  other	  hand,	  SHIP1	  works	  as	  a	  docking	  unit	   and	   upon	  membrane	   localization	   recruits	   the	   adaptor	   molecule	   p26Dok1	  that	  in	  turn	  recruits	  a	  not	  yet	  identified	  Ras	  GTPase	  activating	  protein	  (RasGAP)	  and	   leads	   to	   the	   inhibition	   of	   Ras	   and	   all	   the	   downstream	   signalling	   cascades	  including	  the	  Erk1/2	  MAPK	  pathway(230,	  231).	  As	   for	  PI3K	  family	  enzymes	  or	  PTEN,	   mutations	   in	   SHIP1	   were	   detected	   in	   patients	   affected	   by	   acute	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lymphoblastic	   leukemia	   and	   acute	   myeloid	   leukemia(232)	   and	   there	   are	   also	  evidences	   for	  development	  of	  erytroleukemia	  promoted	  by	   loss	  of	  SHIP1(233).	  Genetically	   modified	   mice	   lacking	   SHIP1(234)	   were	   vital	   but	   suffered	   from	  progressive	  splenomegaly,	  massive	  myeloid	  infiltration	  of	  the	  lung,	  wasting	  and,	  in	  some	  cases,	  a	  shortened	  lifespan.	  Nevertheless	  the	  generation	  of	  SHIP1	  knock	  out	   mice	   gave	   a	   fundamental	   contribution	   to	   asses	   the	   importance	   of	   plasma	  membrane	   localised	   PtdIns(3,4,5)P3	   and	   its	   modulation	   (Table	   4).	   Studies	  performed	  in	  BMMC	  lacking	  SHIP1	  contributed	  to	  name	  this	  lipid	  phosphatase	  as	  the	   “gatekeeper	  of	  mast	  cells	  degranulation”(223).	  On	   the	  other	  hand,	  SHIP1	   is	  dispensable	   for	   the	  generation	  of	  BMMC(223).	   Indeed,	  SHIP1	  knock	  out	  BMMC	  are	  phenotypically	   indistinguishable	  at	   light	  microscopy	  observation	   from	  wild	  type	   BMMC	   and	   exhibit	   increased	   degranulation	   and	   cytokine	   secretion	   in	  response	   to	   IgE	   /	   FcεRI	   cross-­‐linking	   compared	   with	   wild	   type	   cells	   (223).	  Moreover	  SHIP1	  knock	  out	  BMMC	  response	  to	  SCF	  or	  monomeric	  IgE	  stimulation	  with	  aberrant	  degranulation	  unlike	  wild	  type	  cells(235–237).	  	  Interestingly,	  mice	  lacking	  SHIP1	  revealed	  also	  an	  immunoregulatory	  role	  for	  the	  5’	   lipid	   phosphatase;	   an	   interesting	   study	   demonstrated	   that	   in	   mice	   lacking	  SHIP1	  there	  is	  a	  significant	  expansion	  of	  a	  myeloid	  suppressor	  cell	  population	  in	  peripheral	  lymphoid	  tissues	  that	  protects	  mice	  against	  graft	  versus	  host	  disease	  (GVHD)	   induced	   by	   allogenic	   bone	   marrow	   transplantation(238).	   Indeed,	  transient	   silencing	   of	   SHIP1	   expression	   in	   adult	   transgenic	   mice	   induces	   the	  expansion	   of	   a	  Mac1+Gr1+	   cell	   population	   in	   the	   spleen	   and	   in	   the	  mesenteric	  lymphonodes	  that	  is	  able	  to	  suppress	  an	  allogenic	  T	  cell	  response	  following	  bone	  marrow	   transplantation	   and	   moreover	   increases	   the	   donor	   B	   lymphoid	  repopulation	   in	   the	   recipient.	   This	   result	   clearly	   shows	   that	   SHIP1	   does	   not	  merely	   exert	   a	   “gatekeeper”	   activity	   within	   the	   cells,	   limiting	   the	   presence	   of	  PtdIns(3,4,5)P3	   at	   the	   plasma	   membrane,	   but,	   moreover,	   either	   by	   generating	  PtdIns(3,4)P2	  or	  by	  virtue	  of	   its	  docking	  activity,	   it	   regulates	   several,	   yet	   to	  be	  discovered,	  cellular	  pathways.	  SHIP2	  (Figure	  6)	  is	  widely	  expressed	  in	  nonhematopoietic	  cells	  and	  is	  implicated	  in	  insulin	  signalling	  and	  control	  of	  obesity(239–241).	  It	  is	  encoded	  by	  a	  separate	  gene	   but	   still	   retains	   65%	   homology	   with	   SHIP1	   within	   the	   catalytic	   domain.	  Interestingly,	   BMMCs	   lacking	   SHIP2	   show	   an	   enhanced	   antigen	   induced	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degranulation	  and	  cytokine	  release	  in	  comparison	  with	  wild	  type	  cells	  but	  do	  not	  show	   any	   corresponding	   calcium	   influx	   or	   tyrosine	   phosphorylation	   of	  MAPKs	  although	   the	   antigen	   induced	   phosphorylation	   of	   PKB	   at	   serine	   473	   is	  enhanced(242).	  	  The	   phosphatase	   and	   tensin	   homolog	   deleted	   on	   chromosome	   10,	   PTEN	   lipid	  phosphatase	   is	   considered	   a	   physiological	   inhibitor	   of	   PI3K	   signalling.	  Characterised	  almost	  20	  years	  ago	  as	  a	  tumor	  suppressor	  gene(243–245),	  PTEN	  is	   a	   403	   amino	   acid	   protein	   that	   is	   structurally	   divided	   in	   5	   domains:	   a	   PIP2	  binding	  domain,	   PDB,	   a	   phosphatase	  domain,	   a	   C2	  domain,	   a	   carboxy-­‐terminal	  tail	   and	   a	   PDZ-­‐binding	   domain.	   PTEN	   hydrolyses	   the	   3’	   positioned	   phosphate	  from	   PI(3,4,5)P3	   to	   generate	   PI(4,5)P2(246)	   and	   is	   considered	   the	   most	  commonly	  mutated	  gene	  in	  human	  tumors.	   Indeed,	   loss	  of	  PTEN	  function	   leads	  to	  increased	  levels	  of	  PIP3	  and	  following	  activation	  of	  PDK1	  and	  PKB,	  promoting	  an	   uncontrolled	   cell	   growth	   and	   survival(247).	   Generation	   of	   PTEN	   knock	   out	  mice	   lacking	   only	   one	   allele	   provided	   evidences	   of	   its	   tumor	   suppressor	  ability(248)	   although	   homozygous	   knock	   out	   mice	   are	   embryonic	   lethal(249).	  Interestingly,	  in	  a	  mouse	  model	  with	  inducible	  deletion	  of	  PTEN,	  the	  absence	  of	  the	  phosphatase	   generates	  mast	   cells	   hyperplasia	   and	   increased	   the	  mast	   cells	  number	   in	   all	   the	   tissues	   as	   well	   as	   increased	   stimulus	   hypersensitivity	   and	  vascular	  permeability(250).	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Phenotype of SHIP1 KO
SHIP1 KO mice show increased Th2 skewing
due to increased IL-4 secretion from basophils (Kuroda et al. 2011) 
Increased BTK membrane association; hyper-responsive to cross-linking 
of BCR; Loss of anergy, production of auto-antibodies 
(Bolland et al.1998; Helgason et al. 2000; O’Neil et al. 2011)
Enhanced survival and proliferation but impaired maturation; 
Reduced nitric oxide production; DC lacking SHIP1 suppress
T cell proliferation; (Antignano et al. 2010) 
Enhanced degranulation of BMMC, CTMC, and MMC; enhanced 
TLR expression; enhanced cytokine production and release in BMMC; 
(Huber et al. 1998; Kalesnikoﬀ et al. 2002; Ruschmann et al. 2012) 
Increased myeloid suppressor cell number; increased M2 macrophage 
skewing (indirect mechanism via increasedIL-4 secretion from basophils);
Increased ratio of PtdIns(3,4,5)P3 to PtdIns(3,4)P2 on phagosomal 
membrane; decreased early NADPH oxidative activity in phagosomes; 
(Ghanash et al. 2004; Kuroda et al. 2009)  
Deﬁcient receptor repertoire; defective INFγ secretion; increase 
in periferal number; defective cytolytic function; (Fortenbery et al., 2010)
Increased regulatory T cell diﬀerentiation, decreased Th17development; 
enhanced Th1 diﬀerentiation and CD8 cytotoxic activity; decreased 
Th2 diﬀerentiation; (Tarasenkoet al., 2007) 
SHIP1
SHIP2
SH2 5’ phosphatasePH-R C2 Proline rich
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Lipid	  phosphatase	  activators	  and	  inhibitors	  	  Due	  to	  their	  active	  role	  in	  modulating	  PI3K	  signalling,	  lipid	  phosphatases	  such	  as	  SHIP1,	   SHIP2	   or	   PTEN	   have	   become	   an	   interesting	   target	   for	   pharmacological	  modulation	  of	  their	  enzymatic	  activity.	  Having	  a	  peculiar	  expression	  restricted	  to	  the	   hematopoietic	   lineage,	   SHIP1	   has	   been	   identified	   as	   a	   potential	  pharmacological	   target	   for	   the	   treatment	  of	  diseases	   characterised	  by	  an	  over-­‐active	  PI3K	  signalling	  in	  immune	  cells.	  The	  first	  molecule	  able	  to	  promote	  SHIP1	  phosphatase	   activity	   was	   isolated	   by	   a	   marine	   invertebrate,	   Dactylospongia	  
elegans	  collected	  in	  Papua	  New	  Guinea	  and	  was	  described	  in	  2005	  as	  “pelorol”.	  In	  an	  in	  vitro	  assay,	  pelorol	  was	  able	  to	  enhance	  the	  SHIP1	  dependent	  conversion	  of	   inositol-­‐1,3,4,5-­‐tetrakisphosphate	   (IP4)	   to	   inositol-­‐1,3,4-­‐trisphosphate	  (IP3)(258).	   Synthetic	   analogue	   of	   perol,	   AQX-­‐MN100	   and	  AQX-­‐016A	  were	   then	  generated	  by	  Aquinox	  Pharmaceutical,	  Inc.	  and	  were	  characterised	  by	  the	  ability	  to	  bind	  the	  C2	  domain	  of	  SHIP1(259).	  The	  compound	  AQX-­‐151,	  used	  as	  well	   in	  the	   present	  manuscript,	  was	   further	   developed	   starting	   from	   the	   core	   of	   AQX-­‐MN100	   as	   a	   500,000-­‐fold	   more	   water-­‐soluble	   molecule.	   AQX-­‐151	   inhibits	   the	  phosphorylation	   of	   PKB	   in	   stimulated	  MOLT-­‐4	   cells	   and	  has	   a	   dose	   dependent	  protecting	   effect	   on	   mouse	   passive	   cutaneous	   anaphylaxis	   (PCA)	   model(260).	  Currently,	  AQX-­‐1125,	  developed	  by	  Aquinox	  Pharmaceutical,	   Inc.,	   is	   in	  phase	   II	  clinical	  trial	  for	  the	  treatment	  of	  chronic	  obstructing	  pulmonary	  disease	  (COPD),	  bladder	   pain	   syndrome/interstitial	   cystitis	   and	   atopic	   dermatitis	  (Clinicaltrial.gov).	  	  On	  the	  other	  hand,	  several	  attempts	  have	  been	  performed	  in	  order	  to	  inhibit	  the	  lipid	   phosphatase	   activity	   of	   SHIP1.	   The	   3	   alpha-­‐aminocholestane	   (3AC)	   is	  currently	  the	  only	  known	  selective	  SHIP1	  phosphatase	  inhibitor,	  having	  an	  IC50	  of	   10	   µM	   and	   a	   high	   degree	   of	   selectivity	   over	   SHIP2	   and	   PTEN	   lipid	  phosphatases(261)	   even	   though	   there	   are	   no	   details	   about	   the	   mechanism	   of	  action.	   In	   vivo	   testing	   of	   3AC	   showed	   its	   ability	   to	   protect	   transplanted	   mice	  against	   allogenic	   GVHD	   but	   also	   to	   induce	   apoptosis	   in	   SHIP1	   expressing	  leukemia	  and	  myeloma	  cell	   lines,	   suggesting	   that	   inhibiting	  SHIP1	  phosphatase	  activity	   could	   either	   enhances	   allogenic	   transplantation	   or	   improve	   the	  treatment	  of	  hematologic	  tumors(261,	  262).	  Interesting,	  three	  molecules,	  “1PIE”,	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“2PIQ”	  and	  “6PTQ”,	  have	  been	  identified	  as	  potential	  pan-­‐SHIP	  inhibitors	  (SHIP1	  and	  SHIP2)	  and	  showed	  to	  be	  able	  to	  reduce	  the	  cell	  viability	  of	  SHIP2	  expressing	  breast	  cancer	  cell	  lines,	  opening	  a	  novel	  interesting	  alternative	  for	  the	  treatment	  of	  breast	  cancer(263).	  Together	  with	  the	  protecting	  role	  exercited	  by	  the	  SHIP1	  and	  SHIP2	  inhibitors,	  a	  similar	  result	  has	  been	  obtained	  by	  isolating	  molecules	  able	  to	  inhibit	  the	  PTEN	  phosphatase	   activity.	   Interestingly,	   since	   long	   time	   is	   known	   that	   vanadium	  compounds,	   such	   as	   orthovanadate,	   are	   able	   to	   inhibit	   a	   broad	   range	   of	  phosphatase	  enzymes(264),	  nevertheless	  the	  first	  compounds	  with	  a	  recognised	  specificity	  for	  PTEN	  were	  isolated	  in	  2004(265).	  Among	  them,	  VO-­‐OHpic,	  was	  the	  most	  potent	  and	  specific	  compound.	  In	  vivo	  and	  in	  vitro	  experiments	  performed	  in	   presence	   of	   VO-­‐OHpic	   showed	   that	   PTEN	   inhibition	   induces	   a	   cellular	  senescence	   response	   without	   inducing	   any	   DNA	   damage	   and	   inhibits	  tumorigenesis	   in	  vivo,	   in	  a	  human	  xenograft	  model	  of	  prostate	  cancer(266)	  but	  also	   induces	  cardioprotection	  against	   ischemia-­‐reperfusion	   injury(267)	   in	  mice	  and	   overcome	   the	   inhibitory	   effect	   of	   IC87114,	   a	   selective	   PI3Kδ inhibitor	   in	   a	  breast	  cancer	  cell	  lines(268).	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Figure	  8:	  Molecular	  structure	  of	  the	  main	  lipid	  phosphatase	  modulators.	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Abstract	  	  
Background	   IgE	   induced	   activation	   of	   tissue-­‐localized	  mast	   cells	   and	   circulating	  basophils	   is	   the	   triggering	   event	   generating	   type	   I	   hypersensitivity	   reactions.	  A	  fundamental	   step	   in	   IgE-­‐mediated	   activation	   of	  mast	   cells	   is	   the	   recruitment	   of	  class	   I	   PI3Ks	   enzymes	   at	   the	   plasma	   membrane	   where	   they	   phosphorylate	  PtdIns(4,5)P2	   and	   generate	   PtdIns(3,4,5)P3,	   an	   intracellular	   second	   messenger	  with	   fundamental	   signalling	   functions.	   On	   the	   other	   hand,	   the	   levels	   of	  PtdIns(3,4,5)P3	  are	  tightly	  modulated	  by	  the	  activity	  of	  lipid	  phosphatases	  such	  as	  SH2-­‐containing	  inositol-­‐5'-­‐phosphatase-­‐1,	  SHIP1,	  that	  hydrolyses	  PtdIns(3,4,5)P3	  and	  generates	  PtdIns(3,4)P2,	  a	  molecule	  that	  is	  no	  longer	  a	  target	  for	  PI3K	  family	  enzymes.	  
Objective	  In	  the	  present	  work	  we	  tested	  two	  hypotheses:	  (i)	  PI3Kγ,	  a	  member	  of	  class	  IB	  PI3Ks	  activated	  upon	  GPCR	  and	  IgE	  /	  FcεRI	  stimulation,	  generates	  a	  pool	  of	  PtdIns(3,4,5)P3	  in	  bone	  marrow	  derived	  mast	  cells	  (BMMC)	  that	  is	  not	  directly	  hydrolysed	  by	  the	  5’-­‐phosphatase	  SHIP1.	  (ii)	  Dual	  pharmacological	  modulation	  of	  SHIP1	   and	   PI3Kγ	   produces	   a	   synergistic	   inhibition	   of	  mast	   cells	   activation	   and	  therefore	  represents	  a	  promising	  strategy	  for	  the	  treatment	  of	  allergic	  diseases.	  	  
Results	  We	  have	  shown	  that	  AQX-­‐151,	  an	  allosteric	  activator	  of	  SHIP1,	  inhibits	  the	  IgE-­‐induced	   activation	   of	   BMMC	   but	   does	   not	   block	   the	   GPCR-­‐mediated	   PI3Kγ	  activation	   induced	   by	   adenosine.	   The	   same	   result	   was	   obtained	   by	   stimulating	  SHIP1	   phosphatase	   activity	   through	   co-­‐clustering	   of	   the	   FcεRI	   and	   FcγRIIb	   in	  BMMC.	  Furthermore	  the	  treatment	  of	  BMMC	  with	  AQX-­‐151	   in	  combination	  with	  NVS	  PI3-­‐4,	  a	  selective	  PI3Kγ	  inhibitor,	  blocks	  the	  IgE	  induced	  BMMC	  activation	  in	  a	  synergistic	  manner.	  
Conclusion	  With	  the	  present	  work	  we	  demonstrate	  that	  PI3Kγ	  signalling	  is	  able	  to	  bypass	   SHIP1	   phosphatase	   activity	   and	   therefore	   reinforces	   the	   IgE-­‐induced	  signalling	   in	   BMMC.	   By	   demonstrating	   the	   synergistic	   activity	   of	   AQX-­‐151	   and	  NVS	  PI3-­‐4	  in	  inhibiting	  BMMC	  activation	  we	  provide	  a	  proof	  of	  concept	  for	  a	  novel	  pharmacological	  combination	  for	  the	  treatment	  of	  allergic	  disease.	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Introduction	  	  Type	   I	   hypersensitivity	   reactions	   are	   initiated	   by	   the	   clustering	   of	   high	   affinity	  Immunoglobulin	  class	  E	  (IgE)	  receptors	  (FcεRI)	  expressed	  on	  the	  surface	  of	  mast	  cells	  or	  basophils	  and	  are	  characterized	  by	  an	  immediate	  cellular	  activation	  and	  a	  rapid	   tissue	   specific	   response(1).	   The	   FcεRI	   is	   a	   trans-­‐membrane	   signalling	  complex	   composed	   of	   an	   α-­‐chain	   that	   binds	   a	   single	   IgE	  molecule	   but	   does	   not	  have	   any	   signalling	   ability,	   two	   homologous	   disulphide-­‐linked	   γ-­‐chains,	   each	  containing	  one	  immunoreceptor	  tyrosine-­‐based	  activation	  motif	  (ITAM)	  and	  one	  membrane-­‐tetraspanning	   β	   chain	   with	   intracellular	   signalling	   function	   that	  presents	   an	   ITAM	  motif	   as	   well(2).	   Clustering	   of	   several	   α	   chains	   leads	   to	   the	  activation	  of	  the	  FcεRI	  and	  brings	  the	  Src	  family	  kinase	  Lyn,	  constitutively	  bound	  to	   the	   FcεRIβ,	   in	   close	   vicinity	   to	   the	   ITAMs	   of	   both	   β	   and	   γ-­‐chains	   where	   it	  phosphorylates	  them(3,	  4).	  The	  presence	  of	  phosphorylated	  ITAM	  domains	  allows	  the	   recruitment	   of	   SH2	   bearing	   proteins	   at	   the	   plasma	  membrane,	   such	   as	   the	  protein	   tyrosine	   kinase	   Syk	   but	   also	   the	   recruitment	   of	   class	   IA	   PI3K	   adaptor	  subunits(5).	  Plasma	  membrane	  localized	  class	  I	  PI3K	  enzymes	  phosphorylate	  PtdIns(4,5)P2,	  a	  minor	   component	   of	   the	   phospholipidic	   membrane,	   at	   the	   3’	   position	   and	  generate	  PtdIns(3,4,5)P3.	  The	  presence	  of	  PIP2	  and	  PIP3	  at	  the	  plasma	  membrane	  modulates	   several	   cellular	   events	   such	   as	   gene	   expression,	   rearrangement	   of	  cytoskeletal	   structures,	   cell	   motility	   and	   endo-­‐	   or	   exocytosis(5).	   Plasma	  membrane	  localized	  PtdIns(3,4,5)P3	  in	  turn	  recruits	  and	  promotes	  the	  activation	  of	   pleckstrin	   homology	   (PH)	   domain-­‐containing	   proteins	   such	   as	  Phosphoinositide	   dependent	   kinase	   1	   (PDK1),	   Protein	   Kinase	   B	   (PKB),	   Bruton	  tyrosine	   kinase	   (BTK)	   and	   phospholipase	   Cγ	   (PLCγ).	   Active	   PLCγ	  mediates	   the	  cleavage	   of	   PtdIns(4,5)P2	   into	   diacylglycerol	   (DAG)	   and	   inositol	   1,4,5-­‐triphosphate	   (IP3),	   the	   latter	   contributing	   to	   the	   generation	   of	   a	   massive	   Ca2+	  influx	  that	  leads	  to	  the	  granule’s	  content	  release	  in	  mast	  cells(6).	  	  PI3Kγ	   is	   the	   sole	   class	   IB	   PI3K	  member	   and	   is	  mainly	   activated	   downstream	  G	  protein	   coupled	   receptors	   (GPCRs)	   stimulation(7),(8).	   Being	   a	   heterodimeric	  enzyme,	  PI3Kγ	  is	  composed	  by	  a	  catalytic	  subunit,	  p110γ	  and	  an	  adaptor	  subunit,	  p84	   in	   BMMC.	   The	   p110γ/p84	   complex	   has	   been	   described	   in	   the	   contest	   of	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GPCR	   dependent	   PI3Kγ	   signalling	   is	   not	   inhibited	   by	   AQX-­‐151	  
mediated	  activation	  of	  SHIP1.	  	  The	  5’	  phosphatase	  SHIP1	  is	  a	  key	  regulator	  of	  the	  PtdIns(3,4,5)P3	  levels	  in	  mast	  cells	  and	  is	  considered	  a	  promising	  pharmacological	  target	  for	  the	  development	  of	  anti-­‐inflammatory	  drugs	  due	  to	  its	  sole	  expression	  within	  the	  hematopoietic	  cell	  lineage(11).	   In	   the	   present	   work	   we	   test	   AQX-­‐151	   (Fig.S1A),	   a	   pelorol-­‐derived	  compound	  able	  to	  promote	  SHIP1	  catalytic	  activity(12)	  and	  we	  show	  its	  ability	  to	  inhibit	  bone	  marrow	  derived	  mast	  cells	  (BMMC)	  activation.	  The	  measurement	  of	  the	  release	  of	  β-­‐hexosaminidase	  in	  BMMC	  is	  commonly	  considered	  as	  readout	  of	  the	  stimulus	  induced	  degranulation	  reaction,	  since	  β-­‐hexosaminidase	  is	  contained	  within	  the	  same	  granules	  where	  histamine	  is	  stored(13,	  14).	  Pre-­‐incubation	  of	  IgE	  anti-­‐DNP	  sensitized	  BMMC	  with	  AQX-­‐151	   inhibits,	   in	  a	  dose	  dependent	  manner,	  the	   release	  of	  β-­‐hexosaminidase	   induced	  by	   the	   stimulation	  of	   the	   cells	  with	  an	  experimental	   antigen,	   DNP-­‐HSA.	   AQX-­‐151	   does	   not	   have	   any	   evident	   off-­‐target	  effect	   in	   BMMC	   lacking	   SHIP1(15)	   (Fig.1A).	   SHIP1	   knock-­‐out	   BMMC	   are	  characterised	   by	   a	   higher	   level	   of	   background	   β-­‐hexosaminidase	   release	   in	  unstimulated	   cells	   compared	   to	   wild	   type	   BMMC	   and	   an	   hypersensitive	  degranulation	   response	   upon	   antigen	   stimulation	   (Fig.1B).	   IgE-­‐induced	   BMMC	  activation	  can	  be,	  both	  in	  vivo	  and	  in	  vitro,	  reinforced	  by	  co-­‐stimulatory	  molecules	  that	   activate	   different	   receptors	   on	   the	   cellular	   surface	   and	   promote	  PtdIns(3,4,5)P3	  production.	  Indeed,	  Stem	  Cells	  Factor	  (SCF),	  the	  ligand	  of	  cKIT,	  is	  known	   to	   directly	   promote	   PI3Kδ	   activation(16)	   whereas	   adenosine	  preferentially	   binds	   the	   A3	   Adenosine	   Receptor	   (A3AR)	   and	   induces	   PI3Kγ	  activation	  in	  mast	  cells(8).	  We	  pre-­‐incubated	  IgE-­‐sensitized	  BMMC	  with	  AQX-­‐151,	  stimulated	   them	   with	   DNP-­‐HSA	   +	   SCF	   or	   Adenosine	   and	   measured	   mast	   cell	  degranulation.	   AQX-­‐151	   is	   able	   to	   inhibit	   the	   degranulation	   induced	   by	   IgE+Ag	  and	  IgE+Ag+SCF	  but	  does	  not	  block	  the	  adenosine-­‐induced	  reinforcement	  of	   the	  degranulation	   response	   (Fig.1C).	   AQX-­‐151	   inhibits	   also	   the	   antigen-­‐induced	  phosphorylation	   of	   PKB	   in	   IgE	   sensitised	   BMMC	  without	   having	   any	   inhibitory	  
Project	  I	  	  
	   75	  



























Project	  I	  	  
	  76	  
	  



































































- + +- - - -































- - 40 80














































Project	  I	  	  
	   77	  
	  






Project	  I	  	  
	  78	  
Anti	   Immunoglobulin-­‐dependent	   SHIP1	   recruitment	   inhibits	   IgE	  mediated	  
BMMC	   activation	   but	   does	   not	   interfere	   with	   GPCR	   mediated	   PI3Kγ	  
signalling.	  	  Co-­‐clustering	   of	   FcεRI	   and	   FcγRIIb	   in	   BMMC	   induces	   an	   inhibitory	   stimulation	  that	  physiologically	  prevents	  mast	  cells	  activation	  with	  a	  mechanism	  that	  involves	  SHIP1	   recruitment	   at	   the	   plasma	   membrane	   and	   hydrolysis	   of	  PtdIns(3,4,5)P3(18).	   	   	   The	   co-­‐clustering	   of	   the	   two	   receptors	   can	  be	   induced	  by	  incubating	   IgE-­‐sensitized	   BMMC	   with	   a	   polyclonal	   anti-­‐immunoglobulin	   IgG	  antibody	  (Rabbit-­‐Anti-­‐Mouse	  IgG,	  RAM	  IgG,	  Fig.2A)	  and	  results	  in	  the	  activation	  of	  SHIP1(19).	   Such	   an	   effect	   is	   due	   to	   the	   presence	   of	   the	   Fc	   fragment	   of	   the	   IgG	  molecule	  that	  bind	  the	  FcγRIIb	  expressed	  of	  BMMC;	  indeed	  a	  truncated	  version	  of	  the	   same	   antibody	   lacking	   the	   Fc	   portion	   [F(ab’)2	   fragment,	   Fig.2A]	   induces	  clustering	  of	  the	  FcεRI	  without	  interacting	  with	  the	  FcγRIIb,	  and	  promotes	  a	  dose-­‐dependent	  cell	  degranulation	  (Fig.2B,	  blue	  line).	  Indeed,	   incubation	  of	   IgE	   sensitized	  BMMC	  with	  RAM	   IgG	  yielded	  no	   significant	  granule	   release	   over	   a	   broad	   range	   of	   concentrations	   in	  wild	   type	   cells	   (Fig.2B,	  blue	   dashed	   line)	   whereas	   SHIP1	   knock-­‐out	   BMMC	   readily	   degranulated	   in	   a	  concentration-­‐dependent	   manner	   (Fig.2B,	   red	   line).	   Hence,	   incubation	   of	   IgE	  sensitized	  BMMC	  with	  the	  F(ab’)2	  fragment	  represent	  a	  stimulatory	  signal	  being	  able	   to	   induce	   the	   clustering	   of	   the	   IgE/FcεRI	   and	   leads	   to	   a	   dose	   dependent	  cellular	  degranulation.	   Incubation	  of	   IgE	  sensitized	  SHIP1	  KO	  BMMC	  with	  either	  RAM	   IgG	   or	   the	   F(ab’)2	   fragment	   resulted	   in	   almost	   identical	   degranulation	  response	  (Fig.2B,	   red	   line	  and	  red	  dashed	   line).	  Pre-­‐incubation	  of	   IgE	  sensitized	  wild	  type	  BMMC	  with	  RAM	  IgG	  reduced	  the	  BMMC	  degranulation	  promoted	  by	  the	  F(ab’)2	   fragment	  and	  similarly	   reduces	   the	  co-­‐stimulatory	  signalling	   induced	  by	  SCF	   whereas	   adenosine	   stimulation	   was	   unperturbed	   in	   presence	   of	   RAM	   IgG	  (Fig.2C).	  Being	  a	  downstream	  target	  of	  PI3K	  activity,	  the	  phosphorylation	  of	  PKB	  is	   considered	   an	   indirect	   readout	   of	   the	   plasma	   membrane	   levels	   of	  PtdIns(3,4,5)P3.	   The	   clustering	   of	   the	   FcεRI	   but	   also	   adenosine	   or	   SCF	  stimulations	   promote	   the	   activation	   of	   different	   receptors	   and	   different	   class	   I	  PI3Ks	   but	   all	   induce	   the	   activation	   and	   phosphorylation	   of	   PKB.	  Here	  we	   show	  that	  pre-­‐incubation	  of	  IgE	  sensitized	  BMMC	  with	  a	  polyclonal	  Rabbit-­‐Anti-­‐Mouse	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Figure	  2:	  Incubation	  of	  IgE-­‐sensitized	  BMMC	  with	  anti	  Ig	  antibodies	  induces	  
SHIP1	  activation:	  (A)	  Schematic	  representation	  of	  F(ab’)2	  fragment	  and	  RAM	  IgG	  and	  their	  mode	  of	  action.	  FcεRIα	  is	  represented	  in	  green	  and	  FcγRIIb	  in	  blue.	  (B)	  WT	  and	  SHIP1KO	  BMMC	  were	  sensitized	  overnight	  with	  IgE	  anti	  DNP-­‐HSA	  (clone	  SPE-­‐7,	   0.1μg/ml)	   and	   stimulated	   with	   equimolar	   doses	   of	   RAM	   IgG	   or	   F(ab’)2	  fragment	   for	  20	  minutes.	  The	  degranulation	  reaction	  was	  calculated	  from	  the	  β-­‐hexosaminidase	   activity	   in	   the	   cell	   supernatant.	   A	   one-­‐way	   anova	   test	   was	  performed	   within	   the	   wild	   type	   and	   within	   the	   SHIP1-­‐/-­‐	   sub-­‐group,	   F(ab’)2	   vs.	  RAM	   IgG	   (n=2,	   mean	   ±	   SEM,	  ❋P	   <	   .05	   and	  ❋❋P	   <	   .001).	   (C)	  WT	   BMMC	   were	  sensitized	   overnight	   with	   IgE	   anti	   DNP-­‐HSA	   (clone	   SPE-­‐7,	   0.1μg/ml)	   and	  stimulated	  with	  equimolar	  doses	  (100	  nM)	  of	  RAM	  IgG	  or	  F(ab’)2	  	  fragment	  for	  20	  minutes	  +/-­‐	  SCF,	  10	  ng/ml	  or	  Adenosine,	  1	  μM	  (n=2,	  mean	  ±	  SEM,	  ❋P	  <	   .05	  and	  
❋❋P	  <	   .001).	   (D)	   IgE-­‐sensitized	  BMMC	  were	   incubated	  with	  100	  nM	   IgG	   for	  10	  minutes	   and	   then	   stimulated	  with	  100	  nM	  F(ab’)2	   fragment,	   SCF	   (10	  ng/ml)	  or	  Adenosine	  (1	  μM)	  for	  5	  minutes.	  Phosphorylation	  levels	  of	  PKB	  were	  detected	  by	  western	   blotting	   and	   quantified	   using	   ImageJ	   (n=2,	  mean	   ±	   SEM,	  ❋P	   <	   .05	   and	  
❋❋P	  <	  .001).	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Anti	  Ig-­‐dependent	  SHIP1	  recruitment	  protects	  BMMC	  from	  antigen-­‐induced	  
activation.	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Figure	  3:	  Adenosine-­‐induced	  BMMC	  activation	  is	  not	  counteracted	  by	  anti	  Ig	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Figure	   4:	   PI3Kγ	   is	   indispensable	   for	   IgE	   /	   F(ab’)2	   fragment	   induced	  
activation	   of	   BMMC:	   (A)	  WT	   and	   PI3Kγ	   KO	   BMMC	   were	   sensitized	   overnight	  with	   IgE	   anti	   DNP-­‐HSA	   (clone	   SPE-­‐7,	   0.1μg/ml)	   and	   stimulated	  with	   equimolar	  doses	  of	  RAM	  IgG	  or	  F(ab’)2	  fragment	  for	  20	  minutes.	  Degranulation	  was	  followed	  by	   β-­‐hexosaminidase	   activity.	   A	   one-­‐way	   anova	   test	   was	   performed,	   F(ab’)2	  fragment	  stimulated	  wild	   type	  vs.	  F(ab’)2	   fragment	  stimulated	  p110γ	  knock	  out	  (n=2,	  mean	  ±	  SEM,	  ❋P	  <	   .05	  and	  ❋❋P	  <	   .001).	  (B)	  Dose	  response	  curve	  for	  NVS	  PI3-­‐4,	  degranulation	  reaction;	  WT	  BMMC	  were	  sensitized	  overnight	  with	  IgE	  anti	  DNP-­‐HSA	   (clone	   SPE-­‐7,	   0.1μg/ml),	   incubated	  with	   different	   doses	   of	   NVS	   PI3-­‐4	  and	  stimulated	  with	  F(ab’)2	  fragment	  (100nM)	  for	  20	  minutes.	  Degranulation	  was	  followed	  by	   β-­‐hexosaminidase	   activity.	   (C)	   IgE	   sensitized	  WT	  BMMC	  and	  PI3Kγ	  KO	   BMMC	   were	   IL-­‐3	   starved	   in	   medium	   containing	   2%	   FCS	   for	   3h	   and	   then	  stimulated	   with	   different	   concentrations	   of	   F(ab’)2	   fragment.	   Phosphorylation	  status	  of	  PKB	  was	  detected.	  The	  ratio	  pPKB/PKB	  has	  been	  quantified	  using	  ImageJ	  A	  one-­‐way	  anova	  test	  was	  performed,	  F(ab’)2	   fragment	  stimulated	  wild	   type	  vs.	  F(ab’)2	   fragment	   stimulated	  p110γ	  knock	   out	   (n=2,	  mean	  ±	   SEM,	  ❋P	  <	   .05	   and	  
❋❋P	  <	   .001).	  (D)	  Dose	  response	  curve	  for	  NVS	  PI3-­‐4,	  PKB	  phosphorylation;	  WT	  BMMC	  were	  sensitized	  overnight	  with	  IgE	  anti	  DNP-­‐HSA	  (clone	  SPE-­‐7,	  0.1μg/ml),	  were	   IL-­‐3	   starved	   in	   medium	   containing	   2%	   FCS	   for	   3h	   and	   incubated	   with	  different	   doses	   of	   NVS	   PI3-­‐4.	   Phosphorylation	   status	   of	   PKB	  was	   detected.	   The	  ratio	   pPKB/PKB	   has	   been	   quantified	   using	   ImageJ	   (n=3,	   mean	   ±	   SEM).	   (E)	  Western	   blot	   figure	   showing	   one	   of	   the	   experiments	   quantified	   in	   figure	   C.	   (F)	  Western	  blot	  figure	  showing	  one	  of	  the	  experiments	  quantified	  in	  figure	  D.	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Pharmacological	   combination	   of	   AQX-­‐151	   and	   NVS	   PI3-­‐4	   synergistically	  
inhibits	  IgE/Ag	  induced	  BMMC	  activation	  
	  Both	   AQX-­‐151	   (activating	   SHIP1)	   and	   NVS	   PI3-­‐4	   (inhibiting	   PI3Kγ)	   modulate	  PtdIns(3,4,5)P3	  homeostasis	  and	   regulate	   the	   IgE	  mediated	   activation	   of	   BMMC.	  	  The	   autocrine/paracrine	   signalling	   via	   GPCR/PI3Kγ	   is	   however	   insensitive	   to	  AQX-­‐151.	   	   Thus	   we	   tested	   the	   efficacy	   of	   the	   combination	   of	   the	   two	   drugs	   in	  order	  to	  assess	  a	  possible	  drug	  synergism	  for	  IgE	  /	  antigen	  induced	  degranulation	  or	  phosphorylation	  of	  PKB.	   In	  the	  degranulation	  assay,	  AQX-­‐151	  showed	  an	  IC50	  value	  12	  times	  higher	  then	  NVS	  PI3-­‐4	  (11.1	  μM	  versus	  0.947	  μM	  respectively)	  and	  20	   times	   higher	   for	   the	   phosphorylation	   of	   PKB	   (20	   μM	   versus	   1μM)	   (Table1).	  Hence	  we	   designed	   a	   constant	   ratio	   experiment	   using	   a	   12/1	   ratio	   of	   AQX-­‐151	  and	  NVS	  PI3-­‐4	   for	   the	  degranulation	  assay	  and	  20/1	   for	   the	  phosphorylation	  of	  PKB.	  The	  experimental	  data	  were	  then	  tested	  for	  drug	  synergy	  by	  calculating	  the	  Chou-­‐Talalay	  Combinatorial	   Index	  (C.I.)	  with	  dedicated	  software	   that	  provides	  a	  quantitative	  assessment	  of	   the	   synergy.	  The	  CI	  depends	  on	   the	   fraction	  affected	  considered	   (e.g.	  Fa	  =	  0.75	   indicates	  75%	  of	   inhibition)	  and	  determines	  whether	  the	  drug	  combination	  is	  synergistic	  (CI	  <1),	  additive	  (CI	  =	  1),	  or	  antagonistic	  (CI	  >1).	  AQX-­‐151	  and	  NVS	  PI3-­‐4	  show	  synergism	  in	   inhibiting	  BMMC	  degranulation	  at	  low	  doses	  and	  the	  combination	  becomes	  not	  synergistic	  anymore	  at	  the	  higher	  doses	  used	  in	  the	  study	  (Fig.5A).	  For	  instance	  we	  can	  observe	  that	  for	  a	  Fa	  value	  of	  0.49	  (indicates	  49%	  of	  inhibition),	  the	  CI	  value	  is	  0.52,	  indicating	  a	  good	  level	  of	  synergism	   (CI<1	   indicate	   synergism).	   The	   activation	   of	   PKB	  was	   synergistically	  inhibited	  at	  all	  drug	  combinations	  investigated	  (CI	  always	  lower	  then	  1,	  Fig.	  5B),	  with	  a	   tendency	  of	  having	  a	  highest	   synergistic	   effect	   at	  higher	  doses	   (Fa	  =	  0.9,	  Fig.	  5B	  and	  C).	  In	  addition,	  a	  Dose	  Reduction	  Index,	  DRI	  value,	  was	  calculated	  (as	  described	   in	   the	   Material	   and	   Methods	   section).	   DRI	   values	   >1	   indicate	   a	  favourable	   combination	   of	   the	   two	   drugs	   whereas	   a	   DRI	   value	   <1	   would	   be	  interpreted	   as	   an	   antagonistic	   combination.	   To	   achieve	   50%	   of	   degranulation	  inhibition	   (Fa=	   0.5),	   the	   combination	   of	   the	   two	  drugs	   required	   2.32	   times	   less	  PI3Kγ	   inhibitor	  and	  19.3	   times	   less	  SHIP1	  activator	   in	   comparison	   to	   the	   single	  agent	   inhibition.	   Similar	   results	   were	   obtained	   for	   the	   inhibition	   of	   the	  phosphorylation	   of	   PKB	   (Table	   2A	   and	   2B).	   Here	   we	   show	   that	   the	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Figure	  5	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Figure	  5:	  Combination	  of	  NVS	  PI3-­‐4	  and	  AQX-­‐151	   for	   the	   inhibition	  of	   IgE-­‐
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Discussion	  
	  In	  this	  study	  we	  have	  shown	  that	  the	  GPCR-­‐mediated	  activation	  of	  PI3Kγ	  induces	  a	  stimulation	  that	   is	  not	  directly	   inhibited	  by	  SHIP1	  or	  by	   its	  plasma	  membrane	  recruitment	   and	   therefore	   can	   reinforces	   the	   IgE-­‐mediated	   BMMC	   activation.	  Indeed,	  the	  recruitment	  of	  the	  SH2-­‐containing	  5’-­‐lipid	  phosphatase	  (SHIP1)	  at	  the	  plasma	  membrane	  is	  one	  of	  the	  most	  characterised	  mechanisms	  that	  regulate	  the	  PtdIns(3,4,5)P3	  homeostasis(18,	  20,	  21)	  and,	   interestingly,	   there	  are	  several	  key	  receptors	  within	  the	  immune	  system	  that	  are	  known	  to	  recruit	  or	  to	  be	  regulated	  by	  SHIP1(22).	  Our	  results	  demonstrate	  for	  the	  first	  time	  that	  the	  GPCR-­‐mediated	  activation	  of	   PI3Kγ	   generates	   a	  pool	   of	   PtdIns(3,4,5)P3	   that	   is	   not	   controlled	  by	  the	  SHIP1	  inhibitory	  activity	  and	  thus	  can	  be	  considered	  a	  “long	  lasting	  stimulus”	  for	   the	   cells	   while	   the	   activation	   of	   PI3Kδ	   generates	   a	   signal	   that	   is	   readily	  hydrolysed	   by	   SHIP1(20).	  While	   one	   of	   the	  mechanisms	   that	   lead	   to	   the	   FcεRI-­‐mediated	   recruitment	   of	   class	   IA	   PI3K	   members	   is	   clearly	   connected	   to	   the	  presence	   of	   a	   SH2	   domain	   expressed	   in	   the	   p85	   adaptor	   subunits(23–25),	   the	  direct	   activation	   of	   PI3Kγ	   downstream	   of	   FceRI	   has	   not	   been	   clearly	  demonstrated	   yet.	   Nevertheless,	   PI3Kγ	   signalling	   activity	   has	   been	   extensively	  studied	   since	   the	   identification	   of	   p110γ	   as	   a	   lipid	   kinase	   able	   to	   link	   the	  stimulation	  of	  GPCRs	  to	  the	  generation	  of	  PtdIns(3,4,5)P3	  in	  mammalian	  cells(26)	  and	   it	   has	   been	   recently	   reported	   that	   p110γ	   is	   activated	   upon	   antigen/IgE	  mediated	   stimulation,	   in	   a	   GPCR-­‐independent	   manner,	   by	   PKCβ	   and	   does	   not	  associate	   with	   the	   adaptor	   subunit	   p84	   since	   PKCβ	  compete	  with	   it	   for	   the	  binding	  with	  the	  catalytic	  subunit(10).	  In	  the	  present	  work	  we	  postulate	  an	  ideal	  separation	   between	   the	   signalling	   mediated	   by	   the	   activation	   of	   RTKs	   or	   TK-­‐adaptor	   proteins,	   where	   the	   activation	   of	   class	   IA	   PI3Ks	   is	   balanced	   by	   SHIP1	  plasma	   membrane	   recruitment	   and	   the	   signalling	   downstream	   of	   GPRCs	   that	  leads	  to	  the	  activation	  of	  PI3Kγ	  and	  the	  generation	  of	  a	  “wave”	  of	  PtdIns(3,4,5)P3	  that	   bypasses	   the	   “gatekeeper”	   ability	   of	   SHIP1.	   This	   ideal	   separation	   between	  RTK	   and	   GPCR	   signalling	   is	   of	   course	   useful	   for	   the	   investigation	   of	   the	   single	  pathways	   involved	   in	   mast	   cells	   activation	   but	   is	   certainly	   far	   from	   the	  physiological	  regulation	  of	  the	  events.	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In	   the	   present	   work	   we	   used	   an	   experimental	   chemical	   activator	   of	   the	  SHIP1	  phosphatase	  activity,	  AQX-­‐151,	  a	  molecule	  developed	  by	   the	  group	  of	  R.J.	  Andersen(12),	   that	   allowed	  us	   to	   induce	  SHIP1	  activation	   in	  BMMC	  without	   the	  need	   of	   any	   receptor-­‐mediated	   stimulation.	   Of	   note,	   the	   present	   molecule	   has	  never	   been	   tested	   before	   in	  BMMC	   thus	  we	   are	   the	   first	   testing	  AQX-­‐151	   as	   an	  inhibitor	  of	  BMMC	  activation	  and	  degranulation.	  	  The	   results	   obtained	   here	   demonstrate	   that	   upon	   antigen/IgE-­‐mediated	  stimulation,	   the	   pool	   of	   PtdIns(3,4,5)P3	   generated	   by	   BMMC	   is	   sensitive	   to	   the	  SHIP1	  phosphatase	   activity	   and	   thus	   readily	  hydrolysed	  upon	  pre-­‐incubation	  of	  the	  cells	  with	  AQX-­‐151.	  In	  our	  opinion	  this	  result	  does	  not	  indicate	  that	  PI3Kγ	   is	  not	  recruited	  upon	  FceRI	  activation	  but	  rather	  that,	  as	  already	  described(8),	   the	  GPCR-­‐mediated	  activation	  of	  PI3Kγ	  is	  an	  autocrine	  and	  paracrine	  event	  that	  relays	  on	  a	  RTK-­‐mediated	  generation	  of	  PtdIns(3,4,5)P3	  that	   is	  readily	   inhibited	  by	  the	  recruitment	  of	  SHIP1.	  The	   pharmacological	   targeting	   of	   SHIP1,	   both	   by	   activating	   or	   inhibiting	   its	  catalytic	   activity	   is	   an	   interesting	   and	   promising	   strategy	   for	   the	   treatment	   of	  several	   immune	   system-­‐related	   disorders	   such	   as	   asthma,	   allergic	   rhinitis	   or	  atopic	   dermatitis(27,	   28)	   but	   could	   also	   lead	   to	   novel	   approaches	   for	   the	  treatment	   of	   haematological	   tumors	   or	   for	   the	   facilitation	   of	   allogenic	  transplantation(29,	   30).	   Currently,	   AQX-­‐1125	   is	   the	   most	   promising	   allosteric	  SHIP1	  activator	  developed	  by	  Aquinox	  pharmaceutics	  and	  is	  in	  clinical	  trial	  phase	  2	   for	   the	   treatment	   of	   Chronic	   Obstructive	   pulmonary	   disease	   (COPD)	   and	  bladder	  pain	  syndrome.	  	  In	   the	  present	  work	  we	  also	  describe	  another	  way	   to	  promote	  a	   “physiological”	  activation	  of	  SHIP1	  by	  inducing	  the	  co-­‐clustering	  of	  the	  FcεRI	  and	  the	  FcγRIIb(31).	  This	   is	   a	   known	   inhibitory	  mechanism	   discovered	   in	   BMMC	   and	   B	   cells	   and	   is	  based	   on	   the	   ability	   of	   the	   FcγRIIb,	   the	   low	   affinity	   receptor	   for	   IgG,	   to	   recruit	  SHIP1	  at	  the	  plasma	  membrane.	  In	  order	  to	  reproduce	  this	  mechanism	  in	  vitro	  we	  incubated	   IgE	   sensitized	   BMMC	   with	   a	   rabbit-­‐anti-­‐mouse	   anti	   immunoglobulin	  antibody	  (RAM-­‐IgG)	  and	  we	  demonstrated	  that	  although	  this	  mechanism	  leads	  to	  the	  inhibition	  of	  the	  IgE/antigen	  mediated	  activation	  of	  BMMC,	  is	  not	  able	  to	  block	  the	  signalling	  induced	  by	  the	  GPCR	  mediated	  activation	  of	  PI3Kγ.	  Interestingly,	  a	  therapeutical	  approach	  based	  on	  the	  co-­‐clustering	  of	  FcεRI	  and	  FcγRIIb	  has	  been	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proposed	   by	   the	   group	   of	   A.	   Saxon	   that	   generated	   a	   polypeptide	   (GE2	   peptide)	  able	  to	  induce	  the	  co-­‐clustering	  of	  the	  two	  receptors	  and	  demonstrated	  its	  ability	  to	  inhibit	  IgE	  mediated	  reactivity	  in	  human	  cell	  lines	  and	  in	  mice(32).	  During	  the	  realization	   of	   the	   present	   project	  we	  were	   also	   interested	   in	   generating	   such	   a	  polypeptide	  in	  order	  to	  test	  our	  hypothesis	  but	  unfortunately	  due	  to	  the	  relevant	  size	   of	   the	   protein	   (60Kd)	   and	   to	   the	   difficulties	   of	   producing	   a	   secreted	  polypeptide	   without	   the	   presence	   of	   any	   immunoglobulin	   contaminant	   in	   the	  cellular	  medium,	  we	  did	  not	  succeed	  in	  our	  goal.	  	  Here	   we	   also	   confirm	   the	   key	   role	   for	   PI3Kγ	   as	   a	   master	   regulator	   of	   BMMC	  activation.	  Indeed	  we	  show	  that	  BMMC	  activation	  can	  be	  induced	  by	  stimulating	  IgE-­‐sensitized	  cells	  with	  an	  anti-­‐Ig	  antibody	  fragment,	  F(ab’)2,	  that	  cluster	  the	  IgE	  /	  FcεRI	  complexes	  without	  the	  need	  of	  an	  antigen.	  Even	  in	  the	  case	  of	  the	  F(ab’)2	  fragment	   stimulation,	   we	   observed	   a	   defective	   degranulation	   in	   BMMC	   lacking	  PI3Kγ	   and	   a	   strong	   reduction	   in	   the	   F(ab’)2	   fragment	   /	   IgE	   induced	  phosphorylation	   of	   the	   serine	   473	   of	   PKB.	   The	   same	   results	   could	   be	   further	  reproduced	  in	  wild	  type	  BMMC	  incubated	  with	  a	  selective	  PI3Kγ	  inhibitor.	  	  Finally,	  after	  we	  proved	  that	  the	  phosphatase	  activity	  of	  SHIP1	  is	  not	  able	  to	  block	  the	  GPCR	  mediated	  PI3Kγ	   signalling	  and	  we	  confirmed	   the	  key	   role	  of	  PI3Kγ	   in	  modulating	  BMMC	  activation,	  we	   tested	  AQX-­‐151,	   the	  allosteric	  SHIP1	  activator,	  in	   combination	   with	   NVS	   PI3-­‐4,	   a	   selective	   PI3Kγ	   inhibitor	   for	   their	   ability	   to	  inhibit	   IgE	   mediated	   BMMC	   activation.	   Indeed	   we	   observed	   a	   synergistic	  inhibition	   of	   the	   BMMC	   activation	   both	   in	   terms	   of	   reduction	   of	   the	   antigen-­‐induced	   cellular	   degranulation	   and	   the	   phosphorylation	   of	   PKB.	   To	   our	  knowledge	  this	  is	  the	  first	  report	  describing	  the	  use	  of	  a	  dual	  approach	  based	  on	  the	   molecular	   targeting	   of	   PI3Kγ	   and	   SHIP1	   for	   the	   modulation	   of	   the	   IgE	  mediated	  mast	  cells	  activation.	  The	  achievement	  of	  a	  synergistic	  inhibitory	  effect	  obtained	  by	  the	  combination	  of	  the	  two	  compounds	  is	  extremely	  interesting	  for	  a	  future	  clinical	  application	  because	  allows	  a	  potential	  reduction	  of	  the	  doses	  of	  the	  single	   molecule	   employed	   in	   the	   therapy	   and	   reduces	   the	   risk	   of	   high	   dose	  dependent	  side	  effects.	  	  In	   our	   opinion,	   the	   ability	   of	   different	   members	   of	   class	   I	   PI3K	   to	   generate	  different	  pools	  of	  PtdIns(3,4,5)P3	  that	  can	  be	  controlled	  or	  not	  by	  SHIP1	  could	  be	  determined	   by	   two	   factors:	   either	   the	   different	   pools	   of	   PtdIns(3,4,5)P3	   are	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generated	   in	   topological	  distinct	   regions	  of	   the	  plasma	  membrane	  where	  SHIP1	  does	   not	   have	   access	   or	   there	   is	   a	   cross-­‐regulation	  whose	   protagonists	   are	   the	  GPCR	   or	   some	   GPCR	   effector	   and	   SHIP1.	   An	   interesting	   view	   about	   the	   cross	  regulation	  of	  PI3Kγ	  activity	  and	  SHIP1	  could	  be	  deduced	  by	  the	  work	  of	  Zhang	  et	  al(33),	   that	  demonstrated	   that	  SHIP1	  can	  be	  phosphorylated	  by	   the	  cyclic	  AMP-­‐dependent	  protein	  kinase	  (PKA)	  at	  the	  Serine	  440,	  resulting	  in	  an	  increase	  of	  its	  catalytic	  activity.	  Here	  we	  could	  speculate	  that	  being	  the	  A3	  adenosine	  receptor,	  A3AR,	   associated	   with	   a	   trimeric	   G	   protein	   (Gi/beta/gamma)	   known	   to	   inhibit	  cAMP	  generation(34),	  this	  could	  result	  in	  a	  lack	  of	  SHIP1activation	  of	  in	  presence	  of	  adenosine	  stimulation.	  Indeed,	  among	  the	  identified	  adenosine	  receptors	  (AR),	  A1,	  A2a,	  A2b	  and	  A3,	  all	  expressed	   in	  murine	  BMMC,	  A3AR	  seems	  to	  be	  the	  one	  involved	  in	  the	  adenosine-­‐dependent	  activation	  of	  PI3Kγ(8).	  Interestingly	   we	   could	   also	   speculate	   about	   a	   spatial	   topological	   separation	  between	  RTKs	  and	  GPCRs	  plasma	  membrane	   localization	   that	  could	  hamper	   the	  access	  of	  SHIP1	  to	  the	  pool	  of	  PtdIns(3,4,5)P3,	  since	  it	  has	  been	  demonstrated	  that	  PI3Kγ	  itself	  is	  able	  to	  generate	  two	  distinct	  pools	  of	  PtdIns(3,4,5)P3	  depending	  on	  whether	  p110γ	  is	  in	  complex	  with	  p84	  or	  p101.	  	  
Conclusion:	   In	  the	  present	  work	  we	  demonstrate	  that	  the	  signalling	   induced	  by	  the	   GPCR	   mediated	   activation	   of	   PI3Kγ	   is	   not	   directly	   controlled	   by	   the	  phosphatase	  activity	  of	  SHIP1	  and	  is	  able	  to	  reinforce	  the	  IgE	  mediated	  activation	  of	  BMMC.	  Although	  the	  therapeutical	  activation	  of	  the	  SHIP1	  phosphatase	  activity	  is	   a	   valid	   approach	   and	   is	   currently	   under	   clinical	   phase	   testing,	   in	   our	  experiments	   we	   provide	   a	   proof	   of	   concept	   that	   the	   dual	   pharmacological	  targeting	  of	  SHIP1	  and	  PI3Kγ	  could	  generate	  a	  novel	  powerful	  approach	   for	   the	  treatment	  of	  the	  IgE	  mediated	  allergic	  diseases.	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Cell	  culture	  and	  mice	  	  	  Bone	   marrow–derived	   mast	   cells	   (BMMCs)	   were	   differentiated	   from	   bone	  marrow	  of	  8-­‐12	  weeks	  old	  C57BL/6J	  wild-­‐type	  (wt)	  mice,	  p110γ-­‐/-­‐	  mice(35)	  and	  SHIP1	  -­‐/-­‐	  mice(36)	  in	  IMDMcomp	  medium	  (+5	  ng/mL	  murine	  stem	  cell	  factor	  [SCF]	  for	   4	  days)	   at	   37°C	   in	   a	   5%	   CO2	  atmosphere	   and	   subsequently	   cultured	   as	  described	  by	  Laffargue	  et	  al(8).	  PI3Kγ	  knock-­‐out	  and	  SHIP1	  knock-­‐out	  mice	  were	  in	   the	   same	   genetic	   background	   of	  wild	   type	  mice	   and	  were	   used	   age	  matched	  from	  8	  to	  12	  weeks.	  	  
Antibodies	  and	  reagents:	  Affinity-­‐purified	  intact	  IgG	  and	  F(ab’)2	  fragment	  of	  polyclonal	  Rabbit	  anti	  Mouse	  Immunoglobulin	  (H+L)	  (RAM)	  from	  Jackson	  ImmunoResearch	  (West	  Grove,	  PA).	  Anti	  phospho-­‐PKB	  antibody	  made	  in	  mouse	  was	  gently	  provided	  by	  Dr.	  S.	  Korur.	  Anti	  SHIP1	  (P1C1)	  is	  a	  mouse	  monoclonal	  IgG1	  (Santa	  Cruz	  Biotechnology).	  Mouse	  monoclonal	  anti-­‐activated	  MAP	  Kinase	   (MAPK-­‐YT)	  antibodies	  were	   from	  Sigma-­‐Aldrich.	  Adenosine,	  Dinitrophenyl-­‐human	  serum	  albumin	  (DNP),	  mouse	  anti-­‐DNP	  IgE	  (clone	  SPE-­‐7)	  if	  not	  stated	  differently	  were	  from	  Sigma-­‐Aldrich.	  Murine	  stem	  cell	  factor	  (mSCF)	  and	  murine	  IL-­‐3	  were	  from	  Peprotech.	  NVS-­‐PI3-­‐4	  was	  obtained	  from	   Novartis	   Institutes	   for	   BioMedical	   research	   (Horsham,	   UK).	   AQX-­‐151	   was	  kindly	  provided	  by	  Prof.	  Raymond	  Andersen,	  University	  of	  British	  Columbia.	  	  
Bone	  marrow	  derived	  mast	  cells	  generation:	  Bone	  marrow	  (BM)	  was	  obtained	  from	  decapitated	  femurs	  by	  centrifugation,	  and	  cells	  were	  re-­‐suspended	   in	   IMDM	  containing	  10%	  HIFCS,	  2	  mM	  L-­‐Gln,	  10	  μg/ml	  PEST,	   50	   μM	   β-­‐mercaptoethanol,	   additionally	   supplemented	   to	   2	   ng/ml	  recombinant	  murine	  IL-­‐3	  and	  5	  ng/ml	  murine	  SCF	  (only	  added	  once).	  Cells	  were	  cultured	  at	  37°C,	  5%	  CO2	  with	  re-­‐addition	  of	  2	  ng/ml	  IL3	  every	  second	  day.	  After	  4	   weeks,	   BMMC	   differentiation	   was	   monitored	   by	   the	   expression	   of	   c-­‐Kit	   and	  FcεRI	   using	   flow	   cytometry.	   Subsequently,	   bone	   marrow-­‐derived	   mast	   cells	  (BMMCs)	   were	   diluted	   weekly	   to	   0.5×106	   cells/ml	   maintaining	   20%	   recycled	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medium	  mixed	  with	  80%	  fresh	  medium.	  After	  4	  weeks,	  BMMC	  differentiation	  was	  monitored	  by	  the	  expression	  of	  c-­‐Kit	  and	  FcεRI	  using	  flow	  cytometry.	  	  
Beta-­‐hexosaminidase	  release	  assay:	  BMMCs	  were	  sensitized	  overnight	  with	  100	  ng/ml	  IgE	  (SPE-­‐7).	  Concentration	  of	  100ng/ml	   resemble	   the	   physiological	   levels	   of	   antigen	   specific	   IgE	   present	   in	  mouse	   and	   human	   sera	   after	   the	   exposure	   to	   parasites	   and	   allergens(37).	   Cells	  were	   washed	   twice	   and	   re-­‐suspended	   at	   2x106	   cells/ml	   in	   modified	   Tyrodes	  buffer.	   Where	   indicated,	   the	   cells	   were	   pre-­‐incubated	   with	   RAM	   IgG	   for	   10	  minutes	   and	   degranulation	   was	   induced	   by	   the	   indicated	   DNP-­‐HSA	  concentrations	   or	   by	   F(ab’)2	   fragment	   of	   anti	   Ig	   antibody.	   The	   reaction	   was	  stopped	   after	   20	   min	   by	   addition	   of	   0.1	   M	   Na2CO3/NaHCO3.	   Plates	   were	  centrifuged	  at	  4°C	  for	  5	  min	  and	  100	  μl	  aliquots	  (triplicate)	  of	  supernatant	  were	  transferred	   to	  96	  well	  plates.	  Beta-­‐hexosaminidase	  activity	   in	   supernatants	  was	  assessed	  with	  p-­‐nitrophenyl	  N-­‐acetyl-­‐β-­‐D-­‐glucosaminide	  (p-­‐NAG)	  as	  a	  substrate,	  incubated	   1h	   at	   37°C	   and	   the	   reaction	   was	   stopped	   with	   100	   μl	   of	   0.15	  Na2CO3/NaHCO3.	   The	   amount	   of	   p-­‐nitrophenol	   generated	   was	   assessed	   by	  measuring	  the	  absorbance	  at	  410	  nm	  on	  a	  spectrophotometer	  (Spectramax	  340).	  The	   amount	   of	   beta-­‐hexosaminidase	   released	   was	   calculated	   by	   using	   the	  formula:	  	  Release	  (R)	  [%]	  =	  (Aeach	  sample	  –	  Abackground)	  /(Atotal	  lysate)	  x	  100	  
	  
PKB	  phosphorylation	  assay:	  BMMCs	   were	   IL-­‐3	   starved	   in	   IMDM	   growth	   medium	   containing	   2%	   FCS	   for	   3	  hours	  in	  a	  24-­‐well	  plate	  and	  then	  stimulated	  for	  the	  indicated	  time.	  The	  cells	  were	  then	  moved	  on	  a	  Eppendorf	  tube	  and	  the	  stimulation	  was	  stopped	  on	  ice.	  Where	  indicated	  the	  cells	  were	  pre-­‐incubated	  with	  RAM	  IgG	  for	  10	  minutes	  or	  with	  the	  indicated	   inhibitor	   for	   1	   hour	   and	   then	   stimulated.	   Stimulations	   were	   done	   at	  37°C	   for	   the	   indicated	   times.	   The	   cells	   were	   immediately	   collected	   by	  centrifugation,	  spun	  for	  1	  min	  at	  2000	  g	  and	  lysed	  in	  2x	  Laemmli	  sample	  buffer.	  Protein	  samples	  were	  then	  heated	  to	  95°C	  for	  8	  minute,	  centrifuged,	  separated	  by	  SDS-­‐PAGE	   and	   transferred	   to	   polyvinylidene	   fluorid	   (PVDF)-­‐membranes	  (Millipore)	  by	   semi-­‐dry	   transfer.	  Membranes	  were	  blocked	  with	  5%	  (w/v)	  milk	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powder	   (Migros)	   in	  TBS-­‐T	  buffer	   [20	  mM	  Tris/HCl,	  pH	  7.6,	  137	  mM	  NaCl,	  0.1%	  (v/v)	  Tween	  20	  (Fluka)].	  Blots	  were	  incubated	  overnight	  at	  4°C	  with	  the	  primary	  antibody,	   followed	   by	   incubation	   with	   horseradish	   peroxidase	   (HRP)-­‐coupled	  secondary	  goat	  anti-­‐	  mouse	  or	  anti-­‐rabbit	  antibodies	  (Sigma).	  Protein	  bands	  were	  visualized	   by	   enhanced	   chemiluminescence	   (Millipore).	   Images	  were	   quantified	  with	  ImageJ	  1.48v	  software	  (NIH)	  using	  the	  rectangle	  tool.	  Band	  pixel	  values	  were	  background	   corrected	   using	   an	   area	   above	   or	   below	   the	   selected	   band	   as	  background.	  Levels	  of	  protein	  phosphorylation	  were	  normalized	  to	  the	  total	  level	  of	  the	  protein.	  	  
Cytokine	  secretion	  BMMCs	  were	  preloaded	  overnight	  with	  100	  ng/ml	  IgE,	  washed,	  re-­‐suspended	  at	  2x106	  cells/ml	  and	  stimulated	  for	  1h	  at	  37°C.	  Where	  indicated,	  WT	  BMMCs	  were	  incubated	   for	   1	   h	   with	   inhibitors	   or	   0.1%	   DMSO	   before	   stimulations.	   The	   cells	  were	   harvested	   and	   the	   amount	   of	   cytokines	   in	   the	   cellular	   supernatant	   was	  measured	   by	   specific	   ELISA	   kits	   from	   R&D	   Systems	   according	   to	   the	  manufacturer’s	  protocol.	  	  
Isolation	  of	  total	  RNA,	  RT-­‐PCR,	  and	  qPCR	  Total	  RNA	  was	  isolated	  from	  BMMC	  with	  RNeasy	  mini	  kit	  (Qiagen,	  cat.	  no.	  74104)	  according	  to	  the	  manufacturer’s	  protocol.	  cDNA	  was	  generated	  with	  1	  mg	  of	  total	  RNA	  with	  M-­‐MLV	  reverse	  transcriptase	  (RT	  buffer	  and	  protocol,	  Invitrogen)	  and	  RNAsin	   (Promega)	   and	   stored	   at	   –80°C	   until	   ready	   for	   use.	   An	   ABPrism	   7000	  (Applied	  Biosystems,	  Foster	  City,	  CA)	  and	  SYBR	  GREEN	  PCR	  Master	  Mix	  (Applied	  Biosystems)	   were	   used	   for	   qPCR	   analysis	   of	   TNF-­‐α,	   IL-­‐6	   and	   IL-­‐4.	   18s	   mRNA	  served	  as	  an	  internal	  standard	  to	  generate	  calibration	  curves.	  PCR	  assays	  were	  performed	  in	  triplicate	  and	  fold	  induction	  was	  calculated	  against	  control-­‐treated	  samples	  using	  the	  comparative	  Ct	  method	  (ΔΔCt).	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Primers	  sequences	  used:	  	  IL4	  (mus	  musculus)	  Forward	  5’-­‐TGTGCCAAACGTCCTCACA-­‐3’	  Reverse	  5’-­‐GCACCTTGGAAGCCCTACAG-­‐3’	  IL6	  (mus	  musculus)	  Forward	  5’-­‐ACAACCACGGCCTTCCCTACTT-­‐3’	  Reverse	  5’-­‐CACGATTTCCCAGAGAACATGTG-­‐3’	  TNF-­‐alpha	  (mus	  musculus)	  Forward	  5’-­‐ATCCGCGACGTGGAACTG-­‐3’	  Reverse	  5’-­‐CGAAGTTCAGTAGACAGAAGA-­‐3’	  	  
Statistical	  Analysis	  Numeric	   results	  were	   tested	   for	   significance	   using	   a	   two-­‐tailed	   Student’s	   t	   test,	  (paired	  or	  unpaired,	  as	  imposed	  by	  datasets).	  *	  and	  **	  refer	  to	  p-­‐values	  p	  <	  .05	  and	  p	   <	   .001	   respectively.	   Calculations	   were	   carried	   out	   using	   Graph	   Pad	   Prism	   6	  software.	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S2A:	  WT	  and	  SHIP1	  KO	  BMMC	  were	  IL-­‐3	  starved	  in	  medium	  containing	  2%	  FCS	  for	  3h	  then	  incubated	  with	  1μM	  RAM	  IgG	  for	  10	  minutes	  and	  then	  stimulated	  for	  5	  minutes	  with	  10	  ng/ml	  DNP-­‐HSA.	  The	  ratio	  pPKB/PKB	  was	  quantified	  using	  ImageJ	  (n=2,	  mean	  ±	  SEM).	   S2B:	  Overnight	  IgE-­‐sensitized	  BMMC	  were	  incubated	  with	  1	  μM	  RAM	  IgG	  for	  10	   minutes	   and	   then	   stimulated	   with	   10	   ng/ml	   DNP-­‐HSA	   for	   1	   hour.	   The	   cell	  supernatant	  was	   then	   analysed	   by	   ELISA	   for	   the	   detection	   of	   the	   IL6	   released.	   S2C:	  Molecular	  structure	  of	  NVS	  PI3-­‐4.	  
	  
Project	  I	  	  
	  106	  
	  
Table	   1.	   Concentration	   of	   the	   single	   compound	   used	   for	   the	   calculation	   of	   the	  Combinatorial	   Index.	   Degranulation	   assay	   and	   detection	   of	   the	   phosphorylation	  status	  of	  PKB	  were	  performed	  in	  presence	  of	  five	  different	  concentrations	  of	  the	  single	  compound	  and	  in	  combination.	  It	  is	  calculated	  as	  CI	  =	  D1/(Dx)1	  +	  D2/(Dx)2,	  where	  (Dx)1	   is	   the	  dose	  that	  give	  an	  “X”	  effect	  when	  is	   in	  combination	  and	  D1	   is	  the	  dose	  of	  the	  single	  drug	  needed	  for	  obtaining	  the	  same	  effect.	  CI	  =	  1	  indicates	  an	  additive	  effect;	  CI	  >	  1,	  indicates	  antagonism;	  CI<1,	  indicates	  synergism.	  	  	  	  	  	  	  	  
	  






0.23 0.47 0.95 1.9 3.8
0.25 0.5 1 2 4
2.77 5.54 11.1 22.2 44.4
5 10 20 40 80
Degranulation assay
Phosphorylation of PKB
Drugs concentration used for the calculation of the Combinatorial Index (CI)
Fa
A) Dose reduction index (DRI), degranulation assay
NVS PI3-4 
AQX-151 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
14.906 7.503 4.755 3.271 2.321 1.647 1.133 0.718 0.361
16.082 17.206 17.996 18.671 19.313 19.976 20.725 21.677 23.192
B) Dose reduction index (DRI), phosphorylation of PKB
NVS PI3-4 
AQX-151
1.7 1.88 2.02 2.14 2.25 2.37 2.51 2.69 2.99
2.95 5.04 7.2 9.63 12.59 16.46 22.04 31.46 53.75
Fa 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
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Introduction	  	  Leukocytes	   chemotaxis,	   release	   of	   inflammatory	   mediators	   during	   mast	   cells	  degranulation	   or	   reactive	   oxygen	   species	   (ROS)	   formation	   by	   neutrophils	  represent	  some	  of	  the	  most	  important	  defence	  mechanisms	  of	  the	  immune	  system	  that	  are	  tightly	  controlled	  by	  the	  activation	  of	  phosphoinositide-­‐3	  kinase	  gamma	  (PI3Kγ)	  (1-­‐3).	  Being	  a	  central	  enzyme	  in	  innate	  and	  adaptive	  immune	  responses,	  PI3Kγ	   is	   also	   implicated	   in	   various	   inflammatory	   disorders.	   Mice	   lacking	   PI3Kγ	  activity	   are	   resistant	   in	  models	   of	   rheumatoid	   arthritis	   (4),	   allergic	   asthma	   (5),	  glomerulonephritis	   and	   systemic	   lupus	   (6)	   as	   well	   as	   anaphylaxis	   (2,	   7),	  cardiovascular	   disease	   (8),	   and	   diet-­‐induced	   obesity	   (9).	   PI3Kγ therefore	  represents	   a	   highly	   potential	   therapeutic	   target	   in	   inflammatory	   disease,	  cardiovascular	  disorders	  and	  obesity.	  PI3Kγ	  is	  highly	  expressed	  in	  hematopoietic	  tissues	   and	   cells	   (10-­‐13),	   but	   is	   also	   present	   in	   other	   cells,	   including	  cardiomyocytes,	   vascular	   smooth	   muscle	   and	   endothelia	   (14,	   15).	   Broad	   PI3Kγ	  inhibition	  could	   therefore	  potentially	  be	  associated	  with	  various	  adverse	  effects	  including	   decreased	   host	   defence	   (16,	   17).	   The	   possibility	   of	   cell	   type-­‐specific	  PI3Kγ	   targeting,	   that	   will	   allow	   alleviation	   of	   pathological	   condition	   without	  general	  suppression	  of	  host	  immune	  system,	  is	  therefore	  of	  great	  value.	  PI3Kγ	   is	   the	   only	   member	   of	   Class	   IB	   PI3Ks.	   It	   is	   generally	   considered	   to	   be	  activated	   downstream	   of	   G	   protein-­‐coupled	   receptor	   (GPCR)	   (12,	   13,	   18),	  although	  a	  GPCR-­‐independent	  PKCβ-­‐mediated	  PI3Kγ	  activation	  has	  recently	  been	  described	   (19).	   PI3Kγ	   acts	   as	   a	   heterodimer	   between	   a	   catalytic	   p110γ	   subunit	  and	  one	  of	  two	  possible	  adaptor	  proteins	  –	  p84	  (also	  called	  p87PIKAP)	  or	  p101	  (12,	  13,	  18).	   	  We	  previously	  showed	  that	  adaptor	  proteins	  are	  essential	   to	  transduce	  signals	  from	  GPCRs	  to	  PI3Kγ	  (10).	  Some	  of	  the	  functions	  of	  adaptor	  subunits	  are	  overlapping,	   as	   both	   proteins	   were	   able	   to	   promote	   PKB/Akt	   phosphorylation	  and	  migration	  of	  mast	  cells.	  However,	  p101	  and	  p84	  also	  possess	  adaptor-­‐specific	  physiologic	  functions.	  We	  identified	  distinct	  pools	  of	  PtdIns(3,4,5)P3	  at	  the	  plasma	  membrane	   emerging	   from	   the	   two	   PI3Kγ/adaptor	   subunit	   complexes.	   These	  pools	  display	  a	  differential	  sensitivity	  to	  cholesterol	  depletion,	  and	  their	  capacity	  to	   promote	   release	   of	  mast	   cell	   granules	   (10).	   Adaptor-­‐specific	   responses	  were	  also	   described	   in	   neutrophils	   (20,	   21),	   where	   p101	   played	   a	   key	   role	   in	   cell	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Results	  
	  
FTI-­‐277	   affects	   PI3Kγ-­‐dependent	   signalling	   in	   mast	   cells,	   but	   not	   in	  
macrophages	  	  To	  evaluate	   the	  possibility	  of	  differential	   cell-­‐dependent	  Ras	   involvement	   in	   the	  PI3Kγ	  signalling,	  we	  decided	  to	  block	  Ras	  activation	  by	  using	  farnesyltransferase	  inhibitors	   FTI-­‐277.	   Farnesyltransferase	   inhibitors	   (FTIs)	   were	   originally	  developed	   as	   anti-­‐Ras	   compounds	   for	   cancer	   therapy.	   They	   block	   Ras	  farnesylation	  that	  is	  required	  for	  its	  translocation	  to	  the	  plasma	  membrane,	  thus	  inhibiting	  proper	  function	  of	  Ras	  (23-­‐25).	  FTI-­‐277	  indeed	  caused	  relocalization	  of	  GFP-­‐tagged	  H-­‐,	  N-­‐,	  and	  K-­‐Ras	  from	  plasma	  membrane	  to	  the	  cytosol	  in	  mast	  cells	  (fig.	  S1A).	  The	  effect	  was	  more	  profound	  in	  case	  of	  H-­‐Ras	  isoform.	  The	  remaining	  low-­‐level	   plasma	  membrane	   localization	   of	  N-­‐	   and	  K-­‐Ras	   could	  be	   explained	  by	  the	  possibility	  of	  alternative	  geranylgeranylation	  of	  these	  isoforms	  (26).	  	  We	  compared	  the	  action	  of	  FTI-­‐277	  on	  PI3Kγ	  activation	  in	  bone	  marrow-­‐derived	  mast	   cells	   (BMMC)	   and	   bone	  marrow-­‐derived	  macrophages	   (BMMØ).	   Both	   cell	  types	   were	   treated	   with	   5µM	   FTI-­‐277	   for	   72	   hours,	   and	   different	   PI3Kγ-­‐dependent	  responses	  were	  analysed.	  We	  first	  measured	  the	  effect	  of	  FTI-­‐277	  on	  the	  activation	  of	  the	  main	  PI3K	  downstream	  target	  -­‐	  protein	  kinase	  B	  (PKB/Akt).	  To	   distinguish	   between	   PI3Kγ-­‐dependent	   and	   non-­‐PI3Kγ-­‐dependent	   responses	  cells	  were	  stimulated	  with	  either	  GPCR	  ligands	  (adenosine	  (Ade)	  in	  case	  of	  mast	  cells	   and	   complement	   component	   5a	   (C5a)	   in	   case	   of	   macrophages)	   or	   with	  receptor	  tyrosine	  kinase	  (RTK)	  ligands	  (stem	  cell	   factor	  (SCF)	  for	  mast	  cells	  and	  macrophage	   colony-­‐stimulating	   factor	   (M-­‐CSF)	   for	   macrophages).	   In	   mast	   cells	  FTI-­‐277	   led	   to	   a	   significant	   decrease	   in	   PKB	   phosphorylation	   at	   Ser473	   upon	  activation	  with	  Ade,	   but	   had	  no	   effect	   on	  PKB	   activation	   upon	   stimulation	  with	  SCF,	  demonstrating	  that	   inhibitory	  FTI-­‐277	  action	   is	  specific	   for	  PI3Kγ	   (Fig.	  1A).	  The	  FTI-­‐277	  effect	  on	  mast	   cells	  was	   time-­‐dependent,	  with	   increased	   inhibitory	  response	   upon	   longer	   incubation	   with	   the	   compound	   (fig.	   S1B).	   In	   contrast	   to	  mast	   cells,	   Ras	   inhibition	   did	   not	   affect	   neither	   C5a-­‐,	   nor	   M-­‐CSF-­‐	   induced	  activation	  of	  PKB	  in	  macrophages	  (Fig.	  1B).	  	  Leukocytes	  migration	  toward	  the	  site	  of	  injury	  or	  infection	  represents	  a	  key	  step	  in	   the	   innate	   immune	   response,	   as	  well	   as	   in	   the	  progress	  of	   acute	   and	   chronic	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inflammation.	  	  Chemoattractant-­‐mediated	  leukocyte	  recruitment	  has	  been	  shown	  to	  be	  largely	  dependent	  on	  the	  presence	  of	  functional	  PI3Kγ	  (1,	  7).	  We	  therefore	  next	   assessed	   the	   effect	   of	   Ras	   inhibition	   on	   the	   ability	   of	   mast	   cells	   and	  macrophages	   to	   migrate	   in	   vitro	   (Fig.	   1C,D).	   In	   line	   with	   the	   results	   for	   PKB	  phosphorylation,	   only	   Ade-­‐stimulated	   migration	   of	   mast	   cells	   was	   significantly	  impaired	  by	  FTI-­‐277	  (Fig.	  1C).	  Macrophages	  migration	  toward	  GPCR	  agonists	  C5a	  or	  Rantes,	  as	  well	  as	  RTK	  ligand	  M-­‐CSF	  remained	  intact	  upon	  treatment	  with	  the	  inhibitor	   (Fig.	   1D	   and	   fig.	   S2).	   To	   verify	   that	   the	   absence	   of	   FTI	   effect	   on	  macrophages	  is	  not	  explained	  by	  the	  inability	  of	  the	  inhibitor	  to	  enter	  the	  cell	  or	  stay	  inside	  the	  cell,	  we	  checked	  accumulation	  of	  unfarnesylated	  prelamin	  A,	  one	  of	  the	   markers	   for	   farnesyltransferase	   inhibition	   (27).	   BMMC	   and	   macrophages	  demonstrated	   similar	   increase	   in	   the	   level	   of	   prelamin	   A,	   showing	   that	   under	  conditions	  used	  FTI-­‐277	  efficiently	  blocks	  protein	  farnesylation	  in	  both	  cell	  types	  (fig.	  S3A).	  	  Finally,	  we	  analysed	  whether	  Ras	  inhibition	  affects	  the	  ability	  of	  mast	  cells	   to	   produce	   cytokines	   and	   to	   release	   inflammatory	   mediators	   during	  degranulation.	   FTI-­‐277	   significantly	   decreased	   expression	   of	   TNFa	   and	   IL6	   in	  mast	   cells	   stimulated	   with	   IgE/antigen	   and	   Ade	   (Fig.	   1E)	   and	   attenuated	  degranulation	  response	   in	   IgE/antigen-­‐	  activated	  cells	  upon	  co-­‐stimulation	  with	  Ade,	  but	  not	  with	  SCF	  (Fig.	  1F).	  	  Gamma	   subunit	   of	   heterotrimeric	   G-­‐protein	   can	   be	   isoprenylated	   with	   either	  farnesyl-­‐	   or	   geranylgeranyl-­‐	   moiety	   (28).	   To	   exclude	   the	   possibility	   that	   the	  observed	  inhibitory	  action	  of	  FTI-­‐277	  on	  PI3Kγ	  signalling	  is	  a	  result	  of	   impaired	  Gγ	  processing	  and	  functioning,	  we	  stimulated	  mast	  cells	  with	  another	  GPCR	  ligand	  -­‐	  platelet	  activating	  factor	  (PAF).	  PAF	  acts	  through	  Gaq	  subunit	  and	  triggers	  cyclic	  AMP-­‐responsive	   element-­‐binding	   protein	   (CREB)	   phosphorylation.	   Treatment	  with	   FTI-­‐277	   had	   no	   effect	   on	   CREB	   phosphorylation	   in	   mast	   cells	   and	  macrophages	  (fig.	  S3B),	  showing	  that	  G-­‐protein	  activity	  remains	  intact.	  We	   therefore	   have	   shown	   that	   although	   FTI-­‐277	   efficiently	   blocks	   protein	  farnesylation	   in	  mast	  cells	  and	  macrophages,	   it	   impairs	  PI3Kγ	   signalling	   in	  mast	  cells	   only.	   All	   main	   steps	   of	   PI3Kγ-­‐dependent	   mast	   cell	   activation	   –	  phosphorylation	   of	   PKB,	   migration,	   cytokines	   production	   and	   degranulation	   –	  were	   affected	   by	   Ras	   inhibition.	   Macrophages	   responses,	   however,	   remained	  intact	  upon	  treatment	  with	  FTI-­‐277.	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Figure	  1	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Differential	   sensitivity	   to	  Ras	   inhibition	   is	  determined	  by	  PI3Kγ 	  
adaptor	  subunit.	  	  PI3Kγ	  adaptor	  subunits	  p84	  and	  p101	  are	  differentially	  expressed	  in	  various	  cell	  types	   (10-­‐13).	   Mast	   cells	   have	   only	   p84	   adaptor	   protein,	   while	   macrophages	  express	  both	  subunits	  (10).	  To	  evaluate	  and	  compare	  the	  abundance	  of	  p84,	  p101	  and	   p110γ	   in	   these	   cells	   we	   first	   measured	   the	   level	   of	   their	   messenger	   RNAs	  (mRNA)	   by	   quantitative	   polymerase	   chain	   reaction	   (qPCR)	   assay	   (Fig.	   2A).	  	  According	   to	  qPCR	  data,	  while	  mast	   cells	   express	  only	  p84	   subunit,	   p101	   is	   the	  dominating	   adaptor	   protein	   in	  macrophages,	  with	   its	   expression	   level	   being	   10	  times	   higher	   that	   that	   of	   p84.	   Next	   we	   used	   recombinant	   p84/p110γ	   and	  p101/p110γ	   complexes	  kindly	  provided	  by	  R.	  Williams	   to	  quantify	   the	   absolute	  amount	   of	   corresponding	   proteins	   (Fig.	   2B).	   BMMCs	   possess	   similar	   amount	   of	  p84	  and	  p110γ	  (≈39000	  and	  34000	  molecules/cell,	  correspondingly),	  and	  do	  not	  express	  any	  p101.	  The	  amount	  of	  p110γ	  in	  macrophages	  is	  comparable	  with	  that	  in	   mast	   cells	   (≈30000	   molecules/cell),	   while	   p84	   is	   2	   times	   less	   abundant	  (≈19000	   molecules/cell).	   In	   accordance	   with	   qPCR	   data	   the	   number	   of	   p101	  molecules	  per	  cell	  is	  10x	  higher	  than	  p84	  (≈174000),	  making	  p101	  the	  dominant	  adaptor	  protein	  in	  macrophages.	  It	  was	  suggested	  previously	  that	  free	  monomeric	  p101	   is	  unstable	  and	  undergoes	  cytosolic	  degradation	   (29).	  Therefore,	  we	  were	  surprised	  to	  detect	  almost	  6	  times	  higher	  abundance	  of	  p101	  compared	  to	  p110γ.	  It	  is	  possible,	  that	  the	  excess	  of	  the	  p101	  is	  localized	  in	  the	  nucleus,	  as	  was	  shown	  in	  p110γ/p101	  overexpression	  experiments	  (29,	  30).	  	  It	  was	   previously	   reported	   that	   Ras	   is	   indispensible	   for	  membrane	   recruitment	  and	  activation	  of	  p84/p110γ,	  but	  not	  p101/p110γ	  complexes	  (22).	  To	  assess	  if	  the	  observed	   difference	   in	   sensitivity	   to	   FTI-­‐277	   between	   mast	   cells	   and	  macrophages	  could	  be	  explained	  by	  the	  difference	  in	  the	  adaptor	  subunit	  content	  of	   these	  cells,	  we	  used	  mast	  cells	  complementation	   technique	  described	   in	   (10).	  p110γ -­‐/-­‐	   BMMCs	   lack	   both	   PI3Kγ	   catalytic	   and	   adaptor	   subunits.	   These	   cells	  therefore	   could	   be	   used	   as	   a	   model	   system,	   where	   after	   introduction	   of	   either	  p84/p110γ	   or	   p101/p110γ	   differences	   in	   the	   signalling	   outputs	   of	   the	   two	  complexes	  can	  be	  analysed	  in	  the	  same	  cellular	  context.	  We	  reconstituted	  p110γ -­‐/-­‐	  BMMCs	  with	  p84/p110γ	  or	  p101/p110γ	  complexes,	  treated	  them	  with	  FTI-­‐277	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and	  analysed	  Ade-­‐induced	  PKB	  phosphorylation	  at	  Thr308	  (Fig.	  2C)	  and	  Ser473	  (fig.	   S4).	   Only	   cells	   that	   had	   p84	   as	   an	   adaptor	   subunit	   exhibited	   significant	  reduction	   in	   the	   level	   of	   phosphorylated	   PKB	   upon	   FTI-­‐277	   treatment.	   On	   the	  other	   hand,	   PI3Kγ	   activation	   in	   cells	   expressing	   p101	   adaptor	   protein	   was	  insensitive	   to	  FTI-­‐277	  action.	   It	   is	   important	   to	  mention,	   that	   in	  both	  cases	  FTI-­‐277	  caused	  significant	  decrease	  in	  the	  level	  of	  phosphorylated	  mitogen-­‐activated	  protein	  kinase	  (MAPK),	  demonstrating	  efficient	  Ras	   inhibition	   in	  both	  cell	   types.	  As	  a	  complementary	  independent	  approach	  for	  Ras	  inhibition	  we	  overexpressed	  the	  GTPase-­‐activating	  protein	   (GAP)	  domain	  of	  neurofibromin	  1	   (NF1)	   together	  with	  p84/p110γ	  or	  p101/p110γ	  in	  p110γ -­‐/-­‐	  BMMCs.	  The	  ability	  of	  cells	  to	  migrate	  towards	  Ade	  was	  then	  tested	  in	  vitro	  in	  a	  Transwell	  chamber	  migration	  assay	  (Fig.	  2D).	   Similar	   to	   the	   effect	   of	   FTI-­‐277	   on	   PKB	   phosphorylation,	   only	   p84/p110γ	  containing	   cells	   lost	   their	   migratory	   potential	   after	   NF1	   overexpression,	   while	  migration	  of	  cells	  expressing	  p101	  was	   insensitive	   to	  Ras	   inhibition.	  Our	  results	  demonstrate	  that	  PI3Kγ	  adaptor	  subunit	  indeed	  determines	  whether	  cells	  will	  be	  sensitive	   to	   Ras	   inactivation	   or	   not,	   and	   that	   the	   observed	   difference	   between	  mast	   cells	  and	  macrophages	  might	  be	  explained	  by	   the	   fact	   that	  p84	   is	   the	  only	  adaptor	   subunit	   in	   BMMCs,	   while	   p101	   is	   the	   dominant	   adaptor	   protein	   in	  macrophages.	  Another	   possible	   reason	   for	   distinct	   FTI	   action	   on	  mast	   cells	   and	  macrophages	  could	   be	   the	   difference	   in	   the	   expression	   of	   protein	   prenyltransferases.	   Higher	  level	   of	   farnesyltransferase	   (FTase)	   expression	   might	   require	   higher	  concentration	   of	   the	   inhibitor.	   Alternatively,	   higher	   abundance	   of	  geranylgeranyltransferase	   (GGTase)	   might	   result	   in	   a	   more	   efficient	   process	   of	  alternative	  prenylation.	  Both	  cases	  could	  lead	  to	  decreased	  sensitivity	  to	  FTIs.	  We	  assessed	   the	   level	   of	   FTase	   and	   GGTase-­‐I	   expression	   in	   mast	   cells	   and	  macrophages	   (fig.	   S5).	   Both	   enzymes	   act	   as	   heterodimers.	   They	   share	   the	   same	  alpha	  subunit	  encoded	  by	  the	  FNTA	  gene;	  beta	  subunits	  are	  encoded	  by	  the	  genes	  
FNTB	   (FTase)	   or	   PGGT1B	   (GGTase-­‐1)	   (31,	   32).	   Contrary	   to	   our	   hypothesis,	  expression	   level	   of	   FTase	   and	   GGTase-­‐1	   was	   approx.	   2	   times	   lower	   in	  macrophages	   compared	   to	   mast	   cells	   (S5A).	   Moreover,	   treatment	   of	   cells	   with	  FTI-­‐277	   did	   not	   cause	   significant	   difference	   in	   the	   expression	   of	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Figure	  3	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Ras	   knockout	   leads	   to	   the	   compensation	   of	   its	   function	   by	  
another	  isoform.	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Fig.	  4.	  The	   lack	  of	  an	  effect	  of	  N-­‐	  or	  H-­‐Ras	  knockout	  on	  PI3Kg	  signalling	   is	  a	   result	  of	  Ras	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Discussion	  
	  From	  the	  discovery	  of	  the	  second	  possible	  adaptor	  subunit	  for	  PI3Kγ	  	  (12,	  13)	  the	  questions	   regarding	   the	   physiological	   importance	   of	   having	   two	   regulatory	  proteins	   were	   arising.	   In	   the	   recent	   years	   it	   has	   become	   evident	   that	   although	  some	  of	  the	  p84	  and	  p101	  functions	  are	  overlapping,	  adaptor	  subunits	  could	  also	  confer	   specific	  properties	   to	  PI3Kγ	   that	   result	   in	  diverse	   cellular	   responses	   (10,	  11,	  20,	  22).	  Diverse	  outputs	  triggered	  by	  two	  complexes	  are	  most	  likely	  explained	  by	  differences	  in	  the	  spatiotemporal	  distribution	  of	  PtdIns(3,4,5)P3	  derived	  from	  either	   p101/p110γ	   or	   p84/p110γ	  	   (10).	   Ras	  was	   shown	   to	   be	   indispensable	   for	  membrane	   recruitment	   and	   activation	   of	   p84/p110γ,	   but	   not	   p101/p110γ	  complexes	   (22).	   Ras,	   therefore,	   could	   contribute	   to	   the	   differential	   coupling	   of	  PI3Kg	  heterodimers	   to	   downstream	   responses	  by	   ensuring	   their	   distribution	   to	  different	   membrane	   compartments.	   This	   suggests	   that	   targeting	   Ras	   activation	  might	  allow	  specific	  modulation	  of	  p84/p110γ-­‐triggered	  cellular	  outputs.	  p84	   and	   p101	   are	   not	   equally	   distributed	   in	   PI3Kγ	   expressing	   cells.	   Mast	   cells	  possess	   only	   p84	   adaptor	   protein.	   In	   accordance	   with	   the	   role	   of	   Ras	   in	   the	  activation	   of	   p84/p110γ,	   all	   PI3Kγ-­‐mediated	   responses	   in	   mast	   cells	  (phosphorylation	  of	  downstream	  target	  PKB,	  migration,	  cytokines	  production	  and	  degranulation)	   were	   blocked	   upon	   Ras	   inhibition	   with	   farnesyltransferase	  inhibitor	   FTI-­‐277.	   At	   the	   same	   time,	   although	   FTI-­‐277	   blocked	   protein	  farnesylation	  in	  macrophages	  to	  the	  similar	  extend	  as	  in	  mast	  cells	  (as	  controlled	  by	   the	   accumulation	   of	   prelamin	   A),	   it	   had	   no	   effect	   on	   the	   PI3Kγ	   signalling	   in	  macrophages.	  	  A	  possible	  explanation	   for	   the	  absence	  of	  FTI-­‐277	  effect	  on	  macrophages	   lies	   in	  the	  fact	  that	  in	  contrast	  to	  p84-­‐only	  containing	  mast	  cells,	  macrophages	  are	  p101-­‐dominated.	  We	  showed	  that	  p101	  represents	  about	  90%	  of	  p110γ	  adaptor	  protein	  in	  macrophages.	  In	  line	  with	  our	  suggestion,	  reconstitution	  of	  p110γ -­‐/-­‐	  mast	  cells	  with	  p101/p110γ	  complex	  made	  them	  insensitive	  to	  Ras	  inhibition	  with	  FTI-­‐277	  or	  to	  overexpression	  of	  GTPase	  activating	  domain	  of	  NF1.	  It	  is	  however	  likely	  that	  adaptor	  subunit	  is	  not	  the	  only	  reason	  for	  differential	  FTI-­‐277	  action	  on	  mast	  cells	  and	   macrophages.	   In	   contrast	   to	   mast	   cells,	   where	   FTI-­‐277	   caused	   significant	  decrease	   in	   the	   amount	   of	   activated	   N-­‐Ras,	   N-­‐	   and	   K-­‐Ras	   activation	   in	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macrophages	  was	  not	  affected	  by	   the	   inhibitor.	  These	  results	  show	  that	   there	   is	  an	  additional	  mechanism	  in	  macrophages	  protecting	  them	  from	  inhibition	  of	  Ras	  signalling.	   In	   caner	   cells	   treatment	   with	   FTIs	   can	   stimulate	   alternative	  geranylgeranylation	   of	   N-­‐Ras	   and	   K-­‐Ras	   (26).	   Higher	   rate	   of	   alternative	  geranylgeranylation	  in	  macrophages	  compared	  to	  mast	  cells	  could	  hypothetically	  be	   a	   reason	   for	   the	  observed	   insensitivity	  of	  Ras	   activation	   to	  FTI.	  Additionally,	  varying	   half-­‐life	   of	   Ras	   proteins	   in	   different	   cells	   might	   also	   explain	   the	  differential	   susceptibility	   to	   farnesyltransferase	   inhibitors.	   Further	   studies	   are	  needed	  to	  elucidate	  the	  mechanism	  behind	  the	  resistance	  of	  Ras	  proteins	  to	  FTIs	  in	  macrophages,	  and	  whether	   it	  could	  be	  used	  for	  developing	  strategies	   for	  cell-­‐specific	  Ras	  targeting.	  In	  order	  to	  get	  a	  deeper	  understanding	  of	  PI3Kγ	  signalling	  in	  mast	  cells,	  we	  tried	  to	   determine	   the	   specific	   Ras	   isoform	   involved	   in	   the	   activation	   of	   p84/p110γ	  complex.	  Among	  seven	  Ras	  isoforms	  that	  were	  previously	  shown	  to	  interact	  with	  PI3K	  and	  activate	  it	  (N-­‐,	  H-­‐,	  K4A-­‐,	  K4B-­‐,	  R-­‐,	  R1,	  and	  MRas)	  (33),	  only	  N-­‐Ras	  and	  H-­‐Ras	  were	  found	  to	  be	  activated	  downstream	  of	  GPCR.	  N-­‐	  and	  H-­‐Ras,	  but	  not	  K-­‐Ras,	  were	  previously	  reported	  to	  be	  associated	  with	  cholesterol-­‐rich	  lipid	  raft	  domains	  at	  the	  plasma	  membrane	  (reviewed	  in	  (36)).	  Their	  activation	  downstream	  of	  the	  GPCR,	   therefore,	   is	   in	   line	  with	   the	   lipid-­‐raft	  associated	  activation	  of	  p84/p110γ	  complex	   (10).	  However,	  H-­‐Ras	   is	  mainly	   localized	   to	   lipid	   rafts	   in	   inactive	  GDP-­‐bound	  state,	  and	  is	  redistributed	  to	  non-­‐raft	  microdomains	  of	  plasma	  membrane	  upon	   its	   activation	   (37,	   38),	   making	   N-­‐Ras	   more	   probable	   candidate	   for	  p84/p110γ	   activation.	   However,	   we	   were	   not	   able	   to	   verify	   which	   Ras	   protein	  plays	  the	  major	  role,	  since	  knockout	  of	  either	  of	  the	  two	  isoforms	  did	  not	  have	  any	  effect	   on	   the	   PI3Kg	  signalling.	   The	   lack	   of	   the	   effect	   can	   be	   explained	   by	   an	  isoform	  compensation	  mechanism:	  depletion	  of	  one	   isoform	  leads	  to	   increase	   in	  expression	  and	  activation	  of	  another	  Ras	  protein.	  	  Mast	  cells	  have	  a	  central	   role	   in	   the	  pathogenesis	  of	  allergic	  disease.	  Many	  anti-­‐allergic	   therapies	   target	   tissues	  mast	   cell	   activation	  or	  block	   the	   effects	   of	  mast	  cell	  mediators	  on	  adjacent	   tissues	   (39,	  40).	   	  However,	   there	   is	   still	  no	  drug	   that	  can	  solely	  and	  specifically	  inhibit	  mast	  cell	  activation.	  PI3Kγ	  is	  a	  central	  enzyme	  in	  mast	   cell	   recruitment,	   activation	  and	  degranulation	   (2,	  7),	   and	   the	  only	  adaptor	  subunit	   present	   in	  mast	   cells	   –	  p84	  –	   is	   absolutely	   essential	   for	  PI3K	  activation	  
Project	  II	  	  
	  128	  
(10).	   The	   ability	   of	   Ras	   inhibition	   to	   block	   activation	   of	   p84/p110γ,	   but	   not	  p101/p110γ	   complexes	   could,	   therefore,	   represent	   a	   promising	   strategy	   for	  specific	   modulation	   of	   mast	   cell	   activation	   in	   allergic	   disease.	   Insensitivity	   of	  macrophages	   to	   FTIs	   suggests	   that	   this	   kind	   of	   treatment	  might	   leave	   the	   host	  defence	   system	   active.	   However,	   analysis	   of	   neutrophils	   from	   p110γ DASAA/DASAA	  (p110γ	  version	  incapable	  of	  binding	  Ras)	  or	  p84	  -­‐/-­‐	  mice	  revealed	  various	  defects	  in	  PI3Kγ	   activation,	   and	  showed	   that	  p84	   is	   the	  adaptor	  protein	   responsible	   for	  ROS	   production	   in	   neutrophils	   (20,	   21).	   Although	   recombinant	   p110γ DASAA	   had	  the	   same	   basal	   catalytic	   activity,	   could	   bind	   101	   and	   was	   activated	   by	   Gβγ,	  expression	   of	   p110γ	   isoform	   in	   p110γ DASAA/DASAA	   knock-­‐in	   mice	   was	   reduced	  potentially	   due	   to	   some	   changes	   in	   the	   stability	   of	   p110γ DASAA	   protein.	   It	   is	  therefore	   difficult	   to	   rule	   out	   the	   possibility	   that	   impaired	   PI3Kγ	   signalling	   in	  p110γ DASAA/DASAA	  cells	  did	  not	  result	  from	  the	  reduced	  protein	  expression.	  In	  our	  work,	  due	  to	  the	  long	  incubation	  time	  with	  FTI-­‐277,	  it	  was	  impossible	  to	  analyse	  the	   effect	   of	   the	   inhibitor	   on	  primary	  neutrophils.	   Future	   in	  vivo	   analysis	   of	   the	  effect	   of	   Ras	   inhibition	   on	   the	   recruitment	   and	   activation	   of	   different	   immune	  cells	  will	   show	   if	   it	   is	   indeed	  only	  mast-­‐cell	   specific	   or	  whether	   it	   could	   as	  well	  affect	  other	  immune	  responses,	  and	  will	  demonstrate	  the	  feasibility	  and	  potential	  of	  inhibiting	  Ras	  for	  the	  treatment	  of	  allergic	  disease.	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MATERIAL	  AND	  METHODS	  
	  
Cell	  Culture,	  Isolation	  and	  Differentiation:	  Bone	   marrow-­‐derived	   mast	   cells	   (BMMCs)	   and	   macrophages	   (BMMØ)	   were	  derived	   from	  bone	  marrow	  of	  8-­‐12	  weeks	  old	  C57BL/6J	  wild	   type,	   p110γ -­‐/-­‐,	  N-­‐Ras	  -­‐/-­‐	  and	  H-­‐Ras	  -­‐/-­‐	  mice	  (N-­‐Ras	  -­‐/-­‐	  and	  H-­‐Ras	  -­‐/-­‐	  mice	  were	  obtained	  from	  RIKEN	  BRC,	   Japan).	   To	   obtain	   BMMCs	   fresh	   bone	   marrow	   (BM)	   was	   resuspended	   in	  complete	   IMDM	   (10%	   HIFCS,	   2mM	   L-­‐Gln,	   10mg/ml	   PEST,	   50mM	   b-­‐mercaptoethanol,	  2	  ng/ml	  recombinant	  murine	  IL-­‐3	  	  [Peprotech,	  #213-­‐13,	  Rocky	  Hill,	   NJ])	   supplemented	   with	   5	   ng/ml	   murine	   SCF	   (Peprotech,	   #250-­‐03,	   Rocky	  Hill,	  NJ)	  and	  cultivated	  at	  37°C,	  5%	  CO2	  for	  four	  days.	  Subsequently,	  BMMCs	  were	  diluted	  weekly	  to	  0.5×106	  cells/ml	  with	  a	  mixture	  of	  80%	  fresh	  complete	   IMDM	  and	  20%	  recycled	  medium,	  with	  IL-­‐3	  added	  every	  3rd	  day	  (2).	  To	  derive	  BMMØ	  fresh	  BM	  was	  resuspended	  in	  complete	  RPMI	  (10%	  HIFCS,	  2mM	  L-­‐Gln,	  10mg/ml	  PEST,	  50mM	  b-­‐mercaptoethanol)	  supplemented	  with	  20%	  L929-­‐conditioned	  medium.	  Cells	  were	  cultivated	  at	  37°C,	  5%	  CO2	  for	  five	  days	  and	  used	  immediately	   for	   experiments.	   The	   human	   embryonic	   kidney	   293	   (HEK293)	   cell	  line	  was	  grown	  in	  Dulbecco’s	  modified	  essential	  medium	  (DMEM)	  supplemented	  with	  10%	  HI-­‐FCS,	  2	  mM	  L-­‐Gln,	  10mg/ml	  PEST	  at	  37°C,	  5%	  CO2.	  	  
	  
Stimulation	  of	  BMMCs	  and	  BMMØ	  BMMCs	   and	   BMMØ	   treated	   with	   DMSO	   (Sigma,	   #34869)	   or	   FTI-­‐277	   (Sigma,	  #F9803)	   were	   collected	   by	   centrifugation	   (900rpm,	   5min.),	   washed	   and	  resuspended	  in	  starvation	  medium	  (BMMC	  -­‐	  IL-­‐3	  free	  growth	  medium	  containing	  2%	   FCS;	   BMMØ	   –	   RPMI,	   1%	   FCS,	   no	   L929-­‐conditioned	  medium).	   After	   4	   hours	  cells	  were	  stimulated	  for	  2min	  at	  37°C	  with	  adenosine	  (Ade,	  2µΜ,	  Sigma	  #01890)	  or	  stem	  cell	  factor	  (SCF;	  10	  ng/ml,	  Peprotech	  #300-­‐07)	  in	  case	  of	  BMMC,	  or	  10nM	  C5a	   (R&D	   Systems	   #2150-­‐C5-­‐025)	   or	   30ng/ml	   M-­‐CSF	   (Peprotech	   #315-­‐02)	   in	  case	   of	   BMMØ.	   Stimulation	   was	   stopped	   on	   ice,	   the	   cells	   collected	   by	  centrifugation	   (1min.,	   4°C,	   14000	   rpm),	   washed	   in	   1xPBS	   and	   lysed	   at	   1x107	  cells/ml	  in	  2x	  Laemmli	  sample	  buffer	  (125	  mM	  Tris-­‐HCl,	  pH	  6.8,	  4%	  SDS,	  10%	  b-­‐	  Mercaptoethanol,	   20%	   Glycerol,	   bromphenolblue).	   Proteins	   were	   denatured	   at	  95°	  for	  7	  min.,	  subjected	  to	  SDS-­‐PAGE	  and	  immunoblotting.	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For	  degranulation	  experiments	  or	  analysis	  of	  cytokines	  expression	  BMMCs	  were	  incubated	   in	  complete	   IMDM	  with	  100	  ng/ml	  mouse	  anti-­‐DNP	  IgE	  (clone	  SPE-­‐7,	  Sigma	   #D8406)	   overnight,	   and	   then	   stimulated	   with	   1	   ng/ml	   DNP-­‐HSA	   (Sigma	  #A-­‐6661)	   with	   or	   without	   2	   µM	   adenosine	   or	   10ng/ml	   SCF	   for	   20	   min	  (degranulation)	  or	  1	  hour	  (cytokines	  expression)	  at	  37°C.	  
	  
Immunoblotting	  and	  antibodies	  Proteins	   were	   separated	   by	   SDS-­‐PAGE	   and	   transferred	   to	   Immobilon	   PVDF	  membranes	   (Millipore).	   Primary	   antibodies	   used:	   mouse	   monoclonal	   anti-­‐p110γ	  (clone	   H1,	   Alexis),	   rabbit	   monoclonal	   anti-­‐pSer473-­‐PKB/Akt	   (#4058),	  rabbit	   monoclonal	   anti-­‐pThr308-­‐PKB/Akt	   (#4056),	   mouse	   monoclonal	   anti-­‐PKB/Akt	  (#2920),	  rabbit	  monoclonal	  anti-­‐p101	  (#5569),	  rabbit	  monoclonal	  anti-­‐pCREB	   (#9198),	   rabbit	   polyclonal	   anti-­‐R-­‐Ras	   (#8446,	   all	   Cell	   Signaling	  Technology),	   mouse	  monoclonal	   anti-­‐pMAPK	   (#M8159),	   rabbit	   polyclonal	   anti-­‐MAPK	   (#M7927),	   mouse	   monoclonal	   anti-­‐GAPDH	   (#G8795,	   all	   Sigma),	   rabbit	  monoclonal	   anti-­‐H-­‐Ras	   (ab32417,	   abcam),	   mouse	   monoclonal	   anti-­‐N-­‐Ras	   (#sc-­‐31),	  mouse	  monoclonal	  anti-­‐K-­‐Ras	  (#sc-­‐30),	  goat	  polyclonal	  anti-­‐	  Lamin	  A	  (C-­‐20)	  (Prelamin,	   #sc-­‐6214,	   Santa	   Cruz	   Biotechnology),	   anti-­‐p84	   (rabbit	   antisera	   (10),	  mouse	  monoclonal	  anti	  HA	  (HA.11,	  #MMS-­‐101R,	  Covance).	  Secondary	  antibodies	  such	  as	  horseradish	  peroxidase	  (HRPO)-­‐coupled	  rabbit	  anti-­‐mouse	   IgG	  and	  goat	  anti-­‐rabbit	   IgG	   antibodies	   (Sigma)	   were	   visualized	   using	   enhanced	  chemiluminescence	  (#WBKLS0500,	  Millipore).	  	  	  
Cell	  migration	  assay	  Migration	   of	   BMMCs	   and	   BMMØ	   was	   assayed	   in	   24-­‐well	   Transwell	   Supports	  (#3421,	  Corning)	  with	  5.0	  µm	  pore	  polycarbonate	  membranes	  for	  6	  hours.	  	  
BMMC:	  Before	  the	  experiment	  Transwell	  membranes	  were	  coated	  overnight	  with	  1	  mg/ml	   fibronectin/PBS	   at	   4°C,	   then	   blocked	  with	   4%	  BSA/PBS	   for	   1	   hour	   at	  37°C	   and	   equilibrated	   in	   migration	   medium	   (IMDM	   supplemented	   with	   L-­‐Gln,	  PEST,	   1%	   BSA,	   50	   µM	   β-­‐mercaptoethanol,	   and	   20mM	   Hepes,	   pH	   7.4)	   for	   30	  minutes	   at	   37°C.	   BMMC	   were	   washed	   twice	   in	   migration	   medium.	   Cell	  suspensions	  (0.25	  x	  106	  cells	  in	  200	  µl)	  were	  applied	  to	  the	  upper	  compartment	  of	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the	  Transwell	   inserts	   already	   containing	  migration	  medium	   supplemented	  with	  or	  without	  1	  µM	  adenosine	  or	  10ng/ml	  SCF	  in	  the	  lower	  well.	  	  
BMMØ:	  Transwells	  were	  equilibrated	  in	  migration	  medium	  (RPMI,	  supplemented	  with	   L-­‐Gln,	   PEST,	   1%	   FCS,	   50	   µM	   β-­‐mercaptoethanol)	   for	   30	   minutes	   at	   37°C.	  BMMØs	  were	  washed	  twice	  in	  migration	  medium.	  Cell	  suspensions	  (0.5	  x	  105	  cells	  in	   200	   µl)	   were	   applied	   to	   the	   upper	   compartment	   of	   the	   Transwell	   inserts	  already	  containing	  migration	  medium	  supplemented	  with	  or	  without	  10nM	  C5a,	  10ng/ml	  Rantes	  or	  30ng/ml	  M-­‐CSF	  in	  the	  lower	  well.	  	  After	  6	  hours	  cells	  were	   fixed	  with	  4%PFA	  and	  stained	  with	  Hoechst.	  Bottom	  of	  the	   inserts	   as	   well	   as	   lower	   wells	   of	   the	   transwells	   were	   scanned	   using	  fluorescent	  microscope	  and	  cells	  were	  quantified	  with	  ImageJ	  plugin.	  	  
	  
Transfection	  experiments	  	  BMMCs	  were	  transfected	  using	  the	  NucleofectorTM	  protocol	  (Amaxa).	  BMMCs	  (7-­‐10x106)	   were	   resuspended	   in	   100ml	   nucleofection	   solution	   T	   (#VCA-­‐1002,	  Amaxa),	  then	  10-­‐15	  mg	  plasmid	  DNA	  (in	  15	  ml	  10	  mM	  TRIS/1	  mM	  EDTA	  pH	  8.0)	  were	   added.	   Immediately	   after	   electroporation	   cells	   were	   cultured	   in	   5	   ml	  complete	   IMDM	   at	   37°C,	   5%	   CO2	   for	   5	   hours.	   After	   a	   medium	   change	   with	  complete	   IMDM	  with	   DMSO	   or	   5mM	   FTI-­‐277	   transfected	   cell	   populations	  were	  cultured	  for	  24h.	  Stimulations	  occurred	  24	  h	  post-­‐transfection.	  HEK293	  cells	  were	  seeded	   into	  6	   cm	  dishes	  and	  were	   transfected	  with	   JetPEITM	  (Polyplus-­‐transfection)	  using	  2.5	  µg	  of	  total	  plasmid	  DNA.	  Codon	  optimized	  3xHA-­‐Ras	  sequences	  (Table	  S2)	  used	  for	  expression	  in	  HEK293	  cells	  were	  synthesized	  by	  GenScript	  and	  cloned	  into	  pcDNA3.1	  plasmid.	  	  
Mast	  cell	  degranulation	  Release	  of	  histamine	  containing	  granules	  was	  quantified	  by	  the	  determination	  of	  b-­‐hexosaminidase	  in	  the	  cell	  supernatants,	  slightly	  modified	  from	  {Laffargue	  et	  al.,	  2002,}.	  BMMC	  were	   incubated	  with	  100	  ng/ml	  anti-­‐DNP	  IgE	  overnight	  and	  cells	  resuspended	   in	  modified	  Tyrode’s	  buffer	  at	  0.5-­‐1.0x	  106	  cells/ml,	  37°C,	  5%	  CO2.	  	  Degranulation	   was	   induced	   with	   1	   ng/ml	   DNP-­‐HSA	   with	   or	   without	   2	   µM	  adenosine	  or	  10ng/ml	  SCF	  for	  20	  min	  at	  37°C,	  5%	  CO2.	  The	  reaction	  was	  stopped	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and	   β-­‐hexosaminidase	   activity	   measured	   with	   p-­‐nitrophenyl-­‐N-­‐acetyl-­‐b-­‐D-­‐glucosaminide	   (#N9376,	   Sigma).	   Results	   are	   given	   as	   the	   percentage	   of	   total	  TritonX-­‐100	  releasable	  b-­‐hexosaminidase.	  
	  
Quantitative	  real-­‐time	  PCR	  RNA	   was	   isolated	   with	   RNeasy	   mini	   kit	   (#74104,	   Qiagen)	   according	   to	  manufecturer’s	  instructions.	  cDNA	  was	  generated	  with	  2	  mg	  of	  total	  RNA	  using	  M-­‐MVL	   reverse	   transcriptase	   (#28025-­‐013,	   RT-­‐buffer	   #18057-­‐018	   Invitrogen;	  RNAsin,	  #N2111,	  Promega)	  and	  stored	  at	  -­‐80°C	  until	  use.	  A	  StepOnePlus	  (Applied	  Biosystems,	   Foster	   City,	   CA)	   and	   MESA	   Green	   qPCR	   MasterMix	   Plus	   for	   SYBR	  assay	   (#RT-­‐SY2X-­‐20+WOU,	   Eurogentec)	   was	   used	   for	   qPCR.	   Sequences	   of	   the	  primers	  used	  could	  be	  found	  in	  the	  Table	  S1.	  
	  
Ras	  activation	  assay	  
BMMC:	   BMMCs	   (2x107/stimulation)	   were	   starved	   in	   IL-­‐3	   free	   growth	   medium	  containing	  2%	  FCS	  for	  4	  hours.	  Cells	  were	  then	  washed	  twice	  with	  HBBSS	  buffer	  (15mM	   HEPES,	   140mM	   NaCl,	   5mM	   KCl,	   2.8mM	   NaHCO3,	   1.5mM	   CaCl2,	   1mM	  MgCl2,	   0.06mM	   MgSO4,	   5.6mM	   Glucose,	   0.1%	   BSA	   pH	   7.2).	   After	   final	  resuspension	  cells	  were	  kept	  on	  ice	  for	  10min,	  and	  then	  incubated	  at	  37°C	  5	  min	  prior	   to	   stimulations.	   Cells	   were	   stimulated	   with	   4µM	   adenosine	   for	   1	   min	   at	  37°C,	  centrifuged	  at	  13000rpm	  for	  10sec	  and	  resuspended	  in	  lysis	  buffer	  (50mM	  Tris	  pH7.5,	  150mM	  NaCl,	  5mM	  MgCl2,	  1mM	  EGTA,	  1%NP-­‐40,	  protease	  inhibitors)	  containing	   20µg	   GST-­‐tagged	   Raf-­‐RBD.	   Lysates	   were	   kept	   on	   ice	   for	   10	   min,	  followed	   by	   15	   min	   centrifugation	   at	   14000	   rpm,	   4°C.	   Cleared	   lysates	   were	  transferred	  to	  new	  2ml	  tubes,	  and	  40µl	  GSH-­‐sepharose	  beads	  (#17-­‐0756-­‐01,	  GE	  Healthcare)	  preequilibrated	   in	   lysis	  buffer	  were	   added	   to	   each	   reaction.	  After	  1	  hour	  incubation	  on	  a	  wheel	  at	  4°C,	  beads	  were	  washed	  3	  times	  with	  ice-­‐cold	  lysis	  buffer	  and	  resuspended	  in	  Laemmli	  sample	  buffer.	  
BMMØ:	  One	  day	  before	  experiment	  10x106	  BMMØs	  were	  seeded	  in	  a	  10cm	  plate.	  Next	   day	   cells	   were	   starved	   in	   RPMI	   with	   1%	   FCS	   and	   no	   L929-­‐conditioned	  medium	  for	  4	  hours	   followed	  by	  a	  stimulation	  with	  10nM	  C5a	  for	  2min	  at	  37°C.	  After	   stimulation	   cells	  were	  washed	  with	   ice-­‐cold	   PBS	   and	   lysed	   in	   lysis	   buffer	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supplemented	  with	  20µg	  GST-­‐tagged	  Raf-­‐RBD.	  Lysates	  were	  transferred	  to	  1.5ml	  tubes,	  incubated	  on	  ice	  for	  10	  min,	  and	  centrifuged	  for	  15	  min	  at	  14000	  rpm,	  4°C.	  Cleared	   lysates	   were	   transferred	   to	   new	   2ml	   tubes,	   and	   40µl	   GSH-­‐sepharose	  beads	   preequilibrated	   in	   lysis	   buffer	  were	   added	   to	   each	   reaction.	   After	   1	   hour	  incubation	  on	  a	  wheel	  at	  4°C,	  beads	  were	  washed	  3	  times	  with	  ice-­‐cold	  lysis	  buffer	  and	  resuspended	  in	  Laemmli	  sample	  buffer.	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Fig.	   S1.	   FTI-­‐277	   affects	   Ras	   localization	   and	   PI3Kγ	   signalling	   in	  mast	   cells.	   (A)	  BMMCs	   were	   transfected	   with	   constructs	   expressing	   GFP-­‐tagged	   C-­‐terminal	   25	  aminoacids	   of	   H-­‐Ras,	   N-­‐Ras	   or	   K-­‐Ras	   and	   treated	   with	   5µM	   FTI-­‐277.	   24	   hours	  later	   cells	   were	   fixed	   in	   4%	   p-­‐formaldehyde,	   and	   images	   were	   acquired	   by	  confocal	   microscopy.	   Distribution	   of	   Ras	   proteins	   along	   a	   predefined	   line	  spanning	   cells	   was	   analyzed	   (number	   of	   cells	   analysed	   per	   condition	   ≥18).	   (B)	  BMMCs	  were	   treated	  with	  DMSO	   or	   5µM	  FTI-­‐277	   for	   24,	   48	   or	   72	   hours.	   Cells	  were	   then	  starved	   for	  4	  hours	   in	   IL3-­‐free	  medium	  containing	  2%FCS	  and	  either	  DMSO	  or	  5µM	  FTI-­‐277,	  followed	  by	  stimulation	  with	  2µM	  Ade	  for	  2	  min	  at	  37°C.	  pSer473-­‐PKB	  and	  pMAPK	  were	  determined	  by	  Western	  blotting	  and	  normalized	  to	  the	  total	  PKB	  or	  MAPK	  levels,	  correspondingly.	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Fig.	  S3.	  FTI-­‐277	  inhibits	  protein	  farnesylation,	  but	  not	  Gγ	  functioning	  in	  mast	  cells	  and	  macrophages.	  (A)	  Prelamin	  A	  was	  detected	  in	  the	  lysates	  from	  DMSO	  or	  FTI-­‐277	   treated	   BMMCs	   and	   BMMØ	   and	   normalized	   to	   the	   level	   of	   GAPDH	  protein.	  Fold	   increase	   of	   prelamin A	   upon	   FTI-­‐277	   treatment	   was	   quantified	   and	  normalized	   to	   the	   DMSO-­‐treated	   control.	   (B)	   BMMCs	   and	   BMMØ	   were	   treated	  with	  DMSO	  or	  5µM	  FTI-­‐277	  for	  72	  hours,	  starved	  for	  4	  hours	  and	  activated	  with	  1µM	   PAF.	   Phosphorylation	   of	   cyclic	   AMP-­‐responsive	   element-­‐binding	   protein	  (CREB)	   at	   Ser133	  was	   determined	   by	  Western	   blot	   analysis	   of	   cell	   lysates	   and	  normalized	  to	  the	  total	  PKB	  level.	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Appendix	  I:	  
-­‐	  Generation	  of	  PIK3r5	  (p101)	  and	  PI3Kr6	  (p84)	  knockout	  mouse	  strains	  -­‐	  Generation	  of	  p84	  Knock	  in	  mouse	  strain	  -­‐	  Next	  generation	  engineering	  of	  conditional	  mouse	  alleles	  with	  loxP	  and	  FRT	  sites	  by	  dual	  RMCE	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Generation	  of	  PIK3r5	  (p101)	  and	  PI3Kr6	  (p84)	  knockout	  mouse	  
strains.	  	  The	   sole	   member	   of	   class	   IB	   PI3K	   family,	   PI3Kγ,	   is	   a	   heterodimeric	   enzyme	  formed	  by	  a	   catalytic	   subunit,	   p110γ,	   and	  an	  adaptor	   subunit	  between	  p84	  and	  p101.	  	  The	  information	  available	  regarding	  the	  role	  and	  the	  specificity	  of	  the	  two	  adaptor	  subunits	   in	  vivo	  are	  currently	   limited,	  probably	  due	  to	  a	  certain	   level	  of	  redundancy	   in	   their	   biological	   activity	   that	   make	   difficult	   the	   analysis	   of	   the	  adaptor	   subunit	   specific	   responses.	  In	  order	   to	   investigate	   the	  different	   roles	  of	  p101	  and	  p84	   in	  PI3Kγ	  signalling,	  we	  attempted	   to	  generate	  both	  a	  p101	  and	  a	  p84	  knock	  out	  mouse	  strain.	  While	  the	  product	  of	  the	  PIK3r5	  gene,	  p101,	  was	  isolated	  for	  the	  first	  time	  from	  pig	   neutrophils,	   in	   association	   with	   p110γ	   (Stephens	   et	   al.,	   1997),	   p84	   (or	  p87PIKAP)	   was	   identified	   almost	   10	   years	   later	   (Suire	   et	   al.,	   2005;	   Voigt	   et	   al.,	  2006).	   	   In	   2006	   a	   mouse	   strain	   lacking	   p101	   had	   already	   been	   characterised	  (Suire	   et	   al.,	   2006)	  while	   the	   generation	   of	   a	   p84	   knock-­‐out	  mouse	   strain	   have	  only	  been	  published	  in	  2015	  (Deladeriere	  et	  al.,	  2015),	  but	  was	  not	  yet	  available	  while	  this	  project	  was	  in	  progress.	  The	  p101	  knockout	  mouse	  strain	  has	  been	  successfully	  generated	  starting	  from	  a	  JM8A3.N1	  subline	  of	  embryonic	  stem	  (ES)	  cells,	  derived	  by	  C57BL/6N	  mice	  and	  targeted	   with	   the	   “knockout-­‐first	   allele”	   method	   obtained	   by	   EUCOMM.	   The	  blastocyst	   injection	   and	   the	   generation	   of	   chimeric	  mice	  was	   carried	   out	   at	   the	  “Transgenic	   facility”	   of	   the	   Biozentrum,	   Basel,	   under	   the	   supervision	   of	   Dr.	  Daniela	  Klewe-­‐Nebenius.	  The	  p84	  knockout	  mouse	  strain	  project	  started	  with	  the	  ordering	  of	  two	  clones	  of	  E14TG2a.4	  ES	  cells,	  derived	  by	  129P2/OlaHsd	  mice.	  The	  two	   clones	   “E017F02”	   and	   “E324E05”	  were	   both	   genetically	  modified	  with	   the	  “Gene	   Trap”	   technology	   (Skarnes,	   W.	   C.	   et	   al.,	   2004)	   at	   the	   level	   of	   the	   same	  genomic	   locus,	   with	   different	   targeting	   vectors.	   The	   PIK3r6	   gene	   of	   the	   clone	  “E017F02”	   was	   targeted	   with	   the	   “rFROSAbgeo+2s”	   vector	   and	   the	   clone	  “E324E05”	   with	   the	   “rsFlipROSACeo0”	   vector	   (http://www.informatics.jax.org).	  Classical	  PCR,	  3’Race	  and	  western	  blotting	  analysis	  of	  the	  two	  ES	  cell	  clones	  and	  of	  the	   bone	   marrow	   cells	   isolated	   from	   the	   mice	   derived	   from	   the	   two	   clones	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revealed	  that	  the	  targeting	  vector	  was	  only	  present	  in	  one	  of	  the	  two	  clones	  and	  the	   second	   one,	   even	   in	   presence	   of	   the	   targeting	   vector,	   did	   not	   show	   any	  reduction	  of	  expression	  of	  the	  protein	  of	  interest.	  	  	  
                    	  	  	  	  	  	  	  	  	  











































































































































































































































































































































































































































































































	   	   	   Appendix	  I	  	  














































































































































































































































































































































































































	   	   	   Appendix	  I	  	  
	  150	  






	   	   	   Appendix	  I	  	  
	   151	  
Next	   generation	   engineering	   of	   conditional	   mouse	   alleles	   with	  
loxP	  and	  FRT	  sites	  by	  dual	  RMCE	  (protocol	  elaborated	  by:	  Marco	  




-­‐	  ES	  cell	  and	  feeder	  cell	  cultures	  	  
D-­‐PBS	  (1X),	  liquid	  (Gibco,	  14190-­‐144)	  
D-­‐PBS	  with	  Mg2+/Ca2+	  (1X),	  liquid	  (Gibco	  14040-­‐117)	  
D-­‐MEM	  (1X),	  liquid	  (High	  Glucose;	  4.5g/l;	  Gibco	  41966-­‐029)	  
Fetal	  Bovine	  Serum	  (FBS;	  Gibco	  10270-­‐106)	  	  
	  
TIP:	  Is	  essential	  to	  use	  a	  batch	  of	  FBS	  that	  supports	  the	  optimal	  growth	  of	  ES	  cells	  
and	   keeps	   them	   in	   an	   undifferentiated	   state	   so	   that	   their	   germ-­‐line	   transmission	  
potential	  is	  not	  affected.	  We	  recommend	  that	  users	  either	  acquire	  batches	  of	  FBS	  for	  
ES	  cell	  culture	  from	  the	  transgenic	  core	  facility	  that	  will	  produce	  their	  chimeric	  mice	  
or	  ask	  them	  for	  advice	  on	  where	  to	  buy	  serum	  that	  meets	  these	  criteria.	  	  	  
Penicillin-­‐Streptomycin	  (10,000	  units-­‐10	  mg/ml;	  100x;	  Gibco	  15140-­‐122)	  
L-­‐Glutamine	  (200	  mM;	  100x;	  Gibco	  25030-­‐024)	  
β-­‐Mercaptoethanol	  (50	  mM	  stock;	  500x;	  Gibco	  31350-­‐010)	  
Leukemia	  Inhibitory	  Factor	  (LIF;	  107	  units/ml;	  10,000x;	  ESGRO®	  Chemicon	  ESG1107)	  
MEM	  Non	  Essential	  Amino	  Acids	  (10	  mM;	  100x;	  Gibco	  11140-­‐035)	  
MEM	  Sodium	  Pyruvate	  (100	  mM;	  100x;	  Gibco	  11360-­‐039)	  
Trypsin-­‐EDTA	  1X	  (Gibco	  25300-­‐054)	  
NOTE:	  this	  is	  a	  low-­‐concentration	  Trypsin-­‐EDTA	  solution.	  
DMSO	  (Sigma	  D-­‐8418)	  
Mitomycin	  C	  (Sigma	  M-­‐0503).	  Dissolve	  in	  D-­‐PBS	  (Gibco,	  14190-­‐144)	  at	  1	  mg/ml	  (100x	  stock	  solution).	  Store	  at	  4°C,	  light-­‐sensitive	  and	  stable	  for	  up	  to	  2	  weeks.	  	  
Hygromycin	  (Sigma	  H3274).	  Dissolve	  in	  H2O	  at	  25	  mg/ml.	  Sterile	  filter	  the	  solution	  using	  a	  0.2	  μm	  filter	  and	  store	  at	  4°C	  in	  the	  dark.	  The	  working	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concentration	  for	  selection	  of	  resistant	  R1	  ES	  cell	  colonies	  is	  175	  μg/ml.	  
Puromycin	  (Sigma	  P9620;	  10	  mg/ml).	  Store	  frozen	  in	  small	  aliquots.	  The	  working	  concentration	  for	  selection	  of	  resistant	  ES	  cell	  colonies	  is	  1	  μg/ml	  for	  R1	  cells	  and	  0.5	  μg/ml	  for	  ES	  cell	  colonies	  obtained	  by	  transfection	  of	  IKMC	  ES	  cell	  lines.	  
Gelatin	  (Sigma	  G-­‐2500).	  Dissolve	  at	  0.1%	  in	  H2O.	  	  
-­‐	  Prepared	  reagents	  
ES	  cell	  culture	  medium	  (store	  at	  4°C)	  
DMEM	  (high	  glucose),	  15%	  FBS,	  1x	  Penicillin-­‐Streptomycin	  (stock	  is	  100x),	  2	  mM	  
L-­‐Glutamine	  (stock	  is	  100x),	  0.1	  mM	  β-­‐mercaptoethanol	  (stock	  is	  500x),	  0.1	  mM	  
MEM	  Non	  Essential	  Amino	  Acids	  (stock	  is	  100x),	  1	  mM	  MEM	  Sodium	  Pyruvate	  (1mM;	  stock	  100x),	  103	  units/ml	  LIF	  (stock	  is	  10,000x).	  
ES	  cell	  freezing	  medium	  (prepare	  fresh	  and	  sterilize	  the	  solution	  using	  a	  0.2	  μm	  filter;	  keep	  on	  ice)	  50%	  ES	  cell	  culture	  medium	  40%	  FBS	  	  10%	  DMSO	  
Feeder	  cell	  culture	  medium	  (store	  at	  4°C)	  DMEM	  (high	  glucose),	  10%	  FBS,	  1x	  Penicillin-­‐Streptomycin	  (stock	  is	  100x),	  2	  mM	  L-­‐Glutamine	  (stock	  is	  100x)	  	  
-­‐	  Plasmid	  vectors	  for	  dRMCE	  The	   dRMCE	   vectors	   are	   available	   as	   soon	   as	   possible	   from	   Addgene	   and	   are	  protected	   by	   an	  MTA.	   The	   plasmids	   have	   to	   be	   prepared	   as	   transfection	   grade	  DNA	  using	  e.g.	  Nucleobond	  PC	  100	  columns	  (Macherey-­‐Nagel	  740573)	  according	  to	   the	   manufacturer	   instructions.	   After	   washing	   with	   70%	   ethanol,	   the	   DNA	  pellets	   should	   be	   dried	   under	   a	   laminar	   flow	   hood	   for	   10-­‐15	   minutes.	  Subsequently,	  a	  small	  amount	  (100-­‐200	  μl)	  of	  sterile	  H2O	  is	  added	  to	  the	  tube,	  the	  tube	   is	  covered	  with	  Parafilm	  and	   the	  plasmid	  DNA	   left	   to	  dissolve	  overnight	  at	  4°C.	  The	  next	  day,	  the	  plasmid	  solution	  is	  transferred	  with	  minimal	  pipetting	  into	  a	  1.5	  ml	  tube	  and	  the	  concentration	  is	  determined	  using	  a	  UV	  spectrophotometer	  (a	   typical	   working	   concentration	   is	   1-­‐4	   μg/μl).	   Contrary	   to	   targeting	   by	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homologous	   recombination,	   plasmids	   are	  not	   linearized	   for	   dRMCE	  approaches.	  	  
-­‐	  pDIRE	  This	   plasmid	   expresses	   the	   iCre	   and	   FLPo	   recombinases	   in	   mouse	   ES	   cells.	  Experimental	   evidence	   indicates	   that	   the	   use	   of	   this	   plasmid	   is	   essential	   for	  efficient	  and	  correct	  dRMCE-­‐mediated	  replacement.	  
	  
-­‐	  pDRAV	  series	  These	  plasmids	  encode	  single	  loxP	  and	  FRT	  sites	  flanking	  a	  multiple	  cloning	  site	  and	   a	   hygromycin-­‐resistance	   cassette	   that	   can	   be	   removed	   using	   the	   ϕ*C31	  recombinase.	  The	   four	  available	  variants	  differ	   in	   the	   relative	  orientation	  of	   the	  loxP	   and	   FRT	   sites;	   *therefore	   is	   essential	   to	   select	   the	   appropriate	   version	   for	  custom	  modification.	  	  
	  
-­‐	  pDREV	  series	  These	  plasmids	  are	  designed	  to	  modify	  the	  IKMC	  “knock-­‐out	  first”	  mouse	  alleles.	  In	  addition	  to	  the	  5’	  FRT	  and	  3’	   loxP	  sites,	   the	  pDREV	  backbone	  encodes	  a	  H2B-­‐Venus	   reporter	   protein	   that	   is	   expressed	   under	   the	   control	   of	   the	   endogenous	  locus	   due	   to	   the	   presence	   of	   upstream	   splice	   acceptor	   and	  T2A	   sequences.	   The	  three	   pDREV	   variants	   (0,	   1,	   and	   2)	   correspond	   to	   the	   different	   open	   reading	  frames	   and	   great	   care	   should	   be	   taken	   to	   select	   the	   appropriate	   vector.	   The	  pDREV	   plasmids	   can	   be	   further	   modified	   by	   substituting	   the	   H2B-­‐Venus	   open	  reading	  frame	  with	  the	  coding	  sequences	  of	  choice	  in	  the	  form	  of	  an	  RsrII/PacI	  or	  RsrII/SapI	  restriction	   fragment.	  The	  selection	  cassette	  renders	  ES	  cells	   resistant	  to	   Puromycin	   and	   can	   be	   removed	   using	   the	   Dre	   recombinase.	   The	   pDREV	  plasmids	  are	  propagated	   in	  bacteria	   in	   the	  presence	  of	  20	  μg/ml	  nourseothricin	  (ClonNAT;	  WERNER	  BioAgents	  5001000).	  	  
-­‐	  Screening	  reagents	  Specific	   PCR	  primers	   that	   allow	  discrimination	  of	   the	  wild-­‐type	   and	   conditional	  from	   the	   deleted	   and	   correctly	   replaced	   alleles	   need	   to	   be	   designed.	   PCR-­‐grade	  water,	   10x	   PCR	   buffer,	   dNTPs,	   Taq	   polymerase	   and	   reagents	   and	   buffers	   for	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agarose	   gel	   electrophoresis.	   Reagents,	   buffers	   and	   custom-­‐designed	   probes	   for	  Southern	  blotting.	  	  
-­‐	  Reagent	  setup	  The	   primary	   screening	   to	   detect	   correct	   replacement	   following	   dRMCE	   is	   done	  using	  PCR.	  The	  basic	  strategy	  aims	  to	  detect	  a	  correct	  recombination	  event	  at	  the	  3’	   end,	   which	   corresponds	   to	   the	   location	   at	   which	   the	   selection	   cassette	   is	  inserted	  into	  the	  pDRAV	  and	  pDREV	  plasmids.	  In	  a	  second	  step,	  all	  ES	  cell	  colonies	  with	   correct	   3’	   replacement	   are	   re-­‐screened	   to	   detect	   proper	   recombination	   at	  the	   5’	   end	   and	   checked	   for	   insertion	   of	   the	   pDIRE	   plasmid	   (using	   primers	  amplifying	   iCre	   or	   Flpo	   coding	   sequences).	   ES	   cell	   colonies	   containing	   pDIRE	  sequences	   should	   be	   excluded	   due	   to	   potential	   insertional	   mutagenesis	   or	  instability.	   Three	   to	   five	   locus-­‐specific	   primers	   located	   outside	   of	   the	   replaced	  region	  are	  typically	  designed	  to	  amplify	  the	  region	  of	  interest	  in	  combination	  with	  cassette-­‐specific	  oligos.	  In	  general,	  primer	  pairs	  designed	  using	  specific	  software	  (Vector	   NTI,	   Primer3,	   etc)	   reliably	   detect	   the	   desired	   alterations.	   In	   addition,	  primer	   pairs	   that	   amplify	   the	   parental	   conditional	   and	  wild-­‐type	   allele	  must	   be	  designed	  and	  tested	  on	  genomic	  DNA	  from	  the	  parental	  ES	  cell	  line.	  Primer	  pairs	  detecting	  the	  in	  cis-­‐recombined,	  i.e.	  deleted	  allele,	  must	  be	  used	  for	  screening	  as	  a	  certain	  number	  of	  dRMCE	  positive	  ES	  cell	  colonies	  will	  be	  of	  mixed	  origin	  carrying	  either	  the	  correctly	  replaced	  or	  deleted	  locus.	  These	  sets	  of	  oligos	  must	  be	  tested	  prior	  to	  the	  actual	  screening	  of	  ES	  cell	  colonies	  (see	  step	  4.3).	  	  	  
CRITICAL:	  Make	  sure	  all	  necessary	  oligo	  pairs	  are	  designed	  and	  synthesized	  before	  
the	   ES	   cell	   culture	   and	   dRMCE	   experiments	   are	   initiated.	   In	   particular,	   several	  
primer	  pairs	  should	  be	  designed	  and	  tested	  for	  each	  of	  the	  alleles	  to	  be	  probed.	  
	  
TIP:	   When	   considering	   the	   configuration	   of	   the	   deleted	   locus,	   keep	   in	   mind	   that	  
several	  possible	  configurations	  of	  the	  locus	  of	  interest	  may	  result	  from	  simultaneous	  
recombination	   by	   iCre	   and	   Flpo.	   This	   is	   particularly	   important	   when	   using	   IKMC	  
alleles	  with	  promoter-­‐driven	  selection	  cassettes,	  as	  they	  encode	  three	  loxP	  and	  two	  
FRT	   sites.	   We	   have	   evidence	   that	   the	   iCre	   recombinase	   acts	   faster	   than	   the	   Flpo	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recombinase,	  which	  can	  result	   in	  a	  partially	  recombined	  target	  allele	   in	  which	  e.g.	  
the	  lacZ	  cassette	  remains	  .	  	  CRITICAL:	  Correct,	  dRMCE-­‐mediated	  replacement	  events	  are	  identified	  by	  short-­‐range	  PCR,	  but	  candidate	  ES	  cell	  clones	  have	  to	  be	  validated	  by	  Southern	  blotting	  using	  external	  probes	  at	  both	   the	  5’	   and	  3’	   ends.	   In	  addition,	   these	  blots	   can	  be	  used	   to	   exclude	   additional	   integration	   events	   using	   either	   a	   hygromycin	   or	  puromycin	   probe.	   Both	   pDRAV	   and	   pDREV	   plasmids	   include	   some	   restriction	  sites	  than	  can	  be	  used	  for	  Southern	  blot	  analysis.	  If	  no	  convenient	  restriction	  sites	  are	   available,	   we	   encourage	   the	   introduction	   of	   appropriate	   restriction	   sites,	  which	   permit	   verification	   of	   candidate	   ES	   cell	   clones	   by	   Southern	   blot	   analysis.	  Tests	   using	   genomic	   DNA	   from	   the	   parental	   ES	   cell	   line	  must	   be	   done	   prior	   to	  electroporation	   to	   validate	   the	   probes	   and	   the	   restriction	   patterns	   indicative	   of	  correct	  5’	  and	  3’	  replacement	  events.	  	  
Equipment:	  	  Electroporator:	  We	  use	  a	  Biorad	  Gene	  Pulser	  II	  model	  with	  0.4	  cm	  electrode	  gap	  cuvettes	  (Biorad	  165-­‐2088).	   The	   conditions	   of	   electroporation	   given	   in	   this	   protocol	   were	  optimized	   for	   this	   type	   of	   electroporator.	   Please	   refer	   to	   the	   manufacturer’s	  instructions/protocol	  when	  using	  a	  different	  electroporation	  system.	  	  Tissue	  culture	  and	  molecular	  biology	  equipment:	  Laminar	  flow	  tissue	  culture	  hoods,	  CO2	  incubators	  (7.5%	  CO2,	  37°C	  for	  R1	  ES	  cells;	  5%	   CO2,	   37°C	   for	   feeder	   cells),	   stereo	   microscope,	   inverted	   microscope,	   tissue	  culture	  dishes,	  tissue	  culture	  48,	  24	  and	  6-­‐well	  plates,	  96-­‐well	  U-­‐bottom	  plates,	  PP	  tubes	   (15	  and	  50	  ml),	   sterile	  pipettes	   (1,	  2,	  5,	  10,	  25	  and	  50	  ml),	  micropipettes,	  sterile	  tips,	  PCR	  machine,	  equipment	  for	  agarose	  gel	  electrophoresis	  and	  Southern	  blotting	  transfer	  and	  hybridization.	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Procedures:	  	  Successful	  ES	  cell	  culture	  requires	  great	  care	  and	  dedication.	  For	  a	  full	  description	  on	  how	   to	  handle	  ES	  cells	   for	  optimal	  growth	  and	  maintenance	  of	  pluripotency,	  please	   refer	   to	   the	   laboratory	  manual	   “Manipulating	   the	  mouse	   embryo”	   (CSHL	  Press,	  2003;	  Ref.	  4).	  As	  with	  any	  other	  manipulation	  of	  ES	  cells	  for	  the	  generation	  of	   chimeric	   mice,	   previous	   training	   in	   general	   and	   dedicated	   ES	   cell	   culture	  techniques	  is	  required.	  The	  materials/procedures	  described	  here	  are	  the	  ones	  we	  routinely	   use	   for	   R1	   ES	   cells	   and	   represent	   general	   guidelines.	   However,	   as	  different	  ES	  cell	  lines	  may	  have	  slightly	  different	  culture/handling	  procedures,	  is	  important	   that	   the	   supplying	   laboratory	   provides	   the	   necessary	   information	  together	  with	  the	  ES	  cells.	  For	  example,	  all	  the	  “knock-­‐out	  first”	  alleles	  provided	  to	  the	  research	  community	  by	  the	  International	  Knockout	  Mouse	  Consortium;	  IKMC)	  have	   been	   generated	   in	   mouse	   ES	   cell	   lines	   derived	   from	   embryos	   with	   a	  C57BL/6N	  genetic	  background.	  We	  advise	   to	  exactly	   follow	   the	  cell	   line-­‐specific	  protocols	  and	  culture	  conditions	  provided	  by	  EUCOMM	  for	  these	  ES-­‐cell	  lines.	  Independent	   of	   their	   origin,	   we	   recommend	   users	   to	   verify	   the	   germ-­‐line	  transmission	  potential	  of	  the	  parental	  ES	  cell-­‐line	  they	  plan	  to	  use	  for	  dRMCE	  or	  alternatively	   use	   ES	   cell-­‐lines	   with	   proven	   germ-­‐line	   transmission.	   This	   is	  particularly	   important	   in	   the	   case	   of	   conditional	   alleles	   generated	   by	   high-­‐throughput	   approaches,	   as	   the	   resulting	   ES-­‐cell	   clones	   may	   not	   have	   been	  characterized	   in	   great	   detail	   with	   respect	   to	   their	   germ-­‐line	   transmission	  potential	   and/or	   karyotype.	   If	   the	   necessary	   information	   is	   not	   available,	   we	  recommend	   that	  minimally	   two	   independent	   parental	   ES	   cell	   lines	   carrying	   the	  conditional	   allele	   for	   the	   locus	   of	   choice	   are	   characterized	   by	   Southern	   blot	  analysis	  to	  verify	  correct	  targeting.	  In	  parallel,	  these	  parental	  ES-­‐cell	  lines	  should	  be	  karyotyped	  to	  exclude	  clones	  with	  apparent	  chromosomal	  abnormalities.	  In	  case	  the	  germ-­‐line	  transmission	  potential	  is	  not	  known,	  we	  recommend	  the	  use	  of	   two	   independent	   parental	   ES-­‐cell	   lines	   for	   parallel	   manipulation	   by	   dRMCE.	  Detailed	   protocols	   describing	   the	   PCR,	   Southern	   blotting	   and	   other	   molecular	  techniques	  can	  be	  found	  in	  the	  appropriate	  molecular	  biology	  laboratory	  manuals	  such	  as	  e.g.	  the	  Current	  Protocols	  in	  Molecular	  Biology	  series.	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CRITICAL:	  treat	  ES	  cells	  gently	  and	  maintain	  optimal	  growth	  conditions	  at	  all	  times	  
by	  only	  using	  freshly	  prepared	  media,	  minimizing	  handling	  times	  and	  taking	  utmost	  
care	   during	   trypsinizing	   and	   transfer	   of	   cells,	   etc.	   ES	   cells	   have	   to	   be	   cultured	   at	  
relatively	  high	  density	  and	  are	  typically	  split	  1:3	  to	  1:6	  every	  second	  day	  onto	  a	  layer	  
of	  mitotically-­‐arrested	  feeder	  cells.	  Only	  during	  drug	  selection	  after	  electroporation	  
are	   ES	   cells	   grown	  without	   feeder	   cells	   on	   gelatin-­‐coated	   dishes.	   ES	   cells	   grow	   in	  
dense	  colonies	  with	  very	  defined	  borders	  and	  should	  never	  be	  grown	  to	  more	  than	  
70-­‐80%	  confluency;	   individual	  colonies	  should	  never	  touch	  each	  other.	  The	  culture	  
media	   have	   to	   be	   changed	   daily.	   When	   ES	   cells	   are	   split,	   is	   very	   important	   to	  
dissociate	   them	   well	   by	   gentle	   pipetting	   such	   that	   the	   creation	   of	   air	   bubbles	   is	  
avoided.	   The	   quality	   of	   the	   single-­‐cell	   suspension	   has	   to	   be	   checked	   under	   the	  
microscope.	  The	  generation	  of	  a	  single	  cell	  suspension	  by	  gentle	  pipetting	  not	  only	  
prevents	  ES	  cell	  differentiation	  (and	  potential	  loss	  of	  pluripotency),	  but	  is	  important	  
for	   preparing	   cells	   for	   electroporation.	   Sterile	   conditions	   must	   be	   assured	   at	   all	  
times.	  For	  more	  details	  on	  ES	  cell	  culturing	  and	  passaging,	  we	  refer	  the	  user	  to	  the	  
laboratory	  manual	  “Manipulating	  the	  mouse	  embryo”.	  	  
1.	   Expansion	   of	   the	   parental	   ES	   cell	   line	   heterozygous	   for	   the	   conditional	  
allele.	  	  Always	  pre-­‐warm	  the	  media,	  Trypsin-­‐EDTA	  (1x)	  and	  D-­‐PBS.	  ES	  cells	  must	  be	  split	  every	  two	  days.	  Make	  sure	  that	  a	  sufficient	  number	  of	  dishes	  with	  confluent	  and	  mitotically-­‐arrested	  feeder	  cells	  are	  available	  on	  the	  day	  ES	  cells	  are	  split.	  	  Mitotically-­‐arrested	   mouse	   embryonic	   fibroblast	   feeder	   cells	   are	   prepared	   as	  follows:	   the	   feeder	   cell	  medium	   is	   replaced	   by	  medium	   containing	   10	   μg/ml	   of	  Mitomycin	  C	  (100x	  stock	  at	  1	  mg/ml)	  and	  the	  plates	  are	  incubated	  for	  2	  hours	  at	  37°C	   in	   a	   tissue	   culture	   incubator.	   Then	   the	   Mitomycin	   C	   medium	   (toxic)	   is	  removed	  and	  the	  plates	  with	  the	  firmly	  adhered	  feeder	  cells	  are	  washed	  3	  times	  with	  D-­‐PBS	  (with	  Mg2+/Ca2+).	  Add	  feeder	  cell	  medium	  and	  return	  the	  plates	  to	  the	  incubator	  and/or	  seed	  ES	  cells	  onto	  them.	  When	  using	  multi-­‐well	  plates	  (after	  ES-­‐cell	  colony	  picking,	  see	  below),	  it	  is	  better	  to	  Mitomycin	  C	  treat	  the	  feeder	  cells	  in	  10-­‐cm	   tissue	   culture	   plates,	   trypsinize	   and	   plate	   them	   into	   48	  well	   plates	   after	  washing.	  One	  confluent	  10-­‐cm	  dish	  of	  feeder	  cells	  is	  sufficient	  to	  seed	  cells	  into	  all	  wells	  of	  one	  multi-­‐well	  plate	  with	  12	  to	  96	  wells.	  Plates	  with	  confluent	   layers	  of	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Mitomycin	  C	  treated	  feeder	  cells	  can	  be	  used	  up	  to	  maximally	  3	  days	  for	  seeding	  with	  ES	  cells.	  Just	  prior	  to	  plating	  the	  ES	  cells,	  it	  is	  essential	  to	  change	  the	  feeder	  cell	  medium	  to	  ES	  cell	  medium.	  
Step	  1.1	  (day	  1):	  thaw	  one	  aliquot	  of	  frozen	  parental	  ES	  cell	  (~3×106	  cells/vial)	  into	  one	  6-­‐cm	  dish	  of	  mitotically-­‐arrested	  confluent	  feeder	  cells.	  Thaw	  the	  vial	  in	  a	  waterbath	  at	  37°C	  and	  transfer	  the	  contents	  into	  a	  15-­‐ml	  tube	  containing	  10	  ml	   of	   ES	   cell	  medium.	   Centrifuge	   at	   1000	   rpm	   for	   5	  minutes	   and	  resuspend	   the	   pellet	   in	   1ml	   ES	   cell	   medium	   and	   plate	   onto	   the	   6-­‐cm	   dish	  containing	  already	  3ml	  of	  ES	  cell	  medium.	  
Step	  1.2	  (day	  2):	  check	  the	  cells	  under	  the	  microscope	  and	  refresh	  the	  medium.	  	  
Step	  1.3	  (day	  3):	  passage	  the	  cells	  from	  a	  6-­‐cm	  to	  a	  10-­‐cm	  dish.	  Wash	  the	  plate	  with	  2	  ml	  Trypsin-­‐EDTA	  (1x,	  do	  not	  use	  any	  other	  type	  of	  Trypsin	  –	   for	   details	   see	   reagent	   list).	   Replace	   with	   1.5	   ml	   of	   Trypsin-­‐EDTA	   (1x)	   and	  return	  to	   the	   incubator	   for	  15	  minutes	  at	  37°C.	  Tap	  the	  plate	  gently	  and	  pipette	  the	  ES	  cells	  up	  and	  down	  5-­‐7	  times	  with	  a	  2	  ml	  pipette.	  Check	  the	  single	  cell	  status	  under	  a	  microscope.	  Add	  4	  ml	  of	  ES	  cell	  medium	  and	  pipette	  2-­‐3	  more	  times	  using	  a	  5	  ml	  pipette.	  Return	  the	  dish	  to	  the	  incubator	  for	  15	  minutes.	  This	  will	  allow	  the	  feeder	  cells	   to	  re-­‐attach	  and	  allow	  transfer	  of	   the	  ES	  cells	  without	  carrying	  over	  too	   many	   feeder	   cells.	   Transfer	   the	   ES	   cells	   by	   gently	   swirling	   the	   dish	   and	  collecting	   the	  4.5	  ml	  ES	  cell	  medium	   into	  a	  15-­‐ml	   tube.	  Centrifuge	   the	  cells	   (see	  step	  1.1)	  and	  resuspend	  the	  pellet	  in	  2ml	  of	  ES	  cell	  medium.	  Plate	  the	  harvested	  ES	  cells	  into	  one	  10-­‐cm	  dish	  with	  mitotically-­‐arrested	  feeder	  cells	  and	  8	  ml	  of	  ES	  cell	  medium.	   In	   case	   the	  ES	   cell	   in	   the	  original	  6-­‐cm	  dish	  have	  grown	  almost	   to	  80%	  confluency,	  then	  it	  may	  be	  necessary	  to	  split	  the	  cells	  into	  two	  10-­‐cm	  dishes	  (at	  1:3	  to	  1:6	  ratios).	  
Step	   1.4	   (day	   4):	   monitor	   the	   cells	   for	   potential	   confluency	   and	   colony	  morphology.	  Refresh	  the	  medium.	  
Step	  1.5	  (day	  5):	  split	  the	  cells	  onto	  four	  to	  six	  10-­‐cm	  dishes	  with	  feeder	  cells	  (at	  1:4	   to	   1:6	   ratios).	   For	   details	   see	   step	   1.3,	   resuspend	   the	   cells	   in	   7ml	   ES	   cell	  medium	  for	  plating.	  
Step	  1.6	  (day	  6):	  monitor	  the	  cells	  and	  refresh	  the	  medium.	  The	  electroporation	  will	  be	  done	  the	  next	  day.	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2.Electroporation.	  Typical	   electroporation	   conditions	   for	   ES	   cells	   are	   0.24	   kV	   and	   475	   μF	   (high	  capacitance)	  using	  the	  Biorad	  Gene	  Pulser	  II	  system.	  About	  1.5×107	  cells	  in	  0.8ml	  D-­‐PBS	  are	  used	  per	  0.4-­‐cm	  cuvette.	  As	   rule	  of	   thumb,	  one	  about	  70%	  confluent	  10-­‐cm	  dish	  provides	  enough	  ES	  cells	  for	  one	  cuvette.	  Grow	  always	  1-­‐2	  additional	  dishes	   to	   ensure	   that	   sufficient	   amounts	   of	   ES	   cells	   are	   available	   on	   the	   day	   of	  electroporation.	  	  
Experimental	  design:	  Experimental	  cuvette	  1:	  ES	  cells	  (1.5×107)	  +pDIRE	  (50	  μg),	  +	  replacement	  vector	  (50	   μg).	   In	   general,	   a	   single	   cuvette	   is	   enough	   per	   replacement	   construct	  when	  using	  dRMCE.	  Control	  cuvette:	  ES	  cells	  (1.5×107)	  +	  pDIRE	  (50	  μg).	  	  Optional:	  Control	  2	  (no	  DNA)	  and	  Control	  3	  (no	  electroporation).	  These	  controls	  are	  in	  general	  not	  needed	  as	  they	  mainly	  serve	  to	  monitor	  the	  performance	  of	  the	  electroporator	  or	  the	  quality	  of	  the	  media.	  
Step	   2.1:	   trypsinize	   enough	   10-­‐cm	   dishes	   of	   approximately	   70%	   confluent	   ES	  cells	  (for	  details	  see	  step	  1.3	  and	  1.5).	  
CRITICAL:	   assure	   that	   ES	   cells	   form	   a	   single-­‐cell	   suspension.	   If	   necessary,	   pipette	  
them	  further	  in	  the	  Trypsin-­‐EDTA	  (1x)	  solution	  using	  a	  2-­‐ml	  pipette	  (maximally	  12	  
times	  in	  total).	  
TIP:	   prepare	   enough	   10-­‐cm	   dishes	   coated	   with	   0.1%	   gelatin	   during	   the	  
trypsinization	   step.	   Cover	   the	   surface	   of	   the	   tissue	   culture	   dishes	  with	   the	   gelatin	  
solution,	   incubate	   them	   for	  5	  minutes	  at	   room	   temperature	  and	   then	  aspirate	   the	  
solution.	  Leave	  the	  plates	  to	  dry	  in	  the	  hood	  for	  10	  minutes.	  
Step	   2.2:	  Collect	   the	  ES	  cells	  after	  10	  min	  adherence	   to	   remove	   feeder	  cells	   (as	  described	  in	  step	  1.3).	  Take	  great	  care	  not	  to	  transfer	  too	  many	  feeder	  cells.	  Pool	  the	  ES	  cell	  suspensions	  from	  various	  dishes	  in	  50-­‐ml	  tubes.	  Make	  sure	  the	  ES	  cell	  suspension	   is	   homogeneous	   and	   transfer	   a	   100	   μl	   aliquot	   into	   a	   1.5-­‐ml	   tube	  containing	  0.9	  ml	  of	  ES	  cell	  medium	  (1/10	  dilution).	  Count	  the	  cells	  and	  calculate	  the	  total	  amount	  of	  ES	  cells	  in	  each	  50	  ml-­‐tube.	  
TIP:	   take	  care	   to	  not	   let	   the	  cells	  re-­‐adhere	   for	   too	   long	  as	  otherwise	  a	  significant	  
fraction	  of	  the	  ES	  cells	  will	  be	  lost.	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Step	  2.3:	  Centrifuge	  the	  ES	  cells	  at	  1000	  rpm	  for	  10	  minutes.	  Resuspend	  the	  pellet	  in	  D-­‐PBS	  (without	  Mg2+/Ca2+-­‐	  this	  is	  crucial)	  at	  a	  final	  concentration	  of	  1.875×107	  cells	  per	  ml,	  which	  corresponds	  to	  1.5×107	  cells	  in	  0.8ml	  D-­‐PBS.	  
TIP:	   during	   the	   centrifugation	   step,	   open	   and	   label	   the	   cuvettes.	   Pipette	   the	  
appropriate	   amount	   of	   DNA	   into	   each	   cuvette.	   Prepare	   a	   bucket	   with	   ice.	  Step	  2.4:	  add	  0.8ml	  (1.5×107)	  ES	  cell	  suspension	  to	  each	  DNA-­‐containing	  cuvette	  using	  a	  1-­‐ml	  cell	  culture	  grade	  plastic	  pipette	  (this	  is	  important).	  Mix	  the	  solution	  by	  pipetting	  up	  and	  down	  2	  to	  3	  times,	  which	  ensures	  homogenous	  dispersion	  of	  the	  DNA.	  Prepare	  all	  the	  cuvettes	  first,	  then	  electroporate	  one	  after	  the	  other.	  
Step	   2.5:	   pulse	   each	   of	   the	   cuvettes	   and	   place	   them	   on	   ice	   immediately	   after	  electroporation.	   Typical	   time	   constants	   range	   between	   6.0	   to	   6.8	   milliseconds,	  although	   this	   may	   vary	   depending	   on	   the	   electroporator	   used.	   Following	  electroporation,	  let	  the	  cuvettes	  rest	  on	  ice	  for	  20	  minutes.	  
TIP:	   during	   this	   time,	   add	   10	  ml	   of	   ES	   cell	  medium	   (WITHOUT	   selective	   drug)	   to	  
each	   of	   the	   gelatinized	   10-­‐cm	   dishes.	   In	   addition,	   prepare	   one	   15-­‐ml	   Falcon	   tube	  
with	  10	  ml	  fresh	  ES	  cell	  media	  for	  each	  cuvette.	  
Step	   2.6:	   transfer	   the	   content	   of	   a	   single	   cuvette	   into	   a	   15-­‐ml	   Falcon	   tube	  containing	  10	  ml	  of	  ES	  cell	  medium	  with	  a	  1-­‐ml	  plastic	  pipette.	  Rinse	  each	  cuvette	  twice	  with	  1	  ml	  of	  ES	  cell	  medium	  to	  recover	  additional	  cells.	  Do	  not	  centrifuge	  these	  tubes.	  Plate	  2	  ml	  aliquots	  of	  each	  experimental	  cuvette	  (1:5	  ratio)	  into	  three	  10-­‐cm	  dishes.	  For	  the	  control	  cuvette	  (pDIRE	  only)	  plate	  two	  dishes	  (2	  ml	  each).	  Place	  the	  dishes	  into	  the	  tissue	  culture	  incubator.	  	  
3.	  Recovery.	  After	  at	  least	  24	  hours,	  exchange	  the	  medium	  for	  fresh	  ES	  cell	  medium	  (WITHOUT	  selective	  drug).	  This	  allows	  the	  ES	  cells	   to	  recover	   from	  the	  electroporation	  and	  allows	   dRMCE-­‐mediated	   replacement	   and	   expression	   of	   the	   selective	   drug	  resistance	  gene.	  	  
TIP:	  as	  ES	   cells	  attach	  directly	   to	   the	  gelatin,	   the	  medium	  has	   to	  be	   changed	  very	  
gently.	  It	  should	  be	  done	  the	  earliest	  after	  24	  hrs,	  i.e.	  during	  the	  afternoon/evening	  
of	  the	  day	  following	  electroporation.	  	  4.	  Hygromycin/Puromycin	  drug	  selection.	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Step	   4.1:	   two	   days	   following	   electroporation,	   the	   medium	   in	   the	   experimental	  dishes	   (ES	   cells	   electroporated	  with	   the	   pDIRE	   and	   the	   replacement	   vectors)	   is	  exchanged	   for	  ES	  medium	  supplemented	  with	   the	  appropriate	  selective	  drug.	   In	  addition,	  one	  of	  the	  control	  dishes	  (ES	  cells	  electroporated	  with	  pDIRE	  only)	  also	  receives	  medium	  with	  the	  selective	  drug,	  while	  the	  other	  receives	  regular	  ES	  cell	  medium.	  	  
CRITICAL:	   The	   control	   plate	   receiving	  medium	  WITHOUT	   selective	   drug	   serves	   as	  
important	  positive	  control	  for	  ES	  cell	  growth	  and	  should	  be	  clearly	  labeled	  as	  such.	  
TIP:	  As	  puromycin	  selection	  requires	  lower	  drug	  concentrations,	  this	  is	  a	  rather	  low	  
cost	  drug	  selection.	  
Step	   4.2:	   Change	   the	   selection	   and	   control	   medium	   daily.	   The	   first	   clones	   will	  become	  apparent	  after	  7-­‐8	  days	  of	  selection.	  
CRITICAL:	   during	   selection	   make	   sure	   to	   produce	   enough	   Mitomycin	   C	   treated	  
feeder	   cells	   for	   growing	   and	   expanding	   the	   ES	   clones.	   For	   isolation	   of	   ES	   cell	  
colonies,	   two	   48	   multi-­‐well	   plates	   containing	   treated	   feeder	   cells	   per	   dRMCE	  
replacement	   experiment	  will	   be	   needed	   over	   a	   period	   of	   four	   days.	   Over	   a	   2	   days	  
interval,	   generate	   at	   least	   one	   24-­‐well,	   one	   6-­‐well	   and	   one	   10cm	   dish	   per	   ES	   cell	  
colony	  that	  later	  needs	  to	  be	  expanded.	  Step	   4.3:	   The	   ES	   cells	   growing	   in	   the	   control	   dish	   without	   selective	   drug	   will	  become	   sub-­‐confluent	   usually	   in	   2-­‐3	   days.	   Once	   this	   happens,	   wash	   the	   plate	  three	   times	  with	  D-­‐PBS	  and	  proceed	   to	  extraction	  of	  genomic	  DNA	  (see	  part	  8).	  This	  DNA	  sample	  is	  critical	  as	  it	  allows	  testing	  of	  the	  specific	  PCR	  amplifications	  that	  detect	  the	  wild-­‐type,	  conditional	  and	  deleted	  alleles.	  A	  fraction	  of	  ES	  cells	  will	  have	   been	   electroporated	   with	   the	   pDIRE	   vector,	   which	   will	   induce	   cis-­‐recombination	  of	  the	  conditional	  locus	  and	  generation	  of	  the	  deleted	  allele.	  
CRITICAL:	   the	  PCR	  primer	  pairs	   that	  were	  designed	  to	  specifically	  detect	   the	  wild-­‐
type,	   conditional	   and	   deleted	   alleles	   (see	   Figure	   1)	   have	   to	   be	   validated	   prior	   to	  
starting	  the	  isolation	  of	  ES	  cell	  colonies,	  as	  the	  ones	  with	  successful	  replacement	  and	  
clonal	  origin	  need	  to	  be	  identified	  rapidly.	  
Step	   4.4:	   the	   second	  control	  dish	   that	   received	  medium	  with	   the	   selective	  drug	  should	  be	  devoid	  of	  ES	  cells	  after	  about	  5	  days	  when	  using	  puromycin	  or	  7	  days	  when	  using	  hygromycin.	  This	  is	  an	  important	  control	  as	  it	  indicates	  that	  the	  drug	  selection	  is	  working.	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5.	  Isolation	  (picking)	  of	  ES	  cell	  colonies.	  ES	   cell	   colonies	   are	   picked	   using	   a	   stereo-­‐microscope	   (cleaned	   carefully	   with	  ethanol)	  placed	  under	  the	  tissue	  culture	  hood.	  In	  average,	  ES	  cell	  colonies	  are	  big	  enough	  for	  picking	  starting	  at	  day	  9-­‐10	  of	  drug	  selection.	  	  
Step	   5.1:	   ES	   cell	   colonies	   can	   be	   easily	   spotted	   by	   the	   naked	   eye	   through	   the	  bottom	  of	  the	  tissue	  culture	  dish.	  Circle	  the	  colonies	  using	  a	  marker	  and	  carefully	  screen	   them	   under	   the	   microscope	   for	   ES	   cell	   colonies	   with	   round,	   defined	  borders,	  but	  where	  individual	  cells	  are	  not	  easily	  distinguishable	  (Figure	  2).	  
CRITICAL:	  Do	  not	  pick	  ES	  cell	  colonies	  with	  a	  flat	  architecture	  and/or	  that	  are	  much	  
larger	  than	  average	  colonies.	  Due	  to	  the	  high	  number	  of	  ES	  cell	  colonies	  present	  and	  
the	   relatively	   low	   number	   of	   colonies	   that	   need	   to	   be	   picked,	  many	   colonies	  with	  
perfect	  morphology	   (see	  Figure	  2	   for	   examples)	   should	  be	   readily	  apparent	   in	   the	  
three	  plates	  selected	  per	  dRMCE	  construct.	  
Step	   5.2:	   Add	   40μl	   of	   cold	   Trypsin-­‐EDTA	   (1x)	   per	   well	   into	   two	   rows	   of	   a	   96	  multi-­‐well	  plate	  (24	  wells	  in	  total;	  with	  U-­‐shaped	  bottom).	  Keep	  the	  plate	  on	  ice.	  Replace	  the	  medium	  in	  the	  dish	  with	  8ml	  of	  D-­‐PBS	  (with	  Mg2+/Ca2+).	  An	  isolated	  ES	  cell	  colony	  is	  picked	  using	  a	  Gilson	  P20	  pipette	  set	  to	  10	  μl	  by	  aspiration	  and	  transferring	   it	   into	   a	   well	   of	   the	   96-­‐well	   plate	   on	   ice.	   After	   picking	   24	   ES	   cell	  colonies,	  incubate	  cells	  in	  the	  Trypsin	  solution	  for	  7	  minutes	  at	  37°C	  .	  Replace	  the	  D-­‐PBS	   in	  the	  plate	  that	  was	  used	  to	  pick	  the	  ES	  cell	  colonies	  with	   fresh	  medium	  containing	   the	   selective	   drug	   and	   put	   the	   plate	   back	   in	   the	   tissue	   culture	  incubator.	  
Step	  5.3:	  after	  Trypsin	  digestion,	  add	  175	  μl	  of	  ES	  cell	  medium	  without	  selection	  to	  each	  well	  using	  a	  multi-­‐dispenser	  pipette.	  Disperse	  the	  cells	  by	  pipetting	  them	  up	  and	  down	  gently	  a	  few	  times	  with	  a	  Gilson	  P200	  pipette	  set	  at	  170	  μl.	  Transfer	  the	  single	  cell	  suspension	  to	  one	  well	  of	  a	  48	  multi-­‐well	  plate	  with	  Mitomycin	  C-­‐treated	  feeder	  cells	  in	  300	  μl	  of	  ES	  cell	  medium	  WITHOUT	  selective	  drug.	  Return	  the	  48	  multi-­‐well	  plate	  to	  the	  incubator.	  
CRITICAL:	  From	  now	  on,	  only	  use	  medium	  WITHOUT	  selective	  drug,	  as	  feeder	  cells	  
are	  not	  resistant.	  
Step	  5.4:	  A	  similar	  number	  of	  ES	  cell	  colonies	  should	  be	  picked	  the	  two	  following	  days	  by	  repeating	  steps	  5.1-­‐5.3.	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TIP:	   In	   some	   cases,	   we	   have	   observed	   that	   fast	   growing	   clones,	   which	   are	   first	  
apparent,	   are	   negative	   for	   dRMCE-­‐mediated	   replacement.	   These	   clones	   probably	  
arise	   as	   a	   consequence	   of	   early,	   random-­‐integration	   events	   resulting	   in	   rapid	  
expression	   of	   the	   drug	   resistance	   gene.	   We	   therefore	   recommend	   picking	   ES	   cell	  
colonies	   over	   a	   period	   of	   2-­‐3	   days	   (i.e.	   about	   15-­‐20	   clones	   each	   day).	   In	   our	  
experience,	   picking	   40-­‐60	   cell	   colonies	   is	   in	   general	   sufficient	   to	   yield	   several	  
correctly	   replaced	  ES	  cell	   clones.	  Nevertheless,	   the	  plates	  containing	  additional	  ES	  
cell	  colonies	  should	  be	  kept	  and	  the	  ES	  cell	  medium	  changed	  every	  second	  day	  until	  
correctly	  replaced	  ES	  cell	  clones	  are	  identified	  by	  PCR	  analysis	  (part	  8).	  	  
6.	  Expansion	  of	  isolated	  ES	  cell	  colonies	  (48-­‐well	  plate).	  The	  day	   after	   isolation,	   inspect	   the	   cells	   under	   the	  microscope	   for	   viability	   and	  density.	  Exchange	  the	  medium	  by	  adding	  500	  μl	  of	  fresh	  ES	  cell	  medium.	  
CRITICAL:	  To	  avoid	  cross-­‐contamination	  between	  wells,	  the	  tip	  of	  the	  pipette	  used	  to	  
aspirate	   the	   old	   culture	  medium	  has	   to	   be	   flamed	   after	   each	   aspiration.	   The	   new	  
medium	   should	   be	   added	   to	   the	   side	   of	   the	  wells	   using	   a	  multi-­‐dispenser	   pipette.	  
Great	  care	  should	  be	  taken	  to	  avoid	  touching	  the	  borders	  of	  the	  wells.	  	  
7.	  Passaging	  the	  ES	  cell	  colonies	  into	  a	  new	  48	  multi-­‐well	  plate	  (2	  days	  after	  
picking).	  Step	  7.1:	  aspirate	  the	  ES	  cell	  medium	  and	  wash	  the	  wells	  with	  75	  μl	  of	  Trypsin-­‐EDTA	   (1x).	   Exchange	   the	   75	   μl	   Trypsin-­‐EDTA	   (1x,	   75	   μl)	   solution	   once	   and	  incubate	  the	  plate	  at	  37°C	  for	  8-­‐10	  minutes.	  	  
TIP:	  if	  some	  clones	  have	  not	  grown	  enough,	  they	  can	  be	  left	  in	  the	  original	  well	  for	  
an	   additional	   day	   after	   changing	   the	  medium.	   To	   avoid	   prolonged	   trypsinization,	  
process	  only	  4-­‐6	  wells	  at	  a	  time.	  
Step	   7.2:	   during	   the	   incubation,	   remove	  media	   from	   a	   new	  48	  multi-­‐well	   plate	  with	  Mitomycin	  C-­‐treated	  feeder	  cells	  and	  replenish	  the	  well	  with	  300	  μl	  of	  ES	  cell	  medium.	  
Step	  7.3:	  carefully	  tap	  the	  plate	  containing	  the	  ES	  cell	  colonies	  and	  gently	  pipette	  up	   and	  down	   three	   times	  using	   a	  Gilson	  P200	  pipette	   set	   at	   60	  μl.	   Immediately	  add	   600	   μl	   of	   ES	   cell	  medium	   using	   a	  multi-­‐dispenser	   pipette	   to	   inactivate	   the	  Trypsin.	  Gently	  pipette	  up	  and	  down	  four	  times	  using	  a	  Gilson	  P1000	  pipette	  set	  
	   	   	   Appendix	  I	  	  
	  164	  
to	  500	  μl.	  Transfer	  200	  μl	  of	  ES	  cell	  suspension	   into	  a	  single	  well	  of	   the	  new	  48	  multi-­‐well	   plate	   and	   return	   it	   to	   the	   incubator.	   Transfer	   the	   remaining	   ES	   cell	  suspension	  to	  a	  1.5ml	  Eppendorf	  tube	  and	  proceed	  to	  DNA	  extraction	  (part	  8).	  
Step	  7.4:	   the	   following	  day,	  monitor	   the	  cells	  under	   the	  microscope	  and	  change	  the	  medium	  (further	  expansion	  is	  described	  in	  part	  9).	  	  
8.	  PCR	  screening	  to	  detect	  correct	  dRMCE-­‐mediated	  replacement	  events	  (in	  
parallel	  with	  step	  7).	  
	  
Step	   8.1:	   Process	   the	  1.5-­‐ml	   tubes	   containing	  ES	   cells	   for	  DNA	  extraction	   (step	  7.3)	   in	   batches	   of	   24	   samples.	   Pellet	   the	   cells	   in	   a	  microcentrifuge;	   wash	   them	  once	  with	  D-­‐PBS	  and	  re-­‐centrifuge.	  	  
CRITICAL:	  it	  is	  important	  to	  prepare	  genomic	  DNA	  of	  good	  quality	  for	  reliable	  PCR	  
identification	   of	   correct	   replacement	   events.	   Therefore,	   the	   use	   of	   the	   protocol	  
described	   here	   is	   highly	   recommended.	   This	   protocol	   results	   in	   extraction	   of	   DNA	  
suitable	   for	  PCR	  analysis	   that	   is	   free	  of	  major	  contaminants.	  Contaminated	  or	   low	  
quality	  DNA	  prepared	  by	  so-­‐called	  quick	  DNA	  extraction	  protocols	  will	  compromise	  
PCR	  analysis.	  
Step	  8.2:	   lyse	  the	  cell	  pellet	  using	  400	  μl	  of	   lysis	  buffer	  (10	  mM	  Tris-­‐HCl	  pH8.0;	  50mM	  EDTA;	  100mM	  NaCl;	  0.5%	  SDS)	  supplemented	  with	  1	  mg/ml	  of	  Proteinase	  K	  (Merck	  24568;	  stock	  solution	  10	  mg/ml	  in	  H2O).	  Incubate	  for	  2	  hours	  at	  55°C.	  
Step	  8.3:	  spin	  briefly	  to	  concentrate	  the	   liquid	  at	   the	  bottom	  of	  the	  1.5-­‐ml	  tube.	  Add	  350	  μl	  of	  digestion	  buffer	  (without	  Proteinase	  K)	  and	  250	  μl	  of	  6M	  NaCl.	  Mix	  by	  inverting	  the	  tube	  several	  times	  (do	  NOT	  vortex).	  
Step	  8.4:	  centrifuge	  the	  tubes	  for	  10	  minutes	  at	  13,000	  rpm	  in	  a	  microcentrifuge.	  Transfer	   the	   supernatant	   (contains	   the	   genomic	   DNA)	   to	   a	   new	   1.5-­‐ml	   tube	  containing	   500	   μl	   of	   isopropanol.	   Avoid	   transferring	   any	   of	   the	   precipitate	  (contains	  proteins,	  etc).	  Mix	  by	  gentle	  inversion	  for	  two	  minutes	  and	  re-­‐centrifuge	  for	  10	  minutes	  at	  13,000	  rpm.	  
Step	  8.5:	  carefully	  decant	  the	  supernatant	  –	  pay	  special	  attention	  to	  not	  loose	  the	  DNA	  pellet.	  Add	  1	  ml	  of	  70%	  ethanol	  and	  centrifuge	  for	  2	  minutes	  at	  13’000	  rpm.	  Remove	   the	   supernatant	  by	   careful	   decanting	   and	  assure	   that	   the	  DNA	  pellet	   is	  not	  lost.	  Re-­‐centrifuge	  the	  tubes	  and	  remove	  any	  residual	  ethanol	  using	  a	  thin	  tip.	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Step	   8.6:	   air-­‐dry	   the	   DNA	   pellets	   for	   15	   minutes	   and	   resuspend	   in	   50-­‐100	   μl	  (depending	   on	   pellet	   size)	   of	   10	  mM	  Tris-­‐Cl,	   100	   μM	  EDTA	   (pH	  8.0).	   Leave	   the	  solution	  for	  several	  hours	  to	  overnight	  at	  4°C	  to	  resuspend.	  Mix	  by	  brief	  vortexing	  and	  use	  1-­‐3	  μl	  of	  DNA	  solution	  per	  PCR	  reaction	  (in	  50	  μl	  total	  volume).	  
Step	   8.7:	  Use	   the	  previously	  designed	  and	  validated	  PCR	  strategy	   to	   identify	  ES	  cell	  colonies	  with	  correct	  replacement	  events.	  The	  initial	  screen	  should	  focus	  on	  detecting	  correct	  recombination	  at	  one	  end	  of	  the	  locus	  (i.e.	  3’	  recombination).	  To	  control	  DNA	  quality,	  a	  PCR	  amplification	  detecting	  the	  wild-­‐type	  locus	  should	  be	  included	   (all	   ES	   cell	   colonies	   are	  heterozygous).	   ES	   cell	   colonies	  with	   correct	   3’	  replacement	   are	   then	   re-­‐screened	   for	   5’	   recombination.	   As	   a	   fraction	   of	   ES	   cell	  colonies	  might	  be	  of	  mixed	  nature,	  it	  is	  crucial	  to	  verify	  the	  absence	  of	  the	  deleted	  and	   conditional	   alleles	   (for	  more	   details	   see	  Osterwalder	   et	   al.).	   In	   addition,	   all	  positive	  ES	  cell	  colonies	  have	  to	  be	  back-­‐screened	  for	  the	  lack	  of	  integrated	  pDIRE	  sequences.	  It	  is	  possible	  to	  complete	  the	  entire	  PCR	  screening	  procedure	  of	  48	  ES	  cell	  colonies	  in	  one	  day.	  	  
CRITICAL:	   Due	   to	   the	   two-­‐step	   nature	   of	   the	   dRMCE	   procedure,	   there	   is	   a	   small	  
fraction	   of	   correctly	   targeted	   ES	   cell	   colonies	   that	   are	   of	   mixed	   origin	   with	   cells	  
carrying	  the	  deleted	  or	  conditional	  allele.	  These	  mixed	  colonies	  likely	  originate	  as	  a	  
consequence	  of	  early	  unequal	  segregation	  of	  the	  replacement	  vector	  and/or	  pDIRE	  
plasmid.	  Using	  the	  PCR	  strategy	  described	  here,	  mixed	  colonies	  are	  easily	  recognized	  
and	  must	  be	  discarded.	  
ES	   cell	   colonies	  must	  be	   screened	  during	   the	   two	  days	   they	  grow	   in	  48	  multi-­‐well	  
plates	  (part	  7).	   In	  the	  extreme	  situation	  that	  no	  correctly	  replaced	  ES	  cell	  colonies	  
would	  be	  detected,	  more	  could	  be	  picked	  and	  analyzed	  (part	  5-­‐7).	   In	  case	  the	  PCR	  
strategy	  is	  flawed	  and/or	  fails,	  candidate	  colonies	  for	  correct	  replacement	  could	  be	  
tentatively	   identified	   by	   the	   absence	   of	   the	   conditional	   and	   deleted	   alleles	   in	  
combination	  with	   amplification	   of	   the	  wild-­‐type	   allele	   as	   a	   control.	   These	   ES	   cell	  
colonies	   could	   be	   expanded	   and	   frozen	   in	   aliquots	   and	   the	   correct	   replacement	  
proven	  by	  rigorous	  Southern	  blotting	  analysis	  at	  a	  later	  stage.	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9.	  Expansion	  of	  correctly	  replaced	  ES	  cell	  clones.	  	  
Step	  9.1:	  mark	  the	  correctly	  replaced	  clones	  (part	  8)	  in	  the	  48	  multi-­‐well	  plates.	  
Step	  9.2:	  among	  them,	  select	  minimally	  6-­‐8	  ES	  cell	  clones	  that	  have	  good	  colony	  morphology	  (colonies	  with	  defined	  round	  borders	  and	  with	  densely	  packed	  cells)	  and	   are	   ready	   to	   be	   split	   48	   hours	   after	   plating.	   Trypsinize	   these	   clones	   (as	  described	  in	  part	  7)	  and	  transfer	  all	  the	  cells	  into	  one	  well	  of	  a	  24	  multi-­‐well	  plate	  containing	  Mitomycin	  C-­‐treated	  feeders	  in	  ES	  cell	  medium.	  	  
	  
TIP:	  after	  removing	  the	  selected	  ES	  cell	  clones	  from	  the	  48	  multi-­‐well	  plate,	  place	  the	  
plate	  on	  ice.	  Remove	  the	  medium	  from	  the	  additional	  positive	  clones	  (in	  groups	  of	  4-­‐
8)	   and	  gently	   add	  400	  μl	   of	   ice-­‐cold	   freezing	  media.	   Seal	   the	   plate	  with	  Parafilm,	  
wrap	   it	   in	   a	   plastic	   bag	   and	   transfer	   it	   to	   -­‐80°C	   into	   a	   Styrofoam	  box.	   Additional	  
positive	  clones	  can	  be	  recovered	  from	  plates	  stored	  -­‐80°C	  in	  such	  a	  manner	  up	  to	  a	  
few	  months	  later.	  
Step	   9.3:	   change	   the	   ES	   cell	   medium	   daily	   and	   split	   the	   cells	   every	   2	   days	   as	  follows:	   from	   a	   single	   24-­‐well	   to	   a	   single	   6	   well	   and	   then	   into	   a	   10-­‐cm	   tissue	  culture	  dish	  (always	  containing	  Mitomycin	  C	  treated	  feeder	  cells).	  When	  the	  cells	  are	  ready	  to	  be	  split	  into	  a	  10-­‐cm	  dish,	  take	  1/5	  of	  the	  single	  cell	  suspension	  and	  plate	  it	  into	  one	  gelatin-­‐coated	  well	  of	  a	  6	  multi-­‐well	  plate.	  These	  cells	  will	  be	  used	  for	   karyotyping	   to	   detect	   potential	   chromosomal	   abnormalities	   that	   would	  interfere	  with	  the	  generation	  of	  chimeric	  mice.	  DNA	  for	  Southern	  blot	  analysis	  is	  prepared	   by	   replenishing	   the	   wells	   of	   24	   and	   6	   multi-­‐well	   plates	   with	   new	  medium	  after	   transferring	   the	   trypsinized	  cells.	  There	   is	  always	  enough	  ES	  cells	  left	  behind	  that	  can	  be	  re-­‐grown	  and	  used	  to	  prepare	  larger	  amounts	  of	  clean	  DNA	  for	   Southern	   Blot	   analysis.	   Confirmation	   of	   correct	   replacement	   by	   extensive	  Southern	  blot	  analysis	  is	  absolutely	  essential.	  
TIP:	  the	  ES	  cell	  clones	  that	  a)	  have	  a	  normal	  karyotype;	  b)	  harbor	  no	  insertions	  of	  
the	  pDIRE	  vector	  or	  random	  integration	  of	  the	  replacement	  vector	  and	  c)	  have	  been	  
validated	  by	  Southern	  blot	  analysis	   for	  correct	  recombination	  at	  both	  ends	  can	  be	  
directly	  microinjected	  into	  mouse	  blastocysts	  to	  generate	  chimeric	  mice.	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10.	  Freezing	  ES	  cell	  clones	  for	  long-­‐term	  storage.	  	  
Label	   5	   cryotubes	   (Nunc)	   per	   10-­‐cm	   dish	   of	   ES	   cells	   to	   be	   frozen.	   Include	   the	  locus,	  code	  name	  of	  the	  clone,	  date	  and	  the	  initials	  of	  the	  researcher.	  Step	  10.1:	   check	   the	  10-­‐cm	  dishes	  of	  ES	  cells	   for	  optimal	   confluency	   (70%)	  and	  colony	  morphology.	   Change	   the	  media	   2-­‐3	   hours	   before	   the	   freezing	   process	   is	  initiated.	  
Step	  10.2:	  trypsinize	  the	  ES	  cells	  as	  described	  (step	  1.5).	  Centrifuge	  the	  cells	  and	  resuspend	  the	  pellet	  in	  2ml	  of	  ice-­‐cold	  freezing	  medium	  in	  a	  15-­‐ml	  tube.	  Keep	  the	  tube	  on	  ice.	  Add	  an	  additional	  3	  ml	  of	  freezing	  media	  to	  the	  tube	  and	  aliquot	  the	  5	  ml	   of	   cell	   suspension	   into	   the	   5	   cryotubes	   (1	  ml	   each).	   Transfer	   the	   tubes	   to	   a	  Styrofoam	  holder	  and	  wrap	  it	  with	  bubble-­‐wrap.	  Place	  this	  package	  at	  -­‐80°C.	  The	  next	  day	  transfer	  the	  cryotubes	  individually	  to	  into	  a	  cell	  freezing	  box	  that	  fits	  into	  liquid	   nitrogen	   tank	   for	   long-­‐term	   storage.	   ES	   cell	   clones	   frozen	   in	   this	  manner	  can	  be	  stored	  for	  indefinite	  time.	  
TIP:	  One	  or	   several	  of	   these	  vials	   can	  be	   sent	   to	   the	   transgenic	   facility	  and	   the	  ES	  
cells	  defrosted	  and	  expanded	  for	  the	  production	  of	  chimeric	  mice.	  One	  vial	  should	  be	  
thawed	  into	  a	  6-­‐cm	  tissue	  culture	  dish	  containing	  Mitomycin	  C-­‐treated	  feeder	  cells.	  	  
Timing	  	  	  1.	  Generation	  of	  the	  dRMCE	  replacement	  vector:	  1-­‐2	  months.	  The	  time	  needed	  to	  construct	   a	   particular	   dRMCE	   replacement	   vector	   can	   vary	   significantly	   as	   this	  depends	   on	   the	   custom	   design.	   However,	   the	   use	   of	   the	   pDRAV	   and	   pDREV	  plasmids	  reduces	  the	  required	  time	  significantly.	  2.	  Expansion	  of	  ES	  cells	  harboring	  the	  conditional	  allele:	  6-­‐7	  days.	  3.	  Electroporation:	  1	  day.	  4.	  Recovery	  phase:	  2	  days.	  5.	  Hygromycin/Puromycin	  selection:	  8-­‐10	  days.	  6.	  Picking	  of	  ES	  cell	  colonies:	  1-­‐3	  days.	  7.	  Growing	  of	  ES	  cell	  colonies	  in	  48-­‐well	  plates:	  2	  days.	  8.	  Transfer	  into	  new	  48-­‐well	  plates:	  2	  days.	  9.	  PCR	  screening:	  2	  days	  (in	  parallel	  to	  part	  8).	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10.	  Expansion	  of	  verified	  ES-­‐cell	  clones:	  6	  days.	  During	  the	  expansion	  phase,	  the	  PCR	   positive	   ES	   cell	   clones	   are	   validated	   by	   Southern	   Blot	   analysis	   and	  karyotyping.	  	  11.	  Freezing	  of	  sufficient	  vials	  of	  cells	  for	  validated	  ES	  cell	  clones:	  1	  day.	  Total	   time:	  approximately	  5	  weeks	  from	  thawing	  a	  single	  vial	  of	   the	  parental	  ES	  cell	   line	   until	   the	   validated	   and	   correctly	   replaced	   ES	   cell	   clones	   are	   ready	   for	  microinjection	  into	  recipient	  mouse	  blastocysts.	  	  
Anticipated	  Results	  	  Targeting	  frequencies	  by	  dRMCE	  are	  difficult	  to	  predict,	  but	  are	  in	  the	  range	  of	  10-­‐70%	   correct	   replacement.	   Among	   the	   ES	   cell	   colonies	   analyzed	   there	   will	   be	   a	  fraction	   of	   “mixed”	   colonies	   that	   contain	   both	   correctly	   replaced	   cells	   and	   ones	  still	   carrying	   the	   conditional	   or	   deleted	   allele.	   Some	   ES	   cell	   colonies	   could	   also	  have	  undergone	  incomplete	  replacement	  (e.g.	  positive	  for	  loxP	  /Cre	  but	  negative	  for	  FRT	  /Flp-­‐mediated	  recombination	  or	  vice	  versa).	  Furthermore	  a	  small	  fraction	  of	   ES	   cell	   colonies	   might	   have	   additional	   integration	   events	   or	   display	  chromosomal	   abnormalities.	   All	   the	   ES	   cell	   colonies	   that	   are	   of	  mixed	   origin	   or	  aberrant	  in	  any	  manner	  should	  be	  discarded.	  Due	   to	   the	   high	   frequency	   of	   correct	   replacement	   using	   dRMCE,	   is	   relatively	  straightforward	  even	  for	  less	  experienced	  researchers	  to	  expand	  a	  small	  number	  of	   ES	   cell	   colonies	   under	   optimal	   conditions	   and	   complete	   the	   PCR	   screening	  within	  a	  day.	  Our	  experience	  is	  that	  the	  best	  possible	  conditions	  of	  ES	  cell	  culture	  are	  the	  main	  asset	  for	  maintaining	  the	  pluripotency	  of	  these	  ES	  cell	  clones	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Abbreviations	  
	  	  AD	  	  	   	   	   atopic	  dermatitis	  APCs	  	  	   	   	   antigen-­‐presenting	  cells	  AR	  	  	   	   	   allergic	  rhinitis	  ATP	  	  	   	   	   adenosine	  triphosphate	  BCR	  	   	   	   B	  cell	  receptor	  BH	  	  	   	   	   breakpoint-­‐cluster	  region	  homology	  BM	  	   	   	   bone	  marrow	  	  BMMC	  	   	   bone	  marrow-­‐derived	  mast	  cells	  Btk	  	  	   	   	   Bruton’s	  tyrosine	  kinase	  BSA	  	   	   	   bovine	  serum	  albumin	  C2	   	   	   domain	  protein	  kinase	  C	  homology	  domain	  2	  Ca2++	   	   	   	  calcium	  CAMs	  	  	  	   	   cell	  adhesion	  molecules	  CCR	   	   	   CC	  chemokine-­‐binding	  receptor	  CR3	  	   	   	   complement	  receptor	  3	  	  	  CSR	  	   	  	   	   class-­‐switch	  recombination	  CXCR	  	   	   	   CXC	  chemokine-­‐binding	  receptor	  DAG	   	  	   	   diacylglycerol	  	  DC	  	   	   	   dendritic	  cell	  DMSO	  	  	   	   dimethylsulfoxide	  	  DNA	  	   	   	   deoxyribonucleic	  acid	  DNA-­‐PKcs	  	   	   DNA-­‐dependent	  protein	  kinase	  catalytic	  subunit	  DNP-­‐HSA	  	  	   	   dinitrophenyl	  human	  serum	  albumin	  ECM	  	   	   	   extracellular	  matrix	  	  EDTA	  	   	   	   ethylenediaminetetraacetic	  acid	  
e.g.	   	   	   exempli	  gratia	  EGF	  	   	   	   epidermal	  growth	  factor	  	  EGFR	   	  	   	   epidermal	  growth	  factor	  receptor	  EGTA	  	  	  	  	  	  	  	  	  	  	  	  	   ethylene-­‐glycol-­‐bis(2-­‐aminoethylether)-­‐N,N,N’,N’-­‐tetraacetic	  acid	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ELISA	   	   	   enzyme	  linked	  immunosorbent	  assay	  	  EtOH	   	   	   ethanol	  	  FACS	  	   	   	   fluorescence	  activated	  cell	  sorting	  FCS	  	   	   	   fetal	  calf	  serum	  FGFR	  	   	   	   fibroblast	  growth	  factor	  receptor	  FYVE	  	   	   	   Fab1p,	  YOTB,	  Vac1p	  and	  EEA1	  Gab2	  	   	   	   Grb2-­‐associated	  binding	  protein	  2	  Gads	   	   	   Grb2-­‐related	  adaptor	  protein	  2	  GAP	   	   	   GTPase	  activating	  protein	  GDP	  	   	   	   guanosine	  diphosphate	  	  GEF	  	   	   	   guanine	  exchange	  factor	  	  GM-­‐CSF	  	   	   granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  Grb2	  	   	   	   growth	  factor	  receptor-­‐bound	  protein	  2	  	  GPCR	  	   	   	   G-­‐protein	  coupled	  receptor	  	  GTP	  	   	   	   guanosine-­‐5’-­‐triphosphate	  	  HC	  	   	   	   highly	  cytokinergic	  	  HIFCS	  	  	   	   heat	  inactivated	  fetal	  calf	  serum	  	  hr	  	   	   	   hour(s)	  	  HRPO	  	  	   	   horseradish	  peroxidase	  	  IC50	  	   	   	   50%	  inhibitory	  concentration	  IFNγ	  	   	   	   interferon-­‐gamma	  Ig	   	  	   	   immunoglobulin	  	  IgSF	  	   	   	   immunoglobulin	  superfamily	  	  IL	  	   	   	   interleukin	  	  IMDM	  	  	   	   iscove’s	  modified	  dulbecco’s	  medium	  	  IP3	  	  	   	   	   inositol	  1,4,5-­‐trisphosphate	  	  IRS	  	   	   	   insulin	  receptor	  substrate	  	  iSH2	  	   	   	   inter-­‐SH2	  domain	  ITAMs	  	   	   immunoreceptor	  tyrosine-­‐based	  activation	  motifs	  	  ITIMs	  	  	   	   immunoreceptor	  tyrosine-­‐based	  inhibiting	  motifs	  	  kDa	  	   	   	   kilo	  Dalton	  KI	  	   	   	   knock	  in	  	  KO	  	   	   	   knock	  out	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LAT	  	   	   	   linker	  for	  activation	  of	  T	  cells	  	  Lck	  	   	   	   lymphocyte-­‐specific	  protein	  tyrosine	  kinase	  	  L-­‐Gln	  	   	   	   L-­‐glutamine	  LPS	  	  	   	   	   lipopolysaccharide	  	  LT	  	   	   	   leukotriene	  	  mAb	  	   	   	   monoclonal	  antibody	  	  Mac-­‐1	  	  	   	   macrophage	  antigen-­‐1	  	  MAPK	  	  	   	   mitogen-­‐associated	  protein	  kinase	  	  MCs	  	   	   	   mast	  cells	  	  MIP-­‐1α	  	   	   macrophage	  inflammatory	  protein-­‐1	  alpha	  	  MIP-­‐1β	   	   macrophage	  inflammatory	  protein-­‐1beta	  	  mTOR	  	  	   	   mammalian	  target	  of	  rapamycin	  	  NRTK	  	  	   	   non-­‐receptor	  tyrosine	  kinase	  	  NTAL	   	   	   non-­‐T	  cell	  activation	  linker	  	  p85B	  	   	   	   p85-­‐binding	  site	  	  PAF	  	   	   	   platelet-­‐activating	  receptor	  	  PBS	  	   	   	   phosphate	  buffered	  saline	  solution	  	  PC	  	   	   	   poorly	  cytokinergic	  	  PCA	  	   	   	   passive	  cutaneous	  anaphylaxis	  	  PDK	  	   	   	   phosphoinositide-­‐dependent	  kinase	  	  PEST	  	   	   	   penicillin-­‐streptomycin	  	  PG	  	   	   	   prostaglandin	  	  PGN	  	   	   	   peptiglycans	  	  PH	  	   	   	   pleckstrin	  homology	  PKB	  	   	  	   	   protein	  kinase	  B	  	  PKC	  	  	   	   	   protein	  kinase	  C	  	  PI3K	  	   	   	   phosphoinositide	  3-­‐kinase	  	  PI4K	  	   	   	   phosphoinositide	  4-­‐kinase	  	  PLCγ	  	  	   	   	   phospholipase	  C	  gamma	  	  PMA	  	   	   	   phorbol	  12-­‐myristate	  13-­‐acetate	  PSA	  	   	   	   passive	  systemic	  anaphylaxis	  	  PtdIns	  	   	   phosphatidylinositol	  	  PtdIns(3)P	  	   	   phosphatidylinositol	  3-­‐phosphate	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PtdIns(3,4)P2	  	   phosphatidylinositol	  3,4-­‐bisphosphate	  	  PtdIns(4,5)P2	  	   phosphatidylinositol	  4,5-­‐bisphosphate	  	  PtdIns(3,4,5)P3	  	   phosphatidylinositol	  3,4,5-­‐triphosphate	  PTEN	  	   phosphatase	   and	   tensin	   homologue	   deleted	   on	  chromosome	  10	  	  PVDF	  	   	   	   polyvinylidene	  fluoride	  PX	  	   	   	   phox	  homology	  domain	  	  RA	  	   	   	   rheumatoid	  arthritis	  	  RasB	  	   	   	   Ras-­‐binding	  domain	  	  RNA	  	   	   	   ribonucleic	  acid	  rpm	  	   	   	   rotations	  per	  minute	  	  RTK	  	   	   	   receptor	  tyrosine	  kinase	  	  S6K	  	   	   	   S6	  kinase	  	  SCF	  	   	   	   stem	  cell	  factor	  	  SDF-­‐1α	  	   	   	  stromal	  cell-­‐derived	  factor	  1alpha	  	  SDS	  	   	   	   sodium	  dodecyl	  sulfate	  	  SDS-­‐PAGE	  	   	   sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  electrophoresis	  SH2	  	  	   	   	   Src	  homology	  2	  	  SH3	  	  	   	   	   Src	  homology	  3	  	  Shc	  	   	   	   Src-­‐homologue	  and	  collagen-­‐homologue	  	  SHIP	  	   	   	   SH2-­‐containing	  inositol	  5-­‐phosphatase	  	  
Sl	  	   	   	   steel	  locus	  	  Sn	  	   	   	   supernatant	  	  SOCC	   	   	   store-­‐operated	  calcium	  channels	  	  ssRNA	  	   	   single-­‐stranded	  ribonucleic	  acid	  	  TBS	  	   	   	   Tris	  buffered	  saline	  solution	  	  TCR	  	   	   	   T	  cell	  receptor	  	  TH	  	   	   	   T	  helper	  	  TH	  	   	   	   tec	  homology	  	  TLR	  	   	   	   toll-­‐like	  receptor	  	  TNF-­‐α	  	  	   	   tumor	  necrosis	  factor-­‐alpha	  	  ZAP70	  	   	   zeta-­‐chain	  associated	  protein	  kinase	  70	  kD	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Relevant	  Work	  Experience	  –	  Key	  Roles	  &	  Achievements	  
	  
	  
Nov.	  2009	  –	  Dec.2015	   Cancer	   and	   Immunobiology	   research	   group,	  
Department	  of	  Biomedicine,	  University	  of	  Basel	  	  
Job	  position	  –	  PhD	  student	  /	  Researcher	  
 
• Animal-­‐based	  investigation	  of	  the	  role	  of	  lipid	  kinases	  in	  allergic	  responses 
• Molecular	  biology	  analysis 
• Primary	  tissue	  culture	  of	  bone	  marrow	  stem	  cells 
• Analysis	  of	  combinatorial	  index	  in	  drugs	  combination	   
• Coordination	  of	  scientific	  projects	  intra-­‐	  and	  intergroup 
	  
	  
Sept.	  2007	  –	  Ago.2018	   Fachhochschule	  Nordwestschweiz	  (FHNW),	  Basel	  
in	  collaboration	  with	  Vifor	  AG.	  
	  
Job	  position	  –	  Master	  thesis	  practicum	  
 
• Development	  of	  high-­‐throughput	  cellular-­‐based	  assays 
• Investigation	  of	  the	  mechanisms	  that	  regulate	  iron	  homeostasis 
	  
	  
Years	  2006	  –	  2009	  	  Job	  Position	  –	  Private	  Teacher	  	  
	   	   	   	   	  
• Support	  for	  preparation	  of	  high	  school	  exams	  of	  biology,	  chemistry,	  physisc	  and	  maths.	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Education	  	  Year	  2009	   	   University	  of	  Palermo	  /	  FHNW	  Msc	  in	  Industrial	  Biotechnology,	  110/110	  cum	  Laude	  	  Year	  2006	   	   University	  of	  Palermo	  Bsc	  in	  Medical	  Biotechnology,	  110/110	  cum	  Laude	  
	  
Certifications	  
	   -­‐ LTK	   Module	   1,	   Introductory	   Course	   in	   Laboratory	   Animal	   Science.	  FELASA,	  Federation	  of	  Laboratory	  Animal	  Science	  Association.	  	  
Scientific	  publications	  
• Botindari	  F,	  Wymann	  MP.	  Dual	  targeting	  of	  SHIP1	  and	  PI3Kγ	  for	  the	  inhibition	  of	  mast	  cell	  activation	  (in	  preparation).	  	  
• Gogvadze	  E,	  Bohnacker	  T,	  Botindari	  F,	  Collmann	  E,	  Marone	  R,	  Volzmann	  J,	  Wymann	  MP.	  Blocking	  mast	  cell	  activation	  with	  Ras	  inhibitors	  –	  moving	  toward	  cell-­‐specific	  PI3Kγ	  targeting	  (in	  preparation).	  	  
• Breasson	  L,	  Becattini	  B,	  Molinaro	  A,	  Zani	  F,	  Marone	  R,	  Botindari	  F,	  Wymann	  MP	  and	  Solinas	  G.	  PI3Kγ	  activity	  within	  multiple	  cell-­‐types	  cooperatively	  promotes	  adipose	  tissue	  inflammation	  and	  insulin	  resistance	  during	  obesity	  (in	  preparation).	  	  
Last	  scientific	  meeting	  participation	  40th	  FEBS	  congress	  (Federation	  of	  European	  Biochemical	  Society),	  Berlin,	  July	  4-­‐9,	  2015,	  selected	  speaker.	  
Languages	  
Italian:	  mother	  tongue,	  English:	  full	  working	  proficiency.	  
French:	  advanced	  conversational	  level,	  German:	  Basic	  conversational	  level.	  
	  
Voluntary-­‐based	  activities	  Co-­‐founder	   of	   the	   “Department	   of	   Biomedicine-­‐PhD	   students	   association”	   and	  responsible	   for	   the	   fundraising	   and	   relationships	   with	   the	   sponsors/partners	  (KGF,	   BioRad,	   Actelion,	   Abcam).	   Organization	   of	   Scientific	   Winter	   Retreat	   and	  Career	  days	  (from	  2012	  until	  2015).	  	  
